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Introduction
Allergic asthma affects approximately 5% of the adult population and 10-15% of children in developed
countries (1). This disease can be characterized by increased airway responsiveness to a variety of
specific and nonspecific stimuli, accompanied by a chronic inflammatory response in the airways and
excessive mucus production (2-4). The inflammatory response consists mainly of an influx and
subsequent activation of eosinophils and T lymphocytes (reviewed in 5). Thereby, many different
mediators are released, leading eventually to symptoms such as airway obstruction and airway
remodeling (reviewed in 5). Furthermore, in serum of asthmatic patients increased levels of antigen-
specific immunoglobulin (Ig)E can be measured (4), which can bind to Fc e -R1 receptors on mast cells.
Upon antigenic-provocation IgE can be cross-linked leading to mast cell degranulation, thereby
causing an acute bronchoconstrictive response (6).
Recent epidemiological studies have demonstrated that there is an increase in prevalence of asthma
in western society and especially hospitalization due to asthma has increased dramatically (7). Factors
that could contribute to the rise in asthma prevalence include environmental factors, e.g. increased
presence of house-dust mites in newly build, well heated and isolated homes, airway pollution and
decreased exposure to bacterial infections in early childhood. Furthermore, lack of physical activity is
thought to contribute to this phenomenon (reviewed in 1).
Over the past decades some of the immunological disorders that contribute to this disease have been
revealed. One of the most important findings was that a subset of CD4+ T lymphocytes, T helper
(Th)-2 cells are the main regulatory cells of the inflammatory response. Th2 cells were first described
by Mosmann et al. (8) in the mouse and by Wierenga et al. in humans (9). This subset of lymphocytes
is characterized by the production of certain cytokines, including interleukin (IL)-4, and IL5, whereas
Th1 cells mainly produce IL2 and IFN g  (reviewed in 10).
IL4 is important for B-cell IgE production whereas IL5 plays an important role in recruitment and
priming of eosinophils (11, 12). Both IL4 and IL5 play an important role in development of airway
hyperresponsiveness and inflammation in several different animal models of allergic asthma. IL4
receptor blockade has been shown to inhibit development of airway hyperresponsiveness in mice (13,
14), whereas IL5 has been demonstrated to be crucial for induction of inflammation and airway
hyperresponsiveness in guinea pigs and mice (12, 15, 16). However, controversy still exists about the
exact role of these cytokines since IL5 has also been shown not to be necessary for development of
airway hyperresponsiveness (13). Furthermore, IL4-independent airway hyperresponsiveness has
been observed (17). Recently, several new cytokines have been discovered in murine models and
human asthmatics that could be related to the pathogenesis of this disease, e.g. IL9, IL10 and IL13
(reviewed in 18,19-24).
Another cytokine that could be related to the pathology of asthma is IL16. It has been observed that a
large upregulation in expression and presence of IL16 in BAL fluid and bronchial mucosa occurs after
challenge with antigen in asthmatics but not in healthy volunteers or atopic subjects (25, 26).
Furthermore, IL16 uses CD4 as its receptor (27, 28) and induces chemotaxis of CD4+ T cells in vitro
(reviewed in 29) and might therefore be of importance in the pathogenesis of CD4+ T-cell mediated
diseases such as allergic asthma.
Current research is focusing on possible ways to decrease the number of antigen-specific T
lymphocytes or to redirect the Th2-type cytokine production towards a Th1 profile. Other possibilities
include modulation of antigen-presenting cells, inhibition of various co-stimulatory pathways which are
necessary for optimal T-cell stimulation, or use of allergen-immunotherapy. Furthermore, it could be
beneficial to induce unresponsiveness or anergy in CD4+ T lymphocyte subsets that are thought to be
the cause of the pathology associated with allergic asthma. A generally accepted definition of anergy
is "A cellular state in which a lymphocyte is alive but fails to display certain functional responses when
optimally stimulated through both its antigen-specific receptor and any other receptors that are
normally required for full activation" (30). One of the ways to induce anergy in CD4+ T cells is the use
of ligands for CD4 molecules, which are present on these T cells.
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Structure and function of CD4
CD4 is a 55 kDa cell surface glycoprotein that
consists of 4 extracellular immunoglobulin (Ig)-like
domains (D1-D4), a transmembrane region and a
cytoplasmic tail (32-36, Figure 1). The CD4
molecule exists as a monomer molecule on the
cell membrane (reviewed in 37). The src-related
protein tyrosine kinase (PTK) p56lck can be non-
covalently associated with the cytoplasmic tail (38,
39, Figure 1). Initially, the CD4 molecule was
considered to be a marker for Th subsets of
lymphocytes (40). These lymphocytes respond to
antigenic stimulation by proliferating and
production of different cytokines which stimulate
antibody responses or lead to macrophage
activation depending on the subclass of Th cells.
Later, it was discovered that CD4 molecules on T
cells can associate with class II major
histocompatibility complex (MHC-II) molecules on
antigen-presenting cells (APC).
A possible function of this CD4-MHC-II molecule
interaction could be to increase the avidity of
association between the APC and the T cell. This
hypothesis is called ‘the accessory molecule’
hypothesis (37, 41). The TCR-MHC interaction
itself has a typical half-life that would be too short
for effective T cell activation (42), which could be
increased by CD4-MHC interactions.
Another possible function for CD4 could be
amplification of the TCR/CD3 complex-induced
signaling. During the antigen presentation process
by MHC-II molecules, a single antigen-containing
MHC-II molecule interacts with both the TCR and
CD4 (at the a 2- b 2 site, reviewed in 43), leading to
co-clustering of TCR and CD4 (44, 45). CD4
enhances the T cell activation in this hypothesis
by serving as a co-receptor for the TCR/CD3
complex (46, 47) since co-localization of the CD4
and TCR to the same ligand (MHC-II) would generate a more potent activating signal then signaling
via the TCR alone (37, 41). The association between CD4 and the CD3/TCR complex does not occur
in the resting state, but only after MHC-TCR interaction, leading to CD3/TCR complex activation (48).
This ‘signal-amplification by CD4’ hypothesis is sustained by more recent data in which it has been
demonstrated that CD4-TCR transduction cascade does not differ from the transduction cascade
induced by TCR-TCR cross-linking, which implicates that there is a pure synergistically amplifying
function for CD4 on TCR-mediated signaling (49).
CD4 could directly enhance CD3/TCR signaling via recruitment of protein tyrosine kinases (PTK)
including p56lck (50, 51). Upon activation, these PTKs become autophosphorylated and subsequently
several other substrates are phosphorylated, including the cytoplasmic tails of CD3 e - and z -chains
(39, 52). These chains then serve as docking sites for ZAP70, a 70 kDa tyrosine phosphoprotein (53),
which subsequently becomes phosphorylated and thus activated (54, Figure 2). Tyrosine
phosphorylation of so called immunoreceptor tyrosine activation motifs (ITAMs) at the CD3 z -chains is
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crucial for this ZAP-70/CD3 interaction and it has been
suggested that different of these ITAMs play a role in
peripheral T cell activation, either in a quantitative or in a
qualitative manner (55-57). Tyrosine-phosphorylation
therefore is an early (58, 59) and obligatory (60, 61) event in
signaling cascade of the TCR.
Upon phosphorylation and subsequent activation of ZAP70
several different signaling pathways become activated, most
notably the activation of phospholipase Cg 1 (PLCg 1,
reviewed in 62). Phosphorylation and activation of PLCg 1
leads to enhanced hydrolysis of phosphatidylinositol 4,4-
biphosphate (PIP2), giving rise to the second messengers
diacylglycerol (DAG) and inostol 1,4,5-triphosphate (IP3).
These second messengers than activate protein kinase C
(PKC) and trigger the release of Ca2+ from intracellular
sources (reviewed in 62). This rise in intracellular Ca2+
concentrations can be further enhanced by Ca2+ influx via
cell surface voltage-independent Ca2+ channels which
become activated upon TCR activation (63). Since CD3/TCR
activation finally results in increases in intracellular calcium,
calcium ionophores (e.g. ionomycin) or PKC activators (e.g.
phorbol esters) can mimic TCR activation.
TCR/CD3-coupled PTKs are also involved in the activation of
pathways regulated by p21ras (a GTP-binding protein) and
PI-3 kinase. A series of serine/threonine kinase cascades is
controlled by p21ras. The direct downstream targets of PI-3
kinase include phospho-inositides which can be phosphorylated on the D-3 position of the inositol ring.
One of these, phosphatidylinositol tri-phosphate (PIP-3) has been demonstrated to bind SH2 domains
of many other signaling molecules (64).
Upon activation of these three different pathways, TCR signaling finally results in proliferation and
expression of different cytokine-encoding genes, e.g. IL2, via regulation of different transcription
factors (e.g. NF-AT, AP-1 and NF-k B, reviewed in 65). While CD4 could thus contribute to T cell
activation, immunosuppressive effects exerted by CD4 have also been observed. When CD4 is bound
independently of the TCR/CD3 complex, CD3/TCR activation results in suppressed T cell proliferation
and cytokine production (66, 67). Recently, IL16, a natural occurring soluble ligand for CD4 (29, 68)
has been described to have immunosuppressive properties when administered before TCR activation
(69, 70). This is in agreement with the effects of other ligands for CD4 which include monoclonal
antibodies to CD4 and HIV-gp 120. Furthermore, the CD4 molecule has been implicated to play a role
in T cell differentiation.
The role of CD4 in T cell differentiation
CD4 signaling is not only important for TCR-dependent T cell activation but also regulates
differentiation of lymphocytes into either Th1 or Th2 lymphocytes (71). In a system using peptides with
different affinities for the TCR the cytokine profile of restimulated T cells is dependent on the strength
of the initial stimulation (72). Peptides that are based on the normal ligand for the TCR turn naive
TCR-transgenic cells into Th1-type cytokine producing cells upon restimulation, whereas initial
stimulation with an altered peptide ligand (with low affinity for the TCR) differentiates naive T cells to a
Th2-type profile upon restimulation with the high affinity ligand (72). The role of CD4 in this process
was determined using TCR-transgenic mice that were crossed with either CD4 mutant mice or mice
that expressed a truncated form of CD4. Absence of CD4 did not influence development of Th1
cytokine profiles, however, Th2 development was impaired (71). These results indicate that CD4
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signaling is necessary for the generation of Th2-type-
inducing signals. In these experiments exogenously
added IL4 could restore impaired Th2 development
caused by CD4 absence. However, CD4 deficient cells
cultured in presence of IL4 still produce less IL4 than
wild type T cells that were differentiated towards a Th2-
type phenotype (19). Therefore absence of CD4 could
influence Th2 development in two different ways: either
CD4 expression influences TCR-induced signaling or
CD4 can modulate IL4-receptor induced signaling (71).
In contrast with these observations, others observed
that stimulation of naïve T cells with agonist peptides
via MHC-II molecules that are unable to interact with
CD4, a TCR signaling pattern is induced that is
comparable to low affinity peptide signaling. This
suggests that absence of CD4 signaling induces Th2-
development (73). The discrepancy between these
studies could be accounted for by different affinities of
the agonist peptides for the TCR.
IL16 as a CD4-ligand
Thus far IL16 is the only known naturally occurring
soluble ligand for CD4 (29). Competition studies with
F(ab)-fragments of antibodies to CD4 (OKT4) indicated
that IL16 is probably binding CD4 in the proximity of the
epitope recognized by this antibody (D4-region, Figure
3, 29).
IL16 was first discovered as a lymphocyte chemoattractant factor in 1982 (74, 75). Recently murine,
simian and feline IL16 have been cloned and remarkable similarities with human IL16 in both amino
acid sequence and biological activity was demonstrated (76-78). IL16 was reported to be produced by
CD8+ T cells upon stimulation with 5-HT or histamine (Table I). Later it was observed that CD4+ T cells
could also release IL16 after antigen-specific as well as mitogenic stimulation (Table I, 74, 75, 79, 80).
However, in contrast to CD8+ T cells, CD4+ T cells do not contain preformed IL16. Furthermore,
eosinophils, mast cells and epithelial cells are sources of IL16 (Table I, 26, 81, 82). IL16 mRNA
expression as well as immunoreactivity was significantly higher in epithelial cells obtained from
biopsies from asthmatic subjects than in biopsies taken from either healthy controls or non-atopics
(26). Cultured human eosinophils were demonstrated to constitutively express IL16 mRNA and to
contain preformed IL16 which is released into supernatant of unstimulated cultures (81). Mast cells
also contain preformed IL16 which is released into supernatant after stimulation with PMA or C5a (82).
Furthermore, de novo synthesis was increased largely after stimulation of mast cells as was detected
by an increase in IL16 mRNA (82). In contrast to other known interleukins, constitutive IL16 mRNA
expression is almost exclusively limited to lymphatic tissues, underlining the potential of IL16 as an
immunomodulatory molecule (83).
IL16 is encoded by a gene located on human chromosome 15 (15q23.6, 84) and is unrelated to
previously described cytokines or chemokines (27, 76). The molecular mass of IL16 (17 kDa) and the
occurrence of an open reading frame (ORF) of 390 base pairs suggests that IL16 is produced as a
mature 130 amino acid protein with neither a signal peptide or further processing of the protein (27).
However, recent observations suggest that the 130 amino acid protein is part of a much longer ORF,
thereby indicating that the 17 kDA protein is derived from corresponding precursor molecules (83, 85).
This precursor is most likely synthesized as a 67 kDa protein consisting of 631 amino acids. Only
cleaved IL16 is biologically active and this cleavage product consists of 121 C-terminal residues of
Figure 3
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pro-IL16. Cleavage of pro-IL16 into biologically active IL16 is mediated only by caspase-3 (86). The
naturally secreted C-terminal portion of IL16 is proposed to be a cationic homotetramer, suggesting
that CD4 cross-linking is necessary for IL16 to be biologically active (29, Figure 3). However, the
necessity for tertramerization of IL16 to be biologically active is challenged by a more recent
publication in which monomeric forms of IL16 were also able to induce chemotaxis of CD4+ T cells
(87).
Besides chemotaxis induction of CD4+ cells, including T cells, eosinophils and monocytes, IL16 has
been reported to induce upregulation of IL2 receptor expression, upregulation of HLA-DR and
enhanced survival of CD4+ T cells in a synergistic manner with IL2 (Table I, 29, 88-90). Furthermore,
IL16 induces a shift from G0 to G1a in human CD4+ T cells (reviewed in 29). In contrast to these
stimulatory effects, IL16 has been found to inhibit proliferation of CD4+ lymphocytes following
activation with antigen or antibodies to CD3 (69, 70, 91). Furthermore, IL16 has been reported to
inhibit mixed lymphocyte reactions of human peripheral blood mononuclear cells (69). Inhibition of
these T cell responses is not likely to be caused by induction of apoptosis since binding of IL16 to CD4
does not induce apoptosis, but is of a protective nature (92). Furthermore, IL16 does not decrease
CD4 expression, even after long term incubation (70) as has been reported using other CD4 ligands
(93).
The generation of second messengers by IL16 requires the presence of an intact cytoplasmatic tail of
CD4 since truncated CD4 molecules were not able to induce any of the described changes in CD4+ T
cell functions (100). Binding, and subsequent cross-linking of CD4 molecules by IL16 rapidly induces
association of CD4 with p56lck, which is necessary for induction of chemotaxis (101). In agreement
herewith, hybridoma cells that express CD4 molecules with point mutations which uncouple the CD4-
p56lck association, lack both chemotaxis and p56lck activation induced by IL16. However, it seems to
be that only the physical interaction between CD4 and p56lck is sufficient to induce these responses
since inhibition of p56lck activation by herbamycin A does not inhibit IL16 induced chemotaxis (101).
Furthermore, T cell hybridomas, expressing a chimeric receptor combining the extracellular domain of
human CD4 with murine p56lck, which lacks the kinase domain, displayed normal IL16 induced
chemotaxis. These findings are consistent with other reports in which a kinase independent role for
p56lck has been identified in T cell activation (102, 103). While the kinase activity is not necessary for
the induction of chemotaxis, p56lck binding to other signaling molecules (including PLCg 1, Raf-1 and
PI-3 kinase) may explain the requirement for p56lck-CD4 association in the motile responses (101).
Besides p56lck, PI-3 kinase is involved in the induction of chemotaxis by IL16 since wortmannin, a
selective PI-3 kinase inhibitor has been demonstrated to inhibit this response (29). Furthermore,
activation of PKC is associated with CD4-IL16 interaction (100), since CD4 ligation by IL16 increases
[Ca2+]i and the amount of IP-3. This suggestion was corroborated by the finding that IL16 induces a
rapid translocation of PKC activity from the cytosol to the membrane in three different CD4+ cell types
and that inhibitors of both the regulatory and the catalytic domain of PKC inhibited IL16 induced
chemotaxis (104). Finally, activation of PKC alone is sufficient to induce chemotactic responses.
Besides activation of these second messengers, it has also been demonstrated that IL16 activates the
stress-activated protein kinase (SAPK) pathway in CD4+ macrophages (105). After stimulation of
macrophages with IL16, SEK-1 becomes activated, resulting in activation of the SAPKs p46 and p54.
Furthermore, c-jun and p38 MAPK (mitogen-activated protein kinase) become phosphorylated.
However, in contrast to expectations, activation of these SAPKs and MAPK did not lead to detectable
apoptosis (105). The pathophysiological significance of IL16 is supported by observations that
presence of biologically active IL16 is largely upregulated in asthmatics after antigen-specific
provocation as well as in several different animal models of diseases including allergic asthma,
rheumatoid arthritis and colitis (26, 106-108).
HIV-1 gp120 as a CD4-ligand
The CD4 molecule can also serve as the primary receptor for human immunodeficiency virus type-1
(HIV-1, 32, 109, 110), the cause of the acquired immunodeficiency syndrome (AIDS). High affinity
 Chapter 1
13
binding of the viral envelope protein gp120 to CD4 mediates attachment and entry of viral particles
(111, 112). Extensive random and site-directed mutagenesis studies revealed that the primary binding
site of gp120 is located within the first amino-terminal domain of CD4 (D1).
In agreement with IL16, native and recombinant gp120 have been shown to induce PKC-dependent
migration of CD4+ lymphocytes (104, 113). Upregulation of IL2 receptor expression as well as
enhanced turnover of phosphatidylinositol into IP-3 and increases in intracellular Ca2+ are also
observed after gp120-CD4 interaction (100).
CD4-gp120 interaction has been demonstrated to induce activation of p56lck (70, 114), as was
measured by enhanced autophosphorylation and the phosphorylation of the exogenous substrate
enolase (115). P56lck activation by gp120 required association with CD4 since p56lck activity was not
detectable in cells expressing truncated or mutated forms of CD4 (100). However, others failed to
observe detectable changes in p56lck activity or phosphorylation of tyrosine residues after incubation
of CD4+ T cells with gp120 (116, 117).
Soluble gp120 is shed from HIV infected CD4+ T cells in vitro (118). Furthermore, soluble gp120 can
be detected in high concentrations in serum derived from patients suffering from AIDS (119). Finally,
circulating CD4+ T cells from patients with advanced disease appear to be coated with gp120/anti-
gp120 immune complexes (120). Together, these studies suggest that soluble gp120, released into
the extracellular compartments in vivo could bind to CD4 of uninfected cells and thus interfere with
normal CD4+ T cell functions as will be described in the next paragraphs. Besides interference with the
normal function of the CD4 molecule, long term independent CD4 ligation by gp120 (or other CD4
binding molecules such as antibodies) can induce downregulation of CD4 expression on the cell
surface (93, 121). Moreover, CD4 triggering by these ligands might prime T cells for apoptosis in
response to antigen (122, 123) and gp120 could thus interfere with normal CD4+ T cell functioning at
multiple levels.
Immunosuppression by different CD4 ligands or anti-CD4 antibodies
I Immunosuppression by IL16
CD4+ T cells, incubated with IL16 before stimulation with anti-CD3 display a decreased proliferation
and IL2R expression. Furthermore, exogenous administration of IL2 can not restore this decreased
proliferative response (70). The observation that IL16 induces a similar inhibition of proliferation after
antigen-specific stimulation but not after PHA stimulation suggests that the observed effects are
specific for TCR signaling, since PHA probably induces alternative T cell-activating pathways through
CD2 (124). These results also indicate that the inhibitory effects of IL16 are not of a general toxic
nature.
Besides inhibition of proliferation, pretreatment with IL16 also altered the Ca2+ response by delaying
the initial rise following anti-CD3 mAb stimulation and reducing the maximal [Ca2+]i response by
approximately 50% (70). This observation suggests that the mechanisms by which IL16 affects anti-
CD3-induced activation are at the level of second messenger generation.
II Immunosuppression by gp120
As already stated, gp120 is a ligand for CD4. Similar to effects observed with IL16, gp120 inhibits the
proliferative responses of human CD4+ T cell clones. Furthermore, gp120 is unable to inhibit PHA-
induced proliferative responses (125). In contrast with IL16-induced effects, native gp120 or anti-CD4
mAb (Leu3a)-induced inhibition of proliferation is restored by exogenous IL2 (126, 127), whereas IL16
induced decreases in proliferation could not be reversed by IL2 addition (70).
It has also been reported that a secondary antibody to gp120 to cross-link CD4 molecules is needed
to inhibit proliferation of CD4+ T cells (45, 127). This could indicate that the human immune system
actually contributes to the inhibitory role of gp120 on CD4+ T cell functioning by production of anti-
gp120 antibodies (45).
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III Immunosuppression by antibodies to CD4
When CD3 and CD4 are independently and simultaneously cross-linked, calcium mobilization is
inhibited when compared to that induced by cross-linking CD3 alone (128). Similarly, when CD4 is
cross-linked by antibodies (GK1.5 or OKT4D) prior to TCR or CD3 cross-linking, the Ca2+ influx is
inhibited, suggesting that negative signals generated by CD4 cross-linking are dominant over those
generated by TCR/CD3 ligation (45, 129). Finally, when CD3 and CD4 are cross-linked together e.g.
via antigen-presentation by MHC-II, Ca2+ responses are much higher than upon stimulation via solely
CD3, suggesting that CD4 signaling plays an active role in signal transduction of CD3/TCR/MHC/CD4
complexes (114, 129-131).
In agreement with impaired CD3/TCR signaling after blocking CD4, Woods et al. demonstrated that T
cells, stimulated with anti-CD3 antibodies do not proliferate when pre-treated with either the complete
antibody or with F(ab')2 fragments of humanized anti-CD4 antibodies (132). They furthermore found
that production of several cytokines, including IL4 and IL10, as well as expression of several activation
markers, including CD25 and CD69, were diminished by this treatment (132).
Use of antibodies to CD4 in vivo
Several studies in animal models using anti-CD4 antibodies have demonstrated that targeting to the
CD4 molecule is an effective way to suppress graft rejection as well as to prevent autoimmune
diseases. However, in all these studies depleting antibodies were used and therefore the way they act
is self-explanatory; they eliminate CD4+ T lymphocyte subsets. Even though these antibodies are
efficacious in these conditions, they do not provide a satisfactory approach since by depletion of CD4+
T cells, patients are prone to infections. Furthermore, disease is likely to reoccur whenever the CD4+
population is restored after ending the treatment. A more satisfactory therapeutic approach would be
Table I: Summary of IL16-producing cells and IL16-induced effects
IL16-Production Stimulation References
CD8+ T cells Histamine, 5-HT  (79, 80)
CD4+ T cells antigen, mitogen, anti-CD3  (74, reviewed in 29)
Mast cells PMA, C5a  (82)
Eosinophils Unstimulated  (81)
Epithelial cells Histamine  (26, 94)
Effects on CD4+ T lymphocytes References
Chemotaxis of CD4+ cells in vitro,
including eosinophils, T cells and monocytes
 (29, 90, 95)
HLA-DR induction  (96)
IL2R a  expression  (27, 96)
G0-G1 cell cycle change  (29)
Inhibition of antigen-induced or a CD3-induced T cell activation  (70)
Inhibition of mixed lymphocyte reaction  (69)
Prevention of apoptosis and CD95 (Fas-Receptor) expression  (70, 92)
Synergistic activation of CD4+ T cells with IL2  (88)
Inhibition of IL2 production  (97)
Inhibition of HIV transcription/replication  (92, 98, 99)
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modification of the profile of the immune response of pathogenic T cells, thus creating a condition of
active control or suppression.
Over the past decade use of non-depleting antibodies in several animal models provided new insights
in the use of antibodies to CD4 as a therapy in several different disorders (133-135). Cristopher et al.
First demonstrated that the use of IgG2a class anti-CD4 antibodies (KT6) did inhibit in vitro mixed
lymphocyte responses without in vivo depletion of CD4+ T lymphocytes (136). In vivo use of these
antibodies in mice resulted in long-term survival of cardiac grafts that were mismatched for both major
and multiple minor histocompatibility antigens (136). Furthermore, use of KT6 inhibits development of
collagen-induced arthritis (CIA) as well as adoptive transfer of CIA into severe combined
immunodeficicient (SCID) mice (137). Besides inhibition of disease phenotype, antigen-induced
cytokine production of lymphocytes derived from KT6-treated mice upon restimulation in vitro
appeared to be shifted from Th1 type cytokines towards a Th2-type profile (137). However, it could
also be postulated that in this study anti-CD4 antibodies did not alter Th1 responses into Th2-type
profiles but merely inhibited Th1 responses, thereby allowing the emergence of Th2-type T cells that
are specific for the same antigen (137). Whether non-depleting antibodies can really alter T cell
responses in vivo remains to be established but in vitro data suggest that indeed CD4 signaling can
determine the T cell cytokine profile (71). Based on such data it could at least be speculated that the
use of non-depleting antibodies to CD4 is very beneficial to patients suffering from diseases that are
controlled by CD4+ lymphocytes.
Possible CD4-mediated mechanisms of immunosuppression
The effects of several different ligands for CD4 molecules described so far confirm that CD4 can
function as a signal-transducing receptor which can decrease CD4+ T cell functions when activated
independently of the CD3/TCR complex and can augment T cell responses when activated together
with this complex. Therefore, timing of the CD4-ligation might dictate whether stimulatory or inhibitory
effects on TCR/CD3-mediated signaling are exerted. Based on the presented data, several different
mechanisms can be postulated to explain the qualitative immunosuppression by CD4 ligands
(Figure 4).
Firstly, CD4 occupation by gp120, anti-CD4 mAbs or IL16 could result in a physical blockade of
association of CD4 molecules on T cells and MHC-II molecules on APCs, thereby preventing the
formation of a stable TCR/CD4/MHC complex that has a half-life that is long enough for adequate
signaling. Such a possibility is plausible since the affinity of MHC-II and CD4 binding is much lower
than e.g. gp120/CD4 interaction (32, 111). Evidence has been provided that gp120 impairs binding of
CD4 with MHC-II (138). Furthermore, mutational studies by Fleury et al. demonstrated that the D4
region of the CD4 molecule is important for CD4-MHC class II binding (reviewed in 43) and IL16 binds
CD4 in the D4 region (reviewed in 29). However, this does not explain the ability of CD4 ligands to
inhibit T cell responses which are elicited in the absence of MHC-bearing APCs by e.g. antibodies to
CD3 (Figure 4A).
Secondly, CD4 ligation could result in a diversion of the CD4-p56lck complex, away from the CD3/TCR
complex and their associated second messengers, thereby preventing the formation of an active
CD3/TCR signaling complex (48). In respect to several different studies in which a positive
participation of p56lck is necessary for optimal TCR signaling (50, 51, 139, 140), it appears very likely
that CD4 ligation prior to CD3/TCR activation leads to impaired signaling via sequestration of p56lck.
Uncoupling p56lck from the TCR-signaling complex finally leads to prevention of recruitment and
activation of ZAP70 (141). ZAP70 is essential for TCR signaling since CD4+ T cells are unable to
respond to TCR-mediated stimuli when certain mutations in ZAP70 are present. Such mutations have
recently been demonstrated to be the cause of severe combined immunodeficiency syndromes in
humans (142, Figure 4B).
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A third explanation could be the transduction of a negative
signal initiated by the engagement of CD4, which could
interfere with CD3/TCR signaling, as was originally
observed with anti-CD4 antibodies (66). A role for p56lck
has been suggested in this process. If p56lck is activated in
the absence of CD3/TCR activation this kinase might have
access to ligands that are normally not available when
CD4-associated p56lck is part of the CD3/TCR signaling
complex. In this hypothesis, CD4-induced signaling, when
turned on in the absence of CD3/TCR activation, might
induce a qualitatively different signal which could interfere
with subsequent CD3/TCR-induced signals. Alternatively,
too early p56lck activation could result in inappropriately
timed tyrosine phosphorylation of cytoplasmic proteins and
thus inhibit signal transmission or exhaust T cell activation
capabilities (Figure 4C).
Binding of CD4-ligands to CD4 could also induce
conformational changes of this CD4 molecule (143),
thereby preventing e.g. coupling to MHC-II molecule or
intracellular signaling (Figure 4D).
Finally, recent evidence revealed that CD4-dimerization
(Figure 4E) is necessary for optimal CD4 functioning (43).
Furthermore, it has been established that the D4 region is
necessary for CD4 oligomerization, and that synthetic
peptide analogs derived from the D4 region inhibited CD4-
dependent T-cell activation (144). Since it is known that
IL16 binds CD4 in the D4 region (29), it could be
speculated that IL16/CD4 interaction inhibits CD4
dimerization (Figure 4E).
So far, use of non-depleting antibodies to CD4 have proved
to be extremely effective in down-modulating CD4-mediated diseases in animal models and humans
(reviewed in 133, 145-147). Since IL16 expression is largely upregulated in CD4+ T cell-mediated
diseases, including allergic asthma (26) and since IL16 uses the CD4 molecule as its receptor it could
very well be speculated that IL16 serves as some sort of homeostatic protein in vivo.
Aim of this thesis
The main objective of our studies was to unravel the role of IL16 in the pathogenesis of allergic
asthma. For this purpose we used a murine model for allergic asthma, recently developed by Hessel
et al. (148). After antigen challenge of ovalbumin-immunized male BALB/c mice, increased airway
responsiveness to either methacholine or 5-hydroxytryptamine (5-HT) can be measured, when
compared with saline-challenged animals (149). Furthermore, increased numbers of eosinophils can
de detected in bronchoalveolar lavage fluid as well as a large increase in the amount of ovalbumin-
specific IgE in serum (148, 150). Finally, thoracic lymph node cells (TLN), isolated from antigen-
challenged animals, produce Th2-type cytokines such as IL4 and IL5 upon antigenic restimulation in
vitro (151), whereas TLN cells isolated from saline-challenged animals hardly produce any cytokines
upon restimulation with antigen in vitro.
In human asthmatics IL16 presence in BAL fluid and expression in bronchial mucosa is increased after
antigen-specific stimulation (26). A similar upregulation is observed in the murine model we used in
this thesis. Increased levels of biological active IL16 can be detected in bronchoalveolar lavage fluid
obtained from antigen-sensitized and challenged mice (Figure 5). Using immunohistochemistry, it was
demonstrated that mainly epithelial cells display immunostaining for IL16 after ovalbumin-challenge
Figure 5
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(Figure 6). Finally, lung-draining lymph node cells also contain significantly more IL16 protein after
antigen-challenge when compared to saline-challenged animals (146 vs 73 pg ml-1). To unravel the
functions of IL16 in our murine model we used different approaches.
First, we further characterized the used model using Whole body plethysmograph. In chapter 2 we
discuss the use of this recently developed technique to determine airway hyperresponsiveness and
the occurrence of early and late asthmatic responses after antigen challenge. Furthermore,
development of airway hyperresponsiveness in time was compared with infiltration of eosinophils into
the lungs.
Secondly, we determined the role of histamine and 5-hydroxytryptamine (5-HT) on IL16 production in
our model since these autacoids are known to be released by murine mast cells upon antigen-specific
stimulation (152, 153) and since both histamine and 5-HT can induce production and release of IL16
by lymphocytes and epithelial cells (reviewed in 29, 90). Therefore, we used specific 5-HT or histamine
receptor antagonists and determined the effect on antigen-induced IL16 production and subsequent
biological effects. IL16 amounts and activity in BAL fluid were determined using a chemotaxis assay.
Furthermore, airway hyper-responsiveness and presence of eosinophils in BAL fluid were measured
as well as antigen-specific IgE antibody levels in serum (chapter 3).
Thirdly, to explore the function of endogenously produced IL16, animals were treated intranasally with
antibodies to IL16. Furthermore, animals were treated intranasally with peptides of which the amino
acid sequence was based on different parts of the predicted sequence of rhIL16. First, the effects of
these peptides were determined on in vitro IL16-induced chemotaxis (chapter 4). Thereafter, both
antibodies to IL16 and the different peptides were intranasally applied to ovalbumin-sensitized and
saline or ovalbumin-challenged animals. In these experiments development of antigen-induced airway
hyperresponsiveness and infiltration of eosinophils into BAL fluid were determined.
Fourthly, we determined the potentially beneficial effects of systemical or local treatment with rmIL16
or rhIL16 in vivo (chapter 5) since rhIL16 was shown to inhibit antigen-specific or polyclonal activation
of human lymphocytes in vitro (69, 70). In the experiments in which effects of systemic administration
of IL16 were examined, airway hyperresponsiveness, eosinophilia and serum antigen-specific IgE
levels were determined. Furthermore, Th2-type cytokine production by TLN cells derived from in vivo
Figure 6
Localization of IL16 immunoreactivity in airway sections of mice sensitized with OVA and exposed to
repeated OVA inhalations demonstrating staining in the epithelium (A). Much less staining was
observed in sections from ovalbumin-sensitized saline-challenged animals (B, see also 154).
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IL16-treated animals upon antigen-specific restimulation in vitro was measured (chapter 5).
Effects of CD4 cross-linking by either rmIL16 or antibodies to CD4 on antigen-induced proliferation
and cytokine production of murine lymphocytes were also examined (chapter 5 and 6).
Finally, in vitro effects of IL16 or antibodies to CD4 on differentiation of Th0 into either Th1 or Th2-type
T cells were determined using lymphocytes derived from DO11.10 transgenic mice. In this system,
presence of IL4 or antibodies to IL4 determines whether naive Th cells differentiate towards a Th2 or a
Th1-like cytokine producing pattern (71). During the initial stimulation period, antibodies to CD4 or
IL16 were added to the different cultures and effects of either antibodies to CD4 or IL16 were
determined on cytokine production after the initial stimulation with antigen or upon antigen-specific
restimulation (chapter 6).
In the last chapter, the results are discussed and compared to already published data on functions and
effects of IL16 (chapter 7).
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Summary
In asthmatics an immediate asthmatic response occurs after antigen provocation. Furthermore,
asthmatic patients display airway hyperresponsiveness, accompanied by airway eosinophilia. In some
patients late asthmatic responses can be detected. Many controversies still exist about the relations
between different airway responses and inflammatory cell infiltration, and we therefore used a murine
model to investigate correlations between these phenomena. In this study we show presence of
antigen-induced early bronchoconstrictive responses, accompanied by increased serum MMCP-1
levels. However, we were unable to demonstrate late bronchoconstrictive responses either at the time
when eosinophils start to infiltrate the lungs or when both airway hyperresponsiveness and
eosinophilia are established. With sequential exposures to antigen a correlation exists between
development of airway hyperresponsiveness and eosinophilia. In contrast, resolution of this
hyperreactivity appears to be dissociated from eosinophilia after stopping the antigen-challenges.
Based on these data we conclude that mast cell degranulation is the probable cause of early
bronchoconstrictive responses. Furthermore, late bronchoconstrictive responses are not related to the
infiltration of eosinophils or development of airway hyperresponsiveness in this murine model. Finally,
we conclude that airway hyperresponsiveness and eosinophilia are only associated with each other
during the induction phase and not after the final antigen-challenge.
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Introduction
Asthma is characterized by a reversible airway obstruction upon encounter with the antigen and an
increased airway reactivity to various bronchoconstrictive stimuli (6, 155, 156). Furthermore, a cellular
inflammatory response, consisting mainly of eosinophils, can be demonstrated in asthmatic patients
after antigen-provocation, which is thought to be caused by the production of Th2-type cytokines
including IL4 and IL5 (4). In some patients these phenomena are accompanied by a late asthmatic
response (LAR, 157).
The immediate airway response following provocation with antigen is probably caused by the release
of bronchoconstrictive mediators including histamine by activated mast cells (158). Besides release of
these mediators, mast cells may also contribute to the infiltration of eosinophils and the induction of
airway hyperresponsiveness, e.g. via production and release of cytokines such as IL4 (159).
The development of LAR in human asthmatics occurs as a spectrum ranging from no LAR to severe
late asthmatic bronchoconstricitive responses following antigen challenge, which seems to be at least
partially dependent on the dose of antigen (reviewed in 157). Furthermore, it is thought that there is a
direct correlation between infiltration of eosinophils and the occurrence of LAR in asthmatic patients
(157, 160). However, others observed that eosinophilia or the presence of mediators released by
eosinophils could not predict the emergence of LAR (161). Eosinophilic infiltration and subsequent
activation of these inflammatory cells has also been associated with the development of airway
hyperresponsiveness, possibly via destruction of epithelial layers in the lungs (162). Finally, it has
been postulated that occurrence and severity of LAR contributes to the development of airway
hyperresponsiveness (157).
In the past decade, several different murine models have been developed that display some of the
features of asthmatic patients and the use of these models has gained insight in the pathogenesis
underlying these phenomena (149, 163, 164). In the present study we used a well established murine
model in which airway hyperresponsiveness and eosinophilia occur after antigen-challenge.
Furthermore, presence of these phenomena is accompanied by an enhanced production of Th2-type
cytokines by ovalbumin-specific T cells derived from lung draining lymph nodes and an increased level
of antigen-specific IgE in serum (149, 165).
To address questions raised by the controversies in literature about the relations between changes in
airway functions and inflammatory cell infiltration, we used whole body plethysmography to measure
airway bronchoconstrictions. Whole body plethysmography has recently been adapted for measuring
airway responses in mice (166) and using this technique it is possible to determine the kinetics of
development of antigen-induced airway hyperresponsiveness in the same animals. This technique can
also be used to measure direct effects of antigen provocation and to monitor airway functions for long
periods of time and thus to determine whether late bronchoconstrictive responses occur in this murine
model. We therefore used this technique to determine if a relationships exist between the occurrence
of early and late bronchoconstrictive responses, development of airway hyperresponsiveness and the
cellular inflammatory response in antigen-sensitized and challenged mice.
Materials and Methods
Sensitization and challenge
Specified pathogen free male BALB/c mice (age 6-8 weeks) were obtained from the breeding colony of
the Central Animal Laboratory (Utrecht, The Netherlands). All experiments were approved by the animal
care committee of the Utrecht University. The mice were housed in macrolon cages and provided with
food and water ad libitum. Sensitization was performed by 7 intraperitoneal injections of 10 m g ovalbumin
(grade V) in 0.5 ml pyrogen free saline on alternate days. Four weeks after the last injection, the mice
were exposed either to 8 ovalbumin (2 mg ml-1 in saline) or to 8 saline aerosols for 5 min, on consecutive
days (1 aerosol day-1). The aerosols were generated with a jet nebulizer (Pari IS-2, Pari-Werk GmbH,
Starnberg, Germany) connected to a Plexiglas exposure chamber with a volume of 5 l in which a
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maximum of 6 animals was placed. In some experiments the animals were not challenged by aerosol but
by intranasal application of 50 m l of either vehicle (saline) or ovalbumin (10 mg ml-1) to increase antigen-
deposition. Before the intranasal application the mice were exposed to a short-lasting inhalation
anesthetic (Halothane, ALBIC BV, Maassluis, the Netherlands).
Whole body plethysmography
Airway responsiveness was determined using whole body plethysmography (Buxco Corp., Sharon, CT,
USA). Pressure differences between the chamber containing the animal and a reference chamber were
calibrated using a steady flow. Differences in pressure, measured with a transducer (M45, Validyne
Engineering Corp. Northridge, CA, USA), are caused mainly by changes in volume during a respiratory
cycle (166).
As a measure of bronchoconstriction PENH (enhanced pause) is used, a dimensionless, empirically
established value which is defined as: PEP
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 (see 166). During bronchoconstriction due to
either methacholine or antigen, several characteristic changes occur in the wave form of the flow signal
(166). The most striking differences in signal form occur during the expiration phase of a breath cycle,
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An increase in bronchoconstriction is accompanied by changes in both peak expiratory and inspiratory
pressure ( PEP  and PIP , respectively), which is reflected in the formula for PENH by PEP
PIP
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Before measuring airway responses to bronchoconstrictive stimuli with whole body plethysmography,
basal PENH values were measured for 3 minutes (10 valid breaths were averaged per PENH value).
Aerosol was generated using a jet-nebulizer (Pari IS-2). Ovalbumin-sensitized and saline- or ovalbumin-
challenged animals were subjected to aerosols containing increasing concentrations of methacholine
(ranging from 1.5 to 50 mg ml-1) for 3 min and subsequently data were collected on breathing patterns
during periods which lasted 3 min (protocol adapted from Hamelmann et al., 166).
Development and resolution of airway hyperresponsiveness and kinetics of eosinophilia
The kinetics underlying development and resolution of airway hyperresponsiveness were monitored
during and after the challenge period. Using the same animals, changes in airway responsiveness to
nebulized methacholine were measured at 24 h after the second and fourth antigen or saline-challenge
and at 1, 4 and 6 days after the last challenge. In a separate series of experiments the kinetics of
eosinophil infiltration into the bronchoalveolar lavage fluid were determined. Lungs of ovalbumin-
sensitized and saline- or ovalbumin-challenged animals were lavaged as previously described (149).
Lavages were performed at the same days at which airway responses were measured.
Detection of antigen-induced early airway responses
Antigen-induced immediate airway responses in ovalbumin-sensitized mice were determined. Basal
PENH value was measured and thereafter the mice were exposed to a saline or ovalbumin aerosol which
lasted for 5 min, followed by a measuring period (20 min). To increase antigen deposition into the lungs,
the mice were intranasally treated with 50 m l of either vehicle (saline) or ovalbumin (10 mg ml-1) and
subsequently PENH values were recorded for 20 minutes. The PENH values during this measuring
period were averaged per 2 minutes. From the same animals serum was collected 30 min after
intranasal challenge and mucosal mast cell protease-1 (MMCP-1) contents were measured using an
MMCP-1 enzyme linked immunosorbent assay (Moredun Scientific Ltd. Midlothian, UK), according to
the manufacturer’s instructions.
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Detection of antigen-induced late bronchoconstrictive responses
In order to measure late bronchoconstrictive responses, basal PENH value was recorded in
ovalbumin-sensitized mice for 10 minutes. Thereafter, the mice were challenged with either nebulized
saline or ovalbumin (2 mg ml-1) for 5 minutes or by intranasal application of 50 m l of either saline or
ovalbumin (10 mg ml-1) and subsequently PENH values were collected overnight.
Animals were also i.p. injected with ovalbumin (4 mg kg-1) as a booster at 5 days before overnight
monitoring of PENH. This booster of ovalbumin was used to increase antigen-induced responses
(167). Furthermore, these animals were treated with either vehicle or metyrapone (30 mg kg-1, Sigma
Chemical Company, St. Louis, MO, USA) at 3 days before the measurement, since inhibition of
endogenous corticosterone production has been shown to increase the incidence of late
bronchoconstrictive responses in dogs (168) and to increase antigen-specific immune responses in
rats (169). Subsequently the animals were exposed to either saline or ovalbumin (2 mg ml-1) aerosol
on two separate days. Immediately after the second aerosol, airway functioning was monitored
overnight for changes in PENH values.
Animals were also monitored for occurrence of late bronchoconstrictive responses after eight
consecutive aerosol challenges with either saline or ovalbumin because then eosinophilia and airway
hyperresponsiveness are maximal in our model as was demonstrated in the kinetics study. Presence
or absence late bronchoconstrictive responses was determined by calculating the area under the
individual tracings using the following formula: [ ] [ ]f x  y  y  x  xi i i i
n
i
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Statistical analysis
Comparisons between different groups of animals were made using an analysis of variance (ANOVA)
followed by a Student's t-test (unpaired, two-tailed). Total BAL cell numbers and the number of various
cell types were tested with an analysis of variance (ANOVA). For cell types with low numbers in control
animals (i.e. neutrophils and eosinophils) a Poisson distribution was assumed. Data are expressed as
arithmetic average ± SEM and a difference was considered to be significant when P<0.05). Statistical
analyses were carried out using SPSS/PC+, version 4.0.1 or Microsoft Excel version 7.0.
Results
Detection of antigen-induced early responses
Intranasal application of ovalbumin in sensitized mice induced an increase in PENH values, when
compared to PENH-readings obtained after saline-instillation (Figure 1). After aerosol provocation with
ovalbumin an increase in PENH values could also be observed when compared to saline challenge,
however this increase did not reach statistical significance (data not shown). Maximal increases in
PENH values (approximately 3-fold) were reached at 8 min after the intranasal instillation of ovalbumin
and were resolved at 16 min after antigen challenge (Figure 2A). From the same animals serum was
collected 30 min after intranasal challenge and MMCP-1 levels were measured. In ovalbumin-
sensitized saline-exposed animals MMCP-1 levels in serum amounted to 5.6±0.7 ng ml-1 whereas a 5-
fold increase (P<0.05) in MMCP-1 levels in ovalbumin-sensitized and exposed animals was detected
(25.3±3.4 ng ml-1, Figure 2B).
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Kinetics of airway hyperresponsiveness and eosinophilia
One of the advantages of measuring airway functions with whole body plethysmography in conscious
mice is the possibility of monitoring development of airway hyperresponsiveness during and after the
challenge period. We therefore measured airway responses to increasing concentrations of
methacholine in ovalbumin-sensitized and either saline or ovalbumin-challenged mice. At all different
time points complete concentration response curves were made of which a representative example,
measured at 1 day after the last challenge is shown in Figure 3A. Development of airway
hyperresponsiveness was monitored at days 3 and 5 of the challenge period, as well as at 1, 3 and 6
days after the last challenge. Already at 24h after the second challenge (day 3), ovalbumin-challenged
animals displayed a significant (P<0.05) increase in responsiveness at the highest concentration of
methacholine (50 mg ml-1), when compared to saline-challenged animals (4.7 – 0.3 vs 3.1 – 0.4,
respectively, Figure 3B). This hyperresponsiveness to methacholine was further increased at 24h after
the fourth antigen-challenge (day 5; 6.0 – 0.8 vs 3.2 – 0.3, P<0.05, Figure 3B) and was maximal at 24h
after the last antigen-challenge (day 9; 7.0 – 0.6 vs 4.6 – 0.4, P<0.05, Figure 3A and B). Furthermore, it
was observed that airway hyperresponsiveness to methacholine in ovalbumin-challenged animals was
Figure 1
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Representative examples of changes in PENH values measured after intranasal application (50 m l) of
saline (panel A) or ovalbumin (10 mg ml-1, panel B) in ovalbumin-sensitized mice. Basal recordings
were made for at least 3 min and starting immediately after the challenge, PENH values were recorded
for an additional 20 minutes. Arrows indicate the moment of challenge.
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still present at day 4 days after the last
exposure to methacholine, whereas this
phenomenon was resolved after 6 days
(Figure 3B). No significant differences were
observed in responsiveness to methacholine
in the saline-challenged animals at all different
time-points.
In a parallel series of experiments eosinophil
infiltration into BAL fluid was determined.
Lungs from ovalbumin-sensitized and saline
challenged animals were lavaged at 24h after
the last challenge and hardly any eosinophils
were present in lungs from these animals
(0.2 – 0.2 x 103). At day 3 during the challenge
period eosinophils started to be present in
BAL fluid derived from ovalbumin-challenged
animals (Figure 4). The number of eosinophils
was further increased at day 5 (Figure 4) and
was maximal at 24h after the last (eight)
antigen challenge (day 9, Figure 4). At both 4
and 6 days after the last antigen-challenge
eosinophils remained present in BAL fluid
derived from ovalbumin-sensitized animals
(Figure 4). No differences were observed
between the numbers of either neutrophils or
mononuclear cells present in lungs of either
saline or ovalbumin-challenged animals.
Detection of antigen-induced late
bronchoconstrictive responses
Several different protocols were used to
determine whether late bronchoconstrictive
responses could be measured after antigen
challenge. No differences in airway functioning
monitored for 15h after a single ovalbumin
aerosol challenge or after intranasal instillation
with ovalbumin were observed (n=6 per
treatment group, data not shown) when
compared to control animals.
In a different protocol to determine late
bronchoconstrictive responses, animals were
i.p. treated with a booster before the
ovalbumin challenge to enhance immune
responses (167). Furthermore, these animals
were treated with either vehicle or metyrapone (30 mg kg-1) at 3 days before the measurement to
inhibit production of endogenous corticosterone (149). As was demonstrated in the kinetic study,
eosinophils have already infiltrated the lungs at 24h after the second challenge and therefore it is very
likely that during the measurement period eosinophils are either infiltrating into or already present in
the lungs. However, no differences between saline and ovalbumin-challenged vehicle or metyrapone-
treated animals could be observed in PENH values, when monitored overnight (n=6 per treatment
group, data not shown).
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Increase in PENH values (A) and MMCP-1 serum
levels (B) after intranasal instillation of saline
(hatched bars) or ovalbumin (black bars) in
ovalbumin-sensitized mice. Baseline PENH values
were obtained by measuring for at least 3 minutes.
The effect of either ovalbumin or vehicle was
determined by averaging for 2 minutes during a 20
minute period following intranasal application.
MMCP-1 levels were measured in serum collected at
3h after intranasal instillation of either ovalbumin
(black bars) or saline (hatched bars). Results are
expressed as arithmetic average ± SEM of 7-9
animals per group. * (P<0.05); ** (P<0.01)
significantly different from ovalbumin-sensitized
saline-exposed animals.
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Finally, animals were monitored for presence of
late bronchoconstrictive responses after eight
consecutive aerosol challenges because then
eosinophils and airway hyperresponsiveness
are definitely present in our model (Figures 3
and 4). However, no differences in PENH
values between saline (n=7) or ovalbumin-
challenged (n=8) animals were observed
(Figure 5A and 5B).
Discussion
In this study we demonstrate the presence of
antigen-induced early but not late
bronchoconstrictive responses, even at a time
when both airway hyperresponsiveness and
eosinophilia are well established. Furthermore,
a correlation exists between the increase in
airway hyperresponsiveness to methacholine and the number of eosinophils in bronchoalveolar lavage
fluid upon sequential antigen exposures. In contrast, resolution of airway hyperresponsiveness
Figure 3
A
Basal Sal 1.5 3.1 6.3 12.5 25 500
2
4
6
8
*
*
*
Methacholine (mg ml-1)
PE
NH
B
3 5 9 12 140
2
4
6
8
*
*
* *
Days
PE
NH
Kinetics of the development of airway
hyperresponsiveness to nebulized methacholine at
different time-points. Dose response curves to
methacholine were measured in the same animals
throughout the experiment. PENH values were
recorded for 3 minutes after each exposure to
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bronchoalveolar lavage (BAL) fluid at different
time-points. Lungs from ovalbumin-sensitized
and challenged animals were lavaged at 24h
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SEM of 5-6 animals per group. * (P<0.05)
significantly different from saline-challenged
animals.
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appears to be dissociated from airway eosinophilia. We
observed in the present study that intranasal
application of ovalbumin in sensitized mice induced a
marked increase in PENH value, whereas challenge
with aerosolized antigen did not cause a significant
increase in PENH value. The difference in results
between the methods of delivering antigen to the lungs
are very likely due to limited antigen deposition in the
lungs after aerosol challenge. In contrast with these
observations we previously showed that aerosolized
ovalbumin did cause an immediate bronchoconstrictive
response as was determined by forced oscillatory
techniques (170), which therefore appears to be a more
sensitive technique than whole body plethysmography.
In the present study we observed that the increase in
PENH after antigen instillation is accompanied by an
increase in MMCP-1 levels, which is a result of mast
cell degranulation (171).
In agreement herewith we previously showed that
exposure to ovalbumin causes massive mast cell
degranulation as was detected by electron-microscopy
analysis of airway tissue (170). In humans it is well
known that upon mast cell degranulation histamine is
released which is thought to be responsible for causing
the immediate bronchoconstriction upon antigen
provocation (158). However, it is very unlikely that
histamine release is the cause of the immediate
increase in PENH values in mouse models, even though murine mast cells do release histamine upon
activation (152). It has been demonstrated that histamine can only induce smooth muscle contraction
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in murine tracheas at very high doses in vitro (172) and is unable to induce any detectable
bronchoconstriction in murine airways in vivo (J.J. de Bie, unpublished observations). Besides
histamine, 5-hydroxytryptamine (5-HT) which is a well known constrictive agent for murine airway
smooth muscle cells (149), can be released by activated murine mast cells (153). In BALB/c mice 5-
HT induces a dose-dependent increase in airway pressure overflow (149) and PENH values (J.J. de
Bie, unpublished observations). Based upon these data it can be speculated that mast cell
degranulation and subsequent release of 5-HT, is related to the observed antigen-induced early
bronchoconstrictive response in mice.
An advantage of whole body plethysmography when compared to invasive methods of measuring
airway responses, is the possibility to monitor development of airway hyperresponsiveness in time
after repeated exposures to antigen in the same animals (166). Our data indicate that airway
hyperresponsiveness is already present after 2 antigen-challenges. The difference between saline-
and ovalbumin-challenged animals was maximal at 24h after the last (eight) challenge in our model
and from previous experiments it is known that airway hyperresponsiveness does not further increase
when challenges are continued (J.J. de Bie, unpublished observations). Furthermore, we demonstrate
that ovalbumin-induced airway hyperresponsiveness remains present for at least 4 days after the last
antigen-exposure and is resolved at 6 days after the final ovalbumin-inhalation. In human asthmatics
the increase in non-specific airway hyperresponsiveness observed after a single antigen-challenge
can also persist for several days, lasting up to weeks in some individuals (reviewed in 157).
It can be concluded that early bronchoconstrictive responses can be detected using whole body
plethysmography and correlate with mast cell degranulation after antigenic provocation. However, this
early bronchoconstrictive responses does not predict occurrence of late bronchoconstrictive
responses. Furthermore, no causal relations between the infiltration of eosinophils or development of
airway hyperresponsiveness and the emergence of late bronchoconstrictive responses could be the
detected in this model. Finally, we conclude, based on our study on kinetics of airway
hyperresponsiveness and eosinophilic infiltration, that these two parameters are only associated with
each other during the induction phase but not during the resolution of these symptoms after stopping
the antigen challenges.
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Summary
Since both histamine and 5-hydroxytryptamine (5-HT) can be released by murine mast cells, we
investigated the possible role of these autacoids on airway hyperresponsiveness, eosinophil infiltration
and serum-IgE levels in a murine model of allergic asthma. Ovalbumin-sensitized mice were exposed to
either ovalbumin or saline aerosols on 8 consecutive days. Starting one day before the challenge,
animals were injected i.p. twice a day with a 5-HT type 1 (5-HT1) or type 2 (5-HT2) receptor antagonist
(methiotepine and ketanserin, respectively) or a histamine-type 1 (H1) or type 2 (H2) receptor antagonist
(mepyramine and cimetidine, respectively). Furthermore, animals were injected with a combination of
cimetidine and ketanserin or with an a -adrenoceptor antagonist (phentolamine). In vehicle-treated
ovalbumin-challenged animals airway responsiveness to intravenous injections of methacholine in vivo
was significantly increased when compared to vehicle-treated saline-challenged animals. Furthermore,
ovalbumin challenge of vehicle-treated animals induced a significant increase in both eosinophil numbers
in bronchoalveolar lavage (BAL) fluid and ovalbumin-specific IgE levels in serum compared to saline-
challenged mice. Virtually no eosinophils could be detected in saline-challenged animals after all different
treatments. Treatment with either ketanserin or cimetidine resulted in a partial but significant decrease of
the ovalbumin-induced airway hyperresponsiveness when compared to ovalbumin-challenged controls
and reduced eosinophil infiltration after ovalbumin. Increasing the dose of cimetidine did not further
reduce ovalbumin-induced eosinophilia. Treatment with a combination of ketanserin and cimetidine
almost completely abolished antigen-induced airway hyperresponsiveness, whereas eosinophilia was not
further decreased when compared to either antagonist alone. No effects of these antagonists were
observed on IL16 levels in BAL fluid or on serum antigen-specific IgE levels. Treatment with either the H1-
receptor, the 5-HT1-receptor or the a -adrenoceptor antagonist, did not decrease the observed ovalbumin-
induced airway responsiveness or eosinophilia in vehicle-treated animals. However, higher doses of
either methiotepine or mepyramine did decrease ovalbumin-induced eosinophil whereas no effects of
these antagonists were observed on ovalbumin-specific IgE levels in serum. From these data it can be
concluded that both histamine and 5-HT play a role in antigen-induced airway hyperresponsiveness and
eosinophilia.
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Introduction
Upon antigen challenge IgE-mediated mast cell degranulation occurs, which leads to an immediate
bronchoconstrictive reaction in patients with allergic asthma (6). Besides an immediate
bronchoconstriction, allergic asthma in humans is characterized by antigen-specific IgE in serum, airway
hyperresponsiveness and inflammation of lung tissue (5, 183). Furthermore, Th2 cells are thought to play
an important regulatory role in this disease (reviewed in 10, 184). We have developed a mouse model to
investigate several asthma related phenomena. Increased antigen-specific IgE levels in serum are
present and non-specific airway hyperresponsiveness and eosinophil infiltration in bronchoalveolar lavage
(BAL) fluid have been demonstrated (149, 170). It has also been shown that mast cell degranulation upon
antigen challenge occurs accompanied by an immediate bronchoconstriction and an increase in mucosal
exudation (170). Besides a role in early asthmatic reactions, mast cells have also been implicated in the
development of airway hyperresponsiveness. Using mast cell deficient mice, Nagai et al. demonstrated
that mast cells play an important role in the onset of airway hyperresponsiveness (15). Furthermore, mast
cell activation enhances antigen-induced airway hyperresponsiveness to methacholine in mice (173).
Besides a role in airway hyperresponsiveness, mast cells are also believed to play a central role in
allergic inflammation via release of cytokines, including IL4 and IL5 (185). In contrast, using mast cell
deficient mice, mast cells were shown not to be important for the induction of chronic airway inflammation
(15, 186).
Murine mast cells are known to release both histamine and serotonin (5-hydroxytryptamine, 5-HT) upon
stimulation in vivo (152, 153). Both histamine and 5-HT have been shown to induce IL16 production by
CD8+ T cells (79, 80). IL16, previously known as lymphocyte chemoattractant factor (LCF, 90), is a potent
chemoattractant for human eosinophils (95) and CD4+ T cells (90), which are thought to play a central
role in the pathogenesis of asthma (10). Interestingly, we recently have shown that, upon antigen-
challenge, presence of IL16 in BAL fluid derived from ovalbumin-sensitized and challenged animals can
be detected (154), which is in agreement with the presence of IL16 in human asthmatics (26). In addition,
treatment with neutralizing antibodies to IL16 has an inhibitory effect on airway hyperresponsiveness in
our animal model (154). Other pro-inflammatory actions by histamine and 5-HT include an increase in
vascular permeability, mucus production and various T-cell related effects (158, 187-190).
Since both histamine and 5-HT can be released by murine mast cells upon antigen challenge (152, 153),
we wanted to investigate the role of histamine and 5-HT on asthma-related features. We therefore
measured the presence of IL16 in BAL fluid, in vivo airway responsiveness to methacholine, inflammatory
cell infiltration into the airways and serum levels of antigen-specific IgE after treatment with selective 5-HT
or histamine receptor antagonists in a murine model of allergic asthma.
Materials and Methods
Sensitization and challenge
Specified pathogen free male BALB/c mice (age 6-8 weeks) were obtained from the breeding colony of
the Central Animal Laboratory (GDL), Utrecht, The Netherlands. The mice were housed in macrolon
cages and provided with food and water ad libitum. Active sensitization was performed by 7
intraperitoneal injections of 10 m g ovalbumin (grade V) in 0.5 ml pyrogen free saline on alternate days.
This sensitization procedure has been shown to induce high titres of total immunoglobulin E antibodies in
the serum, of which 80% was ovalbumin-specific (152). Four weeks after the last injection, the mice were
exposed either to 8 ovalbumin (2 mg ml-1 in saline) or to 8 saline aerosols for 5 min, on consecutive days
(1 aerosol per day). The aerosols were generated with a jet nebulizer (Pari IS-2, Pari-Werk GmbH,
Starnberg, Germany) connected to a plexiglas exposure chamber with a volume of 5 l in which a
maximum of 6 animals was placed. One day before the challenge started and during the entire challenge
period, the mice were injected intraperitoneally twice a day with selective 5-HT-type 1 (5-HT1) or type 2 (5-
HT2) receptor antagonists (methiotepine, 1.25 mg kg-1or 2.0 mg kg-1; ketanserin, 12 mg kg-1) or selective
histamine-type 1 (H1) or type 2 (H2) receptor antagonists (mepyramine, 12 mg kg-1 or 20 mg kg-1;
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cimetidine, 10 mg kg-1 or 20 mg kg-1). Doses used were adapted from other studies in which mice were
treated with these receptor antagonists (191-193) or according to the manufacturer’s advice.
Furthermore, animals were injected with a combination of cimetidine (10 mg kg-1) and ketanserin (12
mg kg-1) or with an a -adrenoceptor antagonist (phentolamine, 5 mg kg-1) since ketanserin also has effects
on these receptors (194). Control mice were injected with 0.25 ml sterile saline.
Airway responsiveness in vivo
Airway responsiveness was measured in vivo 24h after the last aerosol exposure using a modified
plethysmograph as described by Corry et al. (13). In short; mice were anesthetized by intraperitoneal
injection of urethane (2 g kg-1), and placed on a heated blanket (30°C). Then, the trachea was cannulated
and a small polyethylene catheter was placed in the jugular vein for intravenous administrations.
Spontaneous breathing of the animals was suppressed by intravenous injection of tubocurarine chloride
(3.3 mg kg-1). When the breathing stopped, the tracheal cannula was attached to a ventilator (C.F.
Palmer, London, UK). The inflation volume of the ventilator was 0.8 ml of which the mouse inhales
approximately 0.15 ml per breath with a rate of 200 breaths per min. Under these conditions, mice
maintain physiologic arterial blood gas parameters (data not shown). Changes in resistance were
measured by use of a plethysmograph, coupled to a pressure transducer (M45, Validyne Engineering
Corp. Northridge, CA, USA). By use of a pulmonary mechanics analyzer (Model 6, Buxco Corp., Sharon,
CT, USA), lung resistance (RL) was measured by quantitating D PtD V-1 (D Pt = change in tracheal
pressure, D V = change in flow) at points of equal volume (70% tidal volume). Changes in tracheal
pressure were measured using a pressure transducer connected to the tracheal ventilation cannula,
changes in flow were measured by use of a pressure transducer connected to the plethysmograph
(pressure changes were calibrated to changes in volume over the physiologic range studied). At time
intervals of at least 4 min and after the response had returned to baseline level, doses of methacholine
ranging from 40 m g kg-1 to 640 m g kg-1 were administered via the jugular catheter. Concentrations of
methacholine were prepared in saline and kept on ice for the duration of the experiment. For each dose of
methacholine the increase in airway resistance was measured at its peak and expressed in cm
H2O ml-1 s-1. At least 6 mice were evaluated per experimental group.
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed in the same animals that were used for airway
hyperresponsiveness measurements. In pilot experiments it was found that combining these techniques
had no effect on the total number of cells derived from the lavage nor on the appearance of the different
cell types. Mice were lavaged 5 times through the tracheal cannula with 1 ml aliquots of pyrogen free
saline at 37°C. The first aliquot was supplemented with the protease inhibitor aprotinine (2 mg ml-1) and
after centrifugation the supernatant of this first ml was stored at -80°C for cytokine measurements. The
BAL cells were washed with cold phosphate-buffered saline (PBS, 400xg, 4°C, 5 min) and the pellet was
resuspended in 200 m l cold PBS. The total number of BAL cells was counted by use of a Bürker-Türk
chamber. For differential BAL cell counts cytospin preparations were made and stained with Diff-Quick
(Merz & Dade A.G., Düdingen, Switzerland). After coding, all cytospin preparations were evaluated by
one observer using oil immersion microscopy. Cells were identified and differentiated into mononuclear
cells, neutrophils and eosinophils by standard morphology. At least 200 cells per cytospin preparation
were counted and the absolute number of each cell type was calculated.
Determination of ovalbumin-specific immunoglobulin E serum levels
Ovalbumin-specific IgE was measured in serum derived from blood isolated from mice after airway
responsiveness measurements were completed. Ninety-six well microplates (Nunc A/S, Roskilde,
Denmark) were coated with 2 m g ml-1 chimeric fusion protein of the human high affinity immunoglobulin E
receptor and human immunoglobulin G (Fce R1-IgG) diluted in PBS. After 12-24h incubation at 4°C the
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plates were washed 5 times with PBS supplemented with 0.05% Tween-20 (PBT). Thereafter, the plates
were blocked with ELISA buffer (2 mM EDTA, 136.9 mM NaCl, 50 mM Tris, 0.5% BSA , 0.05% Tween-20,
pH 7.2) and left to incubate at room temperature for 1 h on an orbital shaker. Serum samples derived
from ovalbumin-challenged animals were diluted 1:10, samples from saline-challenged animals 1:5 in
ELISA buffer. Then, diluted serum samples were added to the plates and left to incubate on an orbital
shaker at room temperature for 2h. Ovalbumin-IgE reference standard dilution series were treated the
same as the serum samples. The standard was obtained by intraperitoneal immunization of mice with
ovalbumin, and arbitrarily assigned a value of 1,000 units ml-1 ovalbumin-specific immunoglobulin E
(195). After washing, 10 m g ml-1 of ovalbumin in ELISA buffer was added to each well and after incubation
at room temperature for 1h washing procedures were repeated. Horse-radish peroxidase-conjugated goat
anti-ovalbumin antibody was diluted in ELISA buffer and added to each well. Incubation was continued for
1 h followed by washing procedures. The last step was a 15-30 min incubation at room temperature with
10 mM OPD substrate solution after which the reaction was stopped by adding H2SO4 (4M). OD was read
at l  492 nm using a Titertek Multiskan (Flow Labs., Irvine, UK).
IL16 migration assay
Since IL16 levels in BAL are to low for detection in a specific ELISA (detection limit 40 pg ml-1) a modified
Boyden chemotaxis chamber was used for IL16 measurements (75). In short, human lymphocytes were
isolated from heparinized venous blood samples of healthy normal volunteers by density centrifugation on
Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, NJ, USA). The cell layer containing peripheral
blood mononuclear cells was recovered and washed 3 times in Medium 199 supplemented with 25 mM
Hepes buffer, 100 units ml-1 penicillin, and 100 m g ml-1 streptomycin. The cells were incubated on a nylon
wool column at 37°C and 5% CO2 for 45 min. The cell population eluted from the column contained >97%
T-lymphocytes as determined by fluorescent staining with anti-CD3 monoclonal antibody (Becton-
Dickinson, Mountain View, CA, USA). 30 m l of BAL fluid derived from ovalbumin or saline-challenged mice
was placed in the lower well and the lymphocytes (1x107 cells in 50 ml Medium 199 enriched with 0.4%
bovine serum albumin) were loaded into the upper well of the Boyden chamber. For blocking
experiments, rabbit-anti-human IL16 polyclonal antibody was added to the lower well as well. In previous
experiments it was shown that 5 m g ml-1 anti-IL16 antibody neutralizes 0.1 nM of recombinant human IL16
protein. Antibodies to IL16 were only added if the migration was enhanced compared to medium induced
migration. The upper and lower well were separated by a nitrocellulose filter with a pore size of 8 m m. The
chamber was incubated for 3h and afterwards the filter was fixed and stained with hematoxylin. Migration
was quantified by counting the number of cells that migrated beyond a depth of 50 m m utilizing an
Optomax automated image analyzer (Burlington, MA, USA). All migration data are expressed as percent
values of cell migration in Medium 199 enriched with 0.4% bovine serum albumin, which was normalized
to 100%. All BAL samples were tested in triplicate.
Drugs and chemicals
Ovalbumin (chicken egg albumin crude grade V), o-phenylenediamine, 3-amino-1,2,4-triazole and
mepyramine were purchased from Sigma Chemical Company (St. Louis, MO, USA), recombinant human
Fce R1-IgG, horse-radish peroxidase-conjugated goat anti-ovalbumin antibody and ovalbumin-IgE
reference standard were generously provided by Dr. P.M. Jardieu, Genentech Inc. (South San Francisco,
CA, USA). Urethane and methacholine (acetyl-ß-methylcholine) were purchased from Janssen Chimica
(Beerse, Belgium), tubocurarine chloride from Nogepha (The Netherlands), Tween-20 from Merck
(Darmstadt, Germany) and phentolamine from Ciba Geigy (Basel, Switzerland). Cimetidine was
purchased from SmithKline Beecham (Irvine, U.K.) and ketanserin and methiotepine from ICN (Costa
Mesa, CA, USA).
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Statistical analysis
Whole concentration-response curves, total BAL cell number and the numbers of the various BAL cell
types were tested with an analysis of variance (ANOVA). For cell types with a very low number in control
animals (i.e. neutrophils and eosinophils) a Poisson distribution was assumed. Comparisons between 2
groups were made using a Student's t-test (unpaired, two-tailed). Data are expressed as arithmetic
average ± SEM and a difference was considered to be significant when P<0.05. Statistical analyses were
carried out using SPSS/PC+, version 4.0.1 (SPSS Inc., Chicago, IL, USA) or GLIM, version 4.0 (NaG Inc.,
Oxford, UK).
Figure 1
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Airway responsiveness to intravenous administration of methacholine in ovalbumin-sensitized mice at 24
h after the last challenge with saline (hatched bars) or ovalbumin (black bars) and treated with vehicle
(A), cimetidine (10 mg kg-1, B), ketanserin (12 mg kg-1, C) or a combination of cimetidine (10 mg kg-1) and
ketanserin (12 mg kg-1, D). Results are expressed as arithmetic average ± SEM (n=6 per group). *
(P<0.05); ** (P<0.01) significantly different from saline-challenged animals. # (P<0.05) significantly
different from vehicle-treated ovalbumin-challenged animals.
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Results
Airway resistance in vivo
Intravenous methacholine (480 m g kg-1) produced a 5-fold
increase in airway responsiveness after ovalbumin
challenge in vehicle-treated animals (P<0.05), whereas a
9-fold increase was observed both at 560 m g kg-1 and at
640 m g kg-1 methacholine, compared to vehicle-treated
saline-challenged mice (P<0.01, Figure 1A). Cimetidine-
treated (10 mg kg-1) ovalbumin-challenged animals
showed a partial but significant decrease in airway
hyperresponsiveness compared to vehicle-treated
ovalbumin-challenged mice (Figure 1A and B). At the
highest dose of methacholine (640 m g kg-1) the observed
decrease was 49% (P<0.05). However, airway
hyperresponsiveness was still present (P<0.05)
compared to cimetidine-treated saline-challenged
animals (Figure 1B). The dose of cimetidine used in this
study inhibited histamine-induced decrease in blood
pressure (data not shown). Ketanserin-treated animals
(12 mg kg-1) also showed a partial but significant
decrease in airway responsiveness compared to vehicle-
treated ovalbumin-challenged mice (Figure 1A and C). At
the highest dose of methacholine (640 m g kg-1) the
decrease was 36% (P<0.05). This decrease however,
was still significantly enhanced compared to ketanserin-
treated saline-challenged animals (P<0.05, Figure 1C).
Higher doses of ketanserin could not be used to further
inhibit development of airway hyperresponsiveness since
it was observed that ketanserin has sedative actions in
mice. No airway hyperresponsiveness could be observed
in animals treated with a combination of ketanserin (12 mg kg-1) and cimetidine (10 mg kg-1) compared to
their saline-challenged controls (Figure 1D). This combination caused a decrease in airway
responsiveness of 69% which was significantly different from vehicle-treated ovalbumin-challenged
animals (P<0.05, Figure 1A and D).
Complete dose-response curves were also made in animals treated with either a selective H1-receptor
antagonist (mepyramine, 12 mg kg-1), a 5-HT1-receptor antagonist (methiotepine, 1.25 mg kg-1) or an a -
adrenoceptor antagonist phentolamine (5 mg kg-1, results not shown). At the highest dose of
methacholine (640 m g kg-1) a significant airway hyperresponsiveness to methacholine was observed in
vehicle-treated mice after ovalbumin challenge (P<0.05) compared to saline-challenged animals
(Figure 2). Treatment with either the H1-receptor, the 5-HT1-receptor or the a -adrenoceptor antagonist
 did not decrease the observed ovalbumin-induced airway hyperresponsiveness (Figure 2).
Eosinophil infiltration
Cells in bronchoalveolar lavage fluid of animals collected at 24 h after the last challenge were
differentiated by light microscopy. No differences in infiltration of mononuclear cells or neutrophils
between all different antagonist treatments could be detected after either ovalbumin or saline challenge
(Tables I and II). Virtually no eosinophils could be detected in BAL fluid derived from saline-challenged
animals treated with vehicle, ketanserin, cimetidine or the combination of antagonists (Tables I and II).
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of methacholine in ovalbumin-sensitized
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challenge period. Results are expressed as
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* (P<0.05); ** (P<0.01) significantly different
from saline-challenged animals.
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After ovalbumin challenge of vehicle-treated animals a significant migration of eosinophils into the BAL
fluid was observed (15.0±5.9 x 104 cells, P<0.05). Treatment with either cimetidine (10 mg kg-1) or
ketanserin (12 mg kg-1) diminished the infiltration of eosinophils with 60% (6.2±3.9 x 104 cells) and 58%
(6.6±2.7 x 104 cells) respectively, compared to the number of eosinophils present in BAL fluid of vehicle-
treated ovalbumin-challenged animals. The combination of cimetidine and ketanserin inhibited the
eosinophil infiltration with 49% (8.0±5.0 x 104 cells, Table I). The higher dose of cimetidine (25 mg kg-1 did
not further diminish eosinophil infiltration (data not shown). No differences were observed in eosinophil
infiltration between vehicle-treated ovalbumin-challenged animals and methiotepine-, phentolamine-, or
mepyramine-treated ovalbumin-challenged animals (Table II). However, higher doses of either
methiotepine (2.0 mg kg-1) or mepyramine (20 mg kg-1) did decrease eosinophil infiltration with 67%
(1.7±1.3 x 105 cells, P=0.09) and 73% (1.4±1.0 x 105 cells, P<0.05) when compared to eosinophil
numbers in BAL fluid derived form vehicle-treated ovalbumin-challenged animals (5.3±1.4 x 105 cells).
Ovalbumin-specific IgE production
Serum levels of ovalbumin-specific IgE were determined in animals treated with vehicle, cimetidine (10 
mg kg-1), ketanserin (12 mg kg-1) or with a combination of both ketanserin (12 mg kg-1) and cimetidine (10
mg kg-1). A significant increase in the level of ovalbumin-specific IgE was found after ovalbumin challenge
of vehicle-treated animals (P<0.05, Table III). No significant differences were observed between the
ovalbumin-induced increase in serum ovalbumin-IgE levels in the groups of mice treated with different
antagonists. Furthermore, no significant differences were observed between the ovalbumin-induced
increase in ovalbumin-specific IgE levels in serum obtained from animals treated with the higher doses of
either mepyramine or methiotepine (data not shown).
Table I: Number of leukocytes in bronchoalveolar lavage fluid
Treatment Challenge Mononuclear
cells
x 105
Eosinophils
x 104
Neutrophils
x 104
Vehicle Sal 3.0±0.4 0.0±0.0 0.1±0.1
Ova 3.3±0.7 15±5.9 (*) 0.0±0.0
Cimetidine Sal 2.9±0.4 0.0±0.0 0.1±0.1
Ova 2.9±0.5 6.2±3.9 (*) 0.0±0.0
Ketanserin Sal 2.6±0.3 0.0±0.0 0.0±0.0
Ova 2.6±0.4 6.6±2.7 (*) 0.1±0.0
Cimetidine +
Ketanserin
Sal 2.5±0.2 0.1±0.1 0.1±0.0
Ova 2.4±0.5 8.0±5.0 (*) 0.1±0.1
Total number of various cell types in BAL fluid recovered at 24h after the last ovalbumin (Ova) or saline
(Sal) challenge in ovalbumin-sensitized mice treated with vehicle, cimetidine (10 mg kg-1), ketanserin (12
mg kg-1) or a combination of ketanserin ( 12 mg kg-1) and cimetidine (10 mg kg-1). Results are expressed
as arithmetic average ± SEM (n=6 per group). * (P<0.05) significantly different from saline-challenged
animals.
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IL16 levels in BAL
Migration of human lymphocytes induced by
BAL fluid collected from vehicle-treated
saline-challenged animals was significantly
less (87±3%) than migration induced by
medium (100%, P<0.05), indicating that
inhibitory factors are present in these BAL
fluid samples. BAL fluid samples from
ovalbumin-challenged vehicle-treated
animals induced a significant increase
(219±21%, P<0.05) of lymphocyte migration
compared to both medium controls and
BAL fluid from saline-challenged vehicle-
treated animals. Of this migration 80±21%
appeared to be due to IL16 as determined
by neutralizing polyclonal antibodies. BAL
fluid derived from ovalbumin-challenged
animals treated with either cimetidine,
ketanserin or the combination of these two
antagonists did not induce a significantly
Table II: Number of leukocytes in bronchoalveolar lavage fluid
Treatment Challenge Mononuclear
cells
x 104
Eosinophils
x 103
Neutrophils
x 103
Vehicle Sal   2.4±0.3   0.0±0.0   0.3±0.3
Ova   3.1±0.4   6.9±1.5 (*)   0.0±0.0
Methiotepine Sal   2.7±0.2   0.0±0.0   0.0±0.0
Ova   2.5±0.1   6.0±2.0 (*)   0.2±0.2
Phentolamine Sal   2.5±0.4   0.0±0.0   0.2±0.2
Ova   2.4±0.2    6.7±2.4 (*)   0.3±0.2
Vehicle Sal   2.3±0.1    0.0±0.0   0.2±0.1
Ova   2.1±0.3    6.6±2.7 (*)   0.0±0.0
Mepyramine Sal   2.0±0.4    0.0±0.0   0.0±0.0
Ova   2.1±0.3    6.9±2.2 (*)   0.0±0.0
Total number of various cell types in BAL fluid recovered at 24h after the last ovalbumin (Ova) or saline
(Sal) challenge in ovalbumin-sensitized mice treated with vehicle, methiotepine (1.25 mg kg-1) or
phentolamine (5 mg kg-1). In a different experiment, animals were treated with vehicle or mepyramine
(12 mg kg-1) Results are expressed as arithmetic average ± SEM (n=6 per group). * (P<0.05)
significantly different from saline-challenged animals.
Table III: Serum ovalbumin-specific IgE levels
Treatment Saline Ovalbumin
Vehicle 157±69   619±171 (*)
Cimetidine 235±84   960±182 (*)
Ketanserin 377±118   801±223
Combination 402±122 1141±220 (*)
Ovalbumin-specific Immunoglobulin E (IgE) levels
(arbitrary units ml-1) measured by ELISA in serum after
saline or ovalbumin challenge in ovalbumin-sensitized
mice after treatment with vehicle, cimetidine (10
mg kg-1), ketanserin (12 mg kg-1) or a combination of
cimetidine (10 mg kg-1) and ketanserin (12 mg kg-1).
Results are expressed as arithmetic average ± SEM (n
is at least 10 per group). * (P<0.05) significantly different
from immunoglobulin E level in serum from saline-
challenged animals.
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different lymphocyte migration when
compared to BAL fluid derived from
vehicle-treated ovalbumin-challenged
animals (Table IV). Furthermore, no
significant differences were observed in
the IL16 dependent part of this migration.
Finally, no differences were observed
between both the lymphocyte migration
and the IL16 attributable part of this
migration induced by BAL fluid samples
obtained from saline-challenged animals
of all different treatments (Table IV).
Discussion
Both the selective 5-HT2 receptor
antagonist ketanserin and the H2 receptor
antagonist cimetidine were capable of
partially decreasing airway
hyperresponsiveness and eosinophil
infiltration, whereas a combination of
ketanserin and cimetidine completely
inhibited airway hyperresponsiveness
without further decreasing eosinophil
numbers in BAL fluid. No effects of either
antagonist alone or the combination of
antagonists on ovalbumin-specific IgE
serum levels or on IL16 levels in BAL fluid
could be detected.
Previously we have developed a murine
model of allergic asthma that shows
several characteristics which are also
observed in human allergic asthma. Non-
specific airway hyperresponsiveness,
eosinophil infiltration and an increase in antigen-specific serum IgE levels are commonly observed in
human allergic asthma and can also be detected in this mouse model (148, 149, 170). Furthermore, upon
antigen challenge, an early bronchoconstrictive reaction together with an increase in mucosal exudation
can be measured, which is believed to be caused by mast cell degranulation after IgE cross-linking (170).
In humans, mast cell degranulation has also been observed after antigen challenge (6). This mast cell
degranulation is believed to play a pivotal role in the early asthmatic reaction and is implicated in the
onset of the inflammation via e.g. TNFa , IL4 and IL5 release (185, 196). Murine mast cells have been
shown to be capable of releasing both histamine and 5-HT (152, 153) but little is known about the role of
these autacoids in phenomena such as inflammation, IgE production and airway hyperresponsiveness.
Therefore, we treated mice with several different selective histamine or 5-HT receptor antagonists to
determine the role of histamine or 5-HT on these parameters.
A possible explanation for the results after treatment with H2 or 5-HT2 receptor antagonists or the
combination of these receptor antagonists could be impaired production of IL16. Upon stimulation of H2
and 5-HT2 receptors, IL16 is released by CD8+ T cells (79, 80). IL16 has been reported to be a very
potent chemoattractant for human eosinophils (95) and CD4+ T cells (90), which are believed to
contribute to airway hyperresponsiveness and inflammation (reviewed in 10, 184). In agreement herewith,
the development of ovalbumin-induced airway hyperresponsiveness was partially impaired by treatment
with monoclonal antibodies to IL16 (154), however, eosinophilia was not affected by treatment with IL16.
Table IV: Migration of lymphocytes induced by BAL fluid
samples
Treatment Total
migration
IL16 dependent
part of migration
Vehicle/Sal 
  87– 3%   0±0%
Vehicle/Ova 219– 21% (*) 80±21%
Cimetidine/Sal 153– 41% 36±30%
Cimetidine/Ova 176±42% 79±%35
Ketanserin/Sal 108±16% 13±12%
Ketanserin/Ova 198±51% 53±27%
Combination/Sal 112±15%   7±6%
Combination/Ova 214±46% 99±27%
Migration of lymphocytes induced by BAL fluid samples
derived from saline (Sal) or ovalbumin (Ova)-challenged
animals treated with either vehicle, cimetidine (10
mg kg-1), ketanserin (12 mg kg-1) or a combination of
cimetidine (10 mg kg-1) and ketanserin (12 mg kg-1).
Furthermore, the IL16 dependent part of the induced
migration is depicted. Results are expressed as
arithmetic average ± SEM (n is at least 5 per group).*
(P<0.05) significantly different from migration induced by
BAL fluid derived from saline-challenged vehicle-treated
animals.
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Thus, a likely explanation for the observed effects on airway hyperresponsiveness after treatment with
cimetidine and ketanserin could be that the release of IL16 is blocked by the antagonists used in this
study. However, in the present study IL16 levels in BAL fluid after ovalbumin challenge were not
decreased by treatment with either antagonist alone or the combination. Thus, it is not very likely that the
observed effects on airway hyperresponsiveness were caused by a decrease in IL16 release. Besides
CD8+ T cells, epithelial cells are a well known source of IL16 in asthmatics (26). Furthermore, IL16 can
also be produced by mitogen and antigen-stimulated mononuclear cells (29), and it is therefore possible
that IL16 levels in BAL were not decreased by H2 and 5-HT2 antagonists.
As was previously stated, mast cells can secrete both histamine and 5-HT (152, 153) and mast cells
degranulate upon antigen challenge in our model (170). Furthermore, it is well known that mast cells are
important in the onset of airway hyperresponsiveness (15, 173). Together with the observed effects of
both cimetidine and ketanserin on airway hyperresponsiveness, it is very tempting to speculate that mast
cells are involved in development of airway hyperresponsiveness via release of both histamine and 5-HT
upon antigen challenge. Our observation that treatment with ketanserin can decrease airway
hyperresponsiveness to methacholine is in agreement with observations made by Cazzola et al. (194)
who demonstrated that 5-HT2 receptor blocking can cause a small but significant modification of airway
hyperresponsiveness in human asthmatic patients. Besides being a 5-HT2 receptor antagonist,
ketanserin also has antagonistic activity on a -adrenoceptors (197). However, the observed inhibition of
airway hyperresponsiveness in our experiments after treatment with ketanserin was 5-HT2 receptor
specific since no effects were observed when either a 5-HT1 receptor antagonist or an a -adrenoceptor
antagonist were used. Treatment with cimetidine resulted in a partial inhibition of both airway
hyperresponsiveness and eosinophil infiltration. However, cimetidine is also capable of binding to H1
receptors although the affinity for H1 receptors is less than the affinity for H2 receptors (197). Furthermore,
H2 receptor antagonists prevent release of histamine and therefore it is difficult to analyze in vivo results
of treatment with such antagonists (198). The observation that H1 as well as 5-HT1 receptor antagonists
could reduce eosinophil infiltration at higher doses could be due to nonselective effects associated with
these high doses, e.g. on other histamine or 5-HT receptors. However, these data do not exclude the
involvement of H1 and 5-HT1 receptors in eosinophil infiltration upon antigen challenge.
An explanation for the observed effects on eosinophil infiltration and airway hyperresponsiveness could
be that both histamine and 5-HT have several pro-inflammatory effects. Therefore inhibition of the action
of these autacoids could lead to a decrease in inflammation and airway hyperresponsiveness. Histamine
e.g., has been reported to augment activation of cytotoxic T lymphocytes in vivo and production of IL2 in
vitro (199). Furthermore, histamine has been shown to inhibit IFNg  production in a H2 receptor restricted
manner (200). IFNg  is well known for its capabilities to down-regulate Th2-mediated responses such as
eosinophil infiltration and airway hyperresponsiveness (reviewed in 184). In contrast, histamine also has
immunosuppressive capacities such as inhibition of antigen- and mitogen-induced T cell responses and
production of cytokines including IL2, IL1 and TNFa  (196). Besides lymphocyte-mediated effects
histamine appears to be chemotactic for eosinophils when studied under in vivo and in vitro
circumstances, which is thought to be mediated via both H1 and H2 receptors (198). This would implicate
that the effects observed by either the H1 or H2 receptor antagonist are due to nonselective inhibition of
histamine receptors, which is in agreement with e.g. the observation that mepyramine only has an effect
on eosinophil infiltration when administered in high doses.
5-HT is involved in T cell activation (189), local recruitment and activation of CD4+ T helper cells (187,
188) and B cell proliferation (190). Therefore, it could be speculated that cimetidine and ketanserin exert
their activity via inhibition of lymphocyte functions. Little is known about the role of either histamine or 5-
HT in antibody production by B cells. However, since antigen-specific IgE levels in serum were not
affected by the different treatments it is not very likely that B cell functioning is impaired by one of the
antagonists alone or by the combination of cimetidine and ketanserin.
Another characteristic that could have contributed to the effects caused by cimetidine and ketanserin as
well as the higher doses of mepyramine and methiotepine, is that both histamine and 5-HT are able to
increase vascular permeability (158, 201). 5-HT has been clearly demonstrated to increase vascular
permeability via 5-HT2 receptor stimulation (201) whereas histamine has been reported mainly to induce
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vascular leakage upon H1 receptor stimulation. This seems to be in contrast with our observations that an
H2 receptor antagonist caused a decrease in airway hyperresponsiveness, whereas an H1 receptor
antagonist (12 mg kg-1) did not cause any effect. However, H1 receptor antagonists alone are less able to
prevent the increase in vasopermeability than combinations of H1 and H2 receptor antagonists in
preventing the increase in vasopermeability (158). Combined with the observations that cimetidine can
bind to both H2 and to H1 receptors (197) and that H2 receptor antagonists prevent histamine release
(198), it could therefore be speculated that cimetidine as well as ketanserin prevented the antigen-
induced increase in vasopermeability after ovalbumin challenge (170). An increase in vascular
permeability could not only lead to oedema of the airway wall which contributes to increased airway
hyperresponsiveness (197) but also to leakage of plasma proteins into the airways, which leads to an
increase of the viscosity of mucus (reviewed in 5). This increase in viscosity retards the mucociliary
clearance of mucus which constitutes an integral part of the inflammatory response (5). Moreover,
histamine is believed to play a direct stimulatory role on the mucus production in the lower airways via H2
receptor stimulation (158). It has previously been established in the used model that an ovalbumin-
induced increase in mucus exudation as well as goblet cell hyperplasia occurs (150). The observed
mucus production could very well predispose ovalbumin-challenged animals to air trapping, especially
after administration of a well known secretagogue for mucus such as methacholine. Thus, it could be
possible that the effects of either the histamine or 5-HT receptor antagonist on airway
hyperresponsiveness are caused by a decrease in antigen-induced mucus production or exudation.
The combination of both cimetidine and ketanserin did completely abolish airway hyperresponsiveness
without further decreasing eosinophil infiltration. The observation that eosinophilia and airway
hyperresponsiveness are not always closely related is in agreement with observations made both in
humans and animal models (148, 181). The observed effects of the combination of ketanserin and
cimetidine, could be due to a complete inhibition of the antigen-induced increase in vascular permeability,
mucus production and possibly T lymphocyte functioning by both histamine and 5-HT. However, since
eosinophil infiltration was not further decreased by the combination of antagonists it is not very likely that
the main effect of these antagonists is impairment of immune cell functions. If these antagonists would
have impaired T lymphocyte functions such as cytokine production, eosinophil infiltration would have
been completely blocked since it is generally accepted that Th2 type cytokines are crucial for
development of eosinophilia (reviewed in 184).
In conclusion, our data suggest that 5-HT and histamine are mediators of antigen-induced airway
hyperresponsiveness and, to a lesser degree, of inflammation in the mouse. Furthermore, it can be
speculated that these actions probably take place via 5-HT2 and H2 receptors. Since a combination of
both antagonists completely inhibited airway hyperresponsiveness it can also be concluded that these
antagonists act in an additive way. However, the exact mechanism by which these antagonists exert their
action on asthma related features and via which receptors remains to be elucidated.
Acknowledgments: The authors would like to thank Dr. D van Heuven-Nolsen and D. van Velsen for
their useful advice and comments as well as for performing the blood-pressure measurements in
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Summary
In this study we examined whether peptides based on the hydrophilic CD4-binding part of the amino acid
sequence of hIL16 can block IL16-induced chemotaxis of murine lymphocytes in vitro. Next, we
compared the effects of intra-airway administration of these peptides with antibodies to IL16 on antigen-
induced features in a murine model of allergic asthma. Peptide 3 inhibited IL16-induced chemotaxis of
murine splenocytes in vitro.  Furthermore, intra-airway administration of peptide 3 largely inhibited the
development of antigen-induced airway hyperresponsiveness while airway eosinophilia was not affected.
Similar effects were observed after intranasal application of antibodies to IL16. These results indicate that
treatment with peptide 3 causes the same effects as antibodies to IL16, possibly via inhibition of
interaction between IL16 and its receptor CD4. Therefore, peptide 3 could be useful as a lead compound
in attempting to limit airway hyperresponsiveness via binding to CD4.
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Introduction
Human allergic asthma is characterized by airway hyperresponsiveness and infiltration of lymphocytes
and eosinophils in the lungs (10). There is an increasing amount of evidence that CD4+ T cells play a
crucial role in orchestrating these different phenomena by production of Th2-type cytokines, including IL4
and IL5 (10, 159).
Besides IL4 and IL5 many other cytokines have been associated with the pathology of asthma, one of
them being IL16 (29). Interleukin-16, has been demonstrated to use the CD4 molecule as its receptor.
Upon binding and cross-linking of CD4 molecules, activation of several second messengers, including
p56lck and PKC, occurs (101, 202, 203). Furthermore, IL16 can evoke different functional responses in
CD4+ cells. One of the most extensively described actions of CD4 cross-linking by IL16 is the induction of
chemotaxis in vitro (74). It has been demonstrated that IL16 can induce such responses in various CD4+
cells, including eosinophils, monocytes and T helper cells (29, 90). Other biological effects of IL16 include
induction of IL2R expression and upregulation of HLA-DR expression in human lymphocytes (29, 90).
Both CD4+ and CD8+ T cells constitutively express messenger RNA for IL16 and the biologically active
protein is secreted from CD8+ T cells after stimulation with either histamine or 5-hydroxytryptamine (5-
HT, 79, 80). Furthermore, CD4+ T cells release IL16 after mitogen, antigen or anti-CD3 stimulation
(29). Bioactive IL16 can also be produced by eosinophils, mast cells and epithelial cells (81, 82, 94).
These data suggest that IL16 may be involved in the pathophysiology of asthma. Indeed, in patients
with allergic asthma as well as in a murine model of allergic asthma IL16 expression in epithelial cells
and presence of bioactive IL16 in bronchoalveolar lavage fluid after antigen-challenge has been
observed (26, 154). Interestingly, inhibition of endogenous IL16 by intraperitoneal administration of
antibodies to IL16 has been demonstrated to partially decrease airway hyperresponsiveness but did
not affect the number of eosinophils in bronchoalveolar lavage fluid in a murine model of allergic
asthma (154).
In a previous study, Keane et al. demonstrated that peptide 3 which is based on the predicted amino
acid sequence of one of the hydrophilic C-terminal regions of IL16 is capable of partially inhibiting
rhIL16-induced chemotaxis of PBMCs (76). They also demonstrated that this peptide displaced OKT4
binding to CD4 molecules. These data suggest that the C-terminal hydrophilic domain of IL16 is
involved in binding to CD4 and is critical for induction of chemotaxis in CD4+ cells (76). Additionally,
these data suggest that this peptide might inhibit IL16-induced activity by binding to CD4 molecules,
thereby preventing cross-linking of CD4 molecules by IL16. Finally, sequence homology of murine and
human IL16 is over 80% and cross-specificity is nearly 100% since identical effects were observed on
Figure 1
1     MDYDFDTTAE DPWVRISDCI KNLFSPIMSE NHGHMPLQPN ASLNEEEGTQ GHPDGTPPKL
61    DTANGTPKVY KSADSSTVKK GPPVAPKPAW FRQSLKGLRN RASEPRGLDP PALSTQPAPA
121   SREHLGSHIR ASSSSSSIRQ RISSFETFGS SQLPDKGAQR LSLQPSSGEA AKPLGKHEEG
181   RFSGLLGRGA APTLVPQQPE QVLSSGSPAA SEARDPGVSE SPPPGRQPNQ KTFPPGPDPL
241   LRLLSTQAEE SQGPVLKMPS QRARSFPLTR SQSCETKLLD EKTSKLYSIS SQVSSAVMKS
301   LLCLPSSISC AQTPCIPKAG ASPTSSSNED SAANGSAETS ALDTGFSLNL SELREYTEGL
361   TEAKEDDDGD HSSLQSGQSV ISLLSSEELK KLIEEVKVLD EATLKQLDGI HVTILHKEEG
421   AGLGFSLAGG ADLENKVITV HRVFPNGLAS QEGTIQKGNE VLSINGKSLK GTTHHDALAI
481   LRQAREPRQA VIVTRKLTPE AMPDLNSSTD SAASASAASD VSVESTAEAT VCTVTLEKMS
                               
 
peptide 1
541   AGLGFSLEGG KGSLHGDKPL TINRIFKGAA SEQSETVQPG DEILQLGGTA MQGLTRFEAW
                                         
peptide 2
601   NIIKALPDGP VTIVIRRKSL QSKETTAAGDS
                           
peptide 3
Alignment of the predicted human pro-IL16 amino acid sequence of the longest open reading frame
(Adapted from Keane et al., (76). Genbank database accession number M90391. Underlined sequences
represent the predicted amino acid sequences on which the different oligopeptides were based.
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migration of human or murine CD4+ T lymphocytes by either rhIL16 or rmIL16 and this
chemoattracting activity could be blocked by anti-human IL16 mAb (clone 14.1, 76).
In the present study we examined the effect of different peptides based on the predicted amino acid
sequence of IL16 on rmIL16-induced chemotaxis of lymphocytes in vitro. Next, we examined the
effects of intranasal administration of these peptides on airway hyperresponsiveness and eosinophilia
in a murine model of asthma. In addition we compared the effects of local administration of these
peptides with administration of antibodies to IL16 on these parameters.
Materials and Methods
Peptides and antibodies
Synthetic oligopeptides corresponding to three hydrophilic domains identified within the hIL16 sequence
were used in this study. The single letter amino acid codes of the different peptides are: MPDLNSSTDSA
(based on amino acids 502-512, Figure 1), designated peptide 1, AASEQSETVQPGDEIL (based on
amino acids 569-584, Figure 1), designated peptide 2 and RRKSLQSKETTAAGDS, peptide 3 (based on
amino acids 616-631, Figure 1). Peptides were produced as previously published (76). Monoclonal
antibodies to hIL16 (clone 14.1) were verified by western blotting with rhIL16 and shown to be neutralizing
by inhibition of chemoattractant activity, IL2 receptor expression and human immunodeficiency virus
(HIV)-1 repression in IL16-treated cells (68, 69). Furthermore, it is known that amino acid sequences of
rhIL16 and rmIL16 are over 80% homologous and share several biological functions, including induction
of chemotaxis with no apparent differences in cross-specificity (76).
Cell isolation and chemotaxis assay
Murine splenocytes were isolated from euthanized BALB/c mice and maintained in RPMI 1640 medium
(Bio-Whittaker, Walkersville, MD) supplemented with 10% FCS and 100 units ml-1 of both penicillin and
streptomycin (complete medium). Erythrocytes were lysed by suspension in one part complete medium to
three parts Gey's solution. This mixture was incubated on ice for 2 min. The reaction was stopped by the
addition of 10 parts complete medium and the cells were then washed twice in complete medium before
use in experiments.
Chemotaxis was performed using a modified Boyden chamber assay as described previously (74, 75).
Cells were suspended at 5x106 ml-1 in complete medium and incubated for 15 min with or without the
different peptides at a concentration of 5 m g ml-1. A nitro-cellulose membrane with a pore size of 12 m m
separated cells in the upper wells from control buffer or experimental supernatants in the lower wells.
Supernatants in the lower wells consisted of rmIL16 (100 nM) or medium alone. Chambers were
incubated at 37° C for 4h, then the membranes were removed, stained with hematoxylin and dehydrated
by sequential washes in ethanol, propanol, and finally xylene. Cell migration was quantitated by light
microscopy, counting the number of cells migrating below a depth of 50 m m. All samples were tested in
duplicate, and four high power fields were examined in each duplicate. Chemotaxis induced by medium
alone was normalized to 100%. In previous experiments it was shown that 5 m g ml-1 anti-IL16 antibody
(clone 14.1) neutralizes chemotaxis induced by 0.1 nM of recombinant human IL16 protein.
Sensitization and challenge
Specified pathogen free male BALB/c mice (age 6-8 weeks) were obtained from the breeding colony of
the Central Animal Laboratory (The Netherlands). All experiments were approved by the animal care
committee of the Utrecht University. The mice were housed in macrolon cages and provided with food
and water ad libitum. Active sensitization was performed by 7 intraperitoneal injections of 10 m g
ovalbumin (grade V) in 0.5 ml pyrogen free saline on alternate days. Four weeks after the last injection,
the mice were exposed either to 8 ovalbumin (2 mg ml-1 in saline) or saline aerosols for 5 min, on
consecutive days (1 aerosol per day). The aerosols were generated with a jet nebulizer (Pari IS-2, Pari-
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Werk GmbH, Starnberg, Germany) connected to a plexiglas
exposure chamber with a volume of 5 l in which a maximum of
6 animals was placed. Approximately 30 min before each
antigen exposure, the mice were treated intranasally with
peptides based on the predicted sequence of IL16 (76) after
inhalation of a short lasting anesthetic (Halothane, ALBIC BV,
Maassluis, The Netherlands). Peptides 1 and 3 were tested at
a dose of 100 m g day-1. In a different series of experiments
peptides 2 and 3 were tested in higher doses (240 m g day-1).
The effects of local administration of anti-hIL16 or control
antibodies were also determined. In this experiment animals
were intranasally treated on the first and fifth day of the
challenge period with either mIgG2a or anti-IL16 monoclonal
antibodies (500 m g per mouse) at 30 min before the antigen or
saline challenge.
Airway responsiveness in vivo
Airway responsiveness was measured in vivo 24 h after the
last aerosol exposure using a modified plethysmograph as
described previously (177). In short: mice were anaesthetized
by intraperitoneal injection of urethane (2 g kg-1), and placed
on a heated blanket (30°C). The trachea and jugular vein were
cannulated. Spontaneous breathing of the animals was
suppressed by i.v. injection of tubocurarine chloride (3.3
mg kg-1). The tracheal cannula was attached to a ventilator
(model 687, Harvard Apparatus, Southnatick, MA, USA). The
mice maintain physiologic arterial blood gas parameters (data
not shown). Changes in flow and pressure were measured
using a plethysmograph coupled to pressure transducers
(M45, Validyne Engineering Corp. Northridge, CA, USA). Lung resistance ( RL ) was measured by
quantitating D
D
V
Pt
 (
D Pt  = change in tracheal pressure, D V  = change in flow) at points of equal volume
(70% tidal volume) using specific software (Model 6, Buxco Corp., Sharon, CT, USA). After the response
had returned to baseline level (after at least 4 min), doses of methacholine ranging from 40 to 640 m g kg-1
were administered via the jugular catheter. For each dose of methacholine the increase in airway
resistance was measured at its peak and expressed in cm H2O ml-1 sec-1. At least 6 mice were evaluated
per experimental group.
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed in the same animals that were used for airway
hyperresponsiveness measurements. Mice were lavaged 5 times through the tracheal cannula with 1 ml
aliquots of pyrogen free saline at 37°C. The BAL cells were washed with cold phosphate-buffered saline
(PBS, 400xg, 4°C, 5 min) and the pellet was resuspended in 200 m l cold PBS. The total number of BAL
cells was counted by use of a Bürker-Türk chamber. For differential BAL cell counts cytospin preparations
were made and stained with Diff-Quick (Merz & Dade A.G., Düdingen, Switzerland). After coding, all
cytospin preparations were evaluated by one observer using oil immersion microscopy. Cells were
identified and differentiated into mononuclear cells, neutrophils and eosinophils by standard morphology.
At least 200 cells per cytospin preparation were counted and the absolute number of each cell type was
calculated.
Figure 2
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The effects of different peptides on
IL16-induced (100 nM) chemotaxis
(black bars) was tested. Chemotaxis
of mouse splenocytes was compared
to complete medium (hatched bars,-)
or to the effect of the different peptides
without IL16 (hatched bars, 1, 2 or 3).
Results are expressed as arithmetic
average ± SEM. * (P<0.05)
significantly different from control
chemotaxis induced by medium or by
the different peptides alone. #
(P<0.05) significantly different from
IL16-induced chemotaxis.
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Drugs and chemicals
Ovalbumin (chicken egg albumin crude grade V) and o-phenylenediamine were purchased from Sigma
Chemical Company (St. Louis, MO, USA). Urethane and methacholine (acetyl-ß-methylcholine) were
purchased from Janssen Chimica (Beerse, Belgium), tubocurarine chloride from Nogepha (The
Netherlands) and Tween-20 from Merck (Darmstadt, Germany).
Figure 3
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Airway resistance after intravenous administration of methacholine in ovalbumin-sensitized mice at 24 h
after the last challenge with saline (hatched bars) or ovalbumin (black bars) and intranasally treated daily
during the challenge period with control peptides (100 
m
g day-1, A or 240 
m
g day-1, C). Furthermore,
animals were treated with peptide 3 (100 
m
g day-1, B or 240 
m
g day-1, D). Results are expressed as
arithmetic average ± SEM of 5-6 animals per group. * (P<0.05); ** (P<0.01) significantly different from
saline-challenged animals. # (P<0.05) significantly different from control peptide-treated ovalbumin-
challenged animals.
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Statistical analysis
Total BAL cell number and the numbers of the various BAL
cell types were tested with an analysis of variance
(ANOVA). For cell types with low numbers, e.g. eosinophils
or neutrophils, a Poisson distribution was assumed. Data
on airway responsiveness were tested for significance
using ANOVA followed by post-hoc comparison using
Bonferroni. Data are expressed as arithmetic average ±
SEM and a difference was considered to be significant
when P<0.05. Statistical analyses were carried out using
SPSS/PC+ (SPSS inc. Chicago, IL).
Results
Chemotaxis assay
The effects of peptides 1, 2 and 3 were measured on
rmIL16-induced mouse lymphocyte motility. Lymphocyte
motility induced by medium alone was normalized to 100%.
The IL16-induced chemoattractive activity amounted to
203– 7%, which was significantly (P<0.05) inhibited by
peptide 3 to 124– 8% (Figure 2). Incubation of the target
cells with either peptide 1 or 2 did not result in any
detectable decrease in IL16-induced chemotaxis (Figure 2).
Furthermore, peptides 1, 2 and 3 did not induce any
chemotaxis by themselves when compared to chemotaxis
induced by medium alone (Figure 2).
Airway resistance in vivo
Peptides 1 and 2 did not inhibit chemotaxis in vitro
(Figure 2) and were therefore used as control peptides in
the in vivo studies. Peptide 1 was used as control peptide
at a dosage of 100 m g day-1, whereas peptide 2 was used
as control at a higher dose (240 m g day-1). In animals
treated daily intranasally with control peptides airway
hyperresponsiveness after ovalbumin challenge was
observed when compared with saline-challenged animals.
In animals treated with control peptide (100 m g day-1)
airway resistance in ovalbumin-challenged animals was
significantly (P<0.01) enhanced to 127– 1
cm H2O ml-1 sec-1, as compared with saline-challenged
animals (20– 16 cm H2O ml-1 sec-1, Figure 3A). In animals
treated with control peptide at a higher dose (240 m g day-1)
airway resistance in response to 640 m g kg-1 methacholine
amounted to 116– 9 cm H2O ml-1 sec-1 after ovalbumin challenge, whereas in saline-challenged animals
airway resistance amounted to 11– 5 cm H2O ml-1 sec-1 (P<0.05, Figure 3C). Treatment with peptide 3
(100 m g day-1) however, significantly (P<0.05) reduced the ovalbumin-induced airway
hyperresponsiveness with 57% to 54– 30 cm H2O ml-1 sec-1 at the highest dose of methacholine, when
compared with ovalbumin-challenged control peptide-treated mice (Figure 3B). A higher dose of peptide 3
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(240 m g day-1) did not further reduce airway resistance
to methacholine (64– 19 cm H2O ml-1 sec-1 at the
highest dose of methacholine, Figure 3D). No
significantly different effects were observed between all
differently-treated saline-challenged animals.
In animals treated intranasally with mIgG2a and
challenged with saline airway responses to the highest
dose of methacholine (640 m g kg-1) amounted to 23– 10
cm H2O ml-1 sec-1, whereas in ovalbumin-challenged
animals airway responses were significantly (P<0.01)
enhanced to 126– 1 cm H2O ml-1 sec-1 (Figure 4A).
Treatment of ovalbumin-challenged mice with
antibodies to IL16 (500 m g at day 1 and 5) significantly
decreased airway resistance with 59%, when
compared to mIgG2a-treated ovalbumin-challenged
animals. However, this airway resistance was still
significantly (P<0.05) enhanced when compared to
saline-challenged anti-IL16-treated animals (12– 5
cm H2O ml-1 sec-1, Figure 4B).
Cellular infiltration into bronchoalveolar lavage fluid
No or hardly any eosinophils could be detected in BAL
fluid derived from saline-challenged animals treated
with the different peptides, mIgG2a or anti-IL16
(Table I). In all differently-treated animals ovalbumin
challenge caused an infiltration of eosinophils into the
BAL fluid (Table I). However, no significant effects of
the different treatments of ovalbumin-challenged
animals on this eosinophilic infiltration were detected.
Furthermore, no significant differences in infiltration of
mononuclear cells or neutrophils were observed
between different treatment groups (data not shown).
Finally, no differences were observed in total number
of cells between the different treatment groups (data
not shown).
Discussion
The study described in this report illustrates that peptide 3, which is based on the predicted amino acid
sequence of hIL16 is capable of inhibiting rmIL16-induced chemotaxis of murine splenocytes. Peptide 3
also largely inhibits antigen-induced airway hyperresponsiveness in a murine model of allergic asthma,
whereas eosinophilic infiltration is not significantly altered. Furthermore, we demonstrate that local
administration of antibodies to IL16 also decreased airway hyperresponsiveness without affecting
eosinophil infiltration, which is in agreement with previous experiments in which antibodies to IL16 were
intraperitoneally administered (154). Peptides 1 and 2 were based on different C-terminal located regions
of the predicted amino acid sequence of hIL16. These peptides have been demonstrated not to interfere
with IL16-induced chemotaxis in vitro in this study or with OKT4 binding to CD4 in another study (76).
Therefore we have used these two peptides as control peptides.
Table I: Number of inflammatory cells in
lavage fluid
Treatment/
Challenge
Dosage
( m g day-1)
Eosinophils
(%)
Control/Sal   100     2±1
Control/Ova   100   42±11 (*)
Peptide 3/Sal   100     1±1
Peptide 3/Ova   100   54±10 (*)
Control/Sal   240     1±0
Control/Ova   240   14±2 (*)
Peptide 3/Sal   240     1±0
Peptide 3/Ova   240   23±5 (*)
mIgG2a/Sal   500     0±0
mIgG2a/Ova   500   14±9 (*)
anti-IL16/Sal   500     2±1
anti-IL16/Ova   500   21±8 (*)
Percentage of eosinophils present in
bronchoalveolar lavage fluid of ovalbumin-
sensitized and saline (Sal) or ovalbumin
(Ova)-challenged mice. Data are expressed
as mean –  SEM. During the challenge
period, the mice were intranasally treated on
a daily basis with control peptide or peptide
3 (100 m g day-1, 30 min before each aerosol
challenge). In a different experiment mice
were treated daily during the challenge
period with either control peptide or peptide
3 (240 m g day-1, 30 min before each aerosol
challenge) or with either mIgG2a or
antibodies to IL16 (500 m g mouse-1 on the
first and fifth day of the challenge period). *
(P<0.05) significantly different from saline-
challenged animals.
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Recently, it has been observed that in antigen-exposed asthmatics as well as in our murine model for
allergic asthma, IL16 expression in epithelial cells and presence of bioactive IL16 in BAL fluid is
upregulated (26, 154). IL16 is a natural soluble ligand for CD4, which activates several CD4-associated
second messengers and induces chemotaxis of CD4+ cells, including T-lymphocytes, monocytes and
eosinophils in vitro (29, 90). So far, no evidence exists on the induction of chemotaxis of CD4+ cells in
vivo. The amino acid sequence of peptide 3 is based on a hydrophilic C-terminal region of hIL16. This
region of hIL16 is very likely to be exposed on the surface of the molecule (76). In this study we
demonstrated that peptide 3 was capable of inhibiting rmIL16-induced chemotaxis of mouse splenocytes
in vitro. In agreement herewith, it was shown in previous experiments that peptide 3 is capable of
decreasing rhIL16 induced chemotaxis of human CD4+ cells (76). Furthermore, peptide 3 can partially
prevent the binding of monoclonal antibodies to CD4 (76). These data, together with the observation that
IL16 uses CD4 as receptor, suggest that the C-terminal hydrophilic region of IL16 is involved in binding of
CD4. Furthermore, these data suggest that peptide 3 interacts with CD4, thereby inhibiting cross-linking
by IL16 and subsequent signaling.
Recently, it has been observed that intraperitoneal administration of antibodies to IL16 can partially inhibit
airway hyperresponsiveness, whereas eosinophilia was not affected (154). In the present study it was
demonstrated that inhibition of IL16 interaction with CD4 by peptide 3 has similar effects as inhibition of
IL16-induced effects by intraperitoneal administration of anti-IL16. Furthermore, as described in this
study, local administration of anti-IL16 also largely inhibits airway hyperresponsiveness without affecting
eosinophil infiltration.
It has been demonstrated that IFN g  plays an important role in the induction of airway
hyperresponsiveness in our murine model since administration of antibodies to IFNg  can inhibit
development of airway hyperresponsiveness without affecting eosinophil numbers in BAL fluid (148).
From that study it can thus be concluded that airway hyperresponsiveness and eosinophilia are not
causally related in this model as has also been observed before in another murine model of allergic
asthma (13). Production of IFNg  by human peripheral blood mononuclear cells can be detected after
incubation in vitro with a combination of IL16 and IL2 (88). Therefore, if peptide 3 inhibits cross-linking of
CD4 molecules by IL16 and subsequent local IFNg  production, it could be speculated that airway
hyperresponsiveness is decreased, whereas eosinophilia is not affected. The same could be true for the
effects of antibodies to IL16. In contrast, others have demonstrated that IFNg  is a potent down regulator of
development of airway hyperresponsiveness in different animal models (204, 205). Therefore, at present
no definite conclusions can be drawn on how IL16 plays a role in development of airway
hyperresponsiveness in this murine model. Furthermore, if peptide 3 decreases airway
hyperresponsiveness via prevention of IL16-CD4 interaction, it can also not be excluded that peptide 3
has direct effects on other CD4+ cells, e.g. monocytes or dendritic cells.
In this study airway eosinophilia was not inhibited by intra-airway treatment with either anti-IL16 or peptide
3. Endogenous IL16 could be important for the induction of airway hyperresponsiveness via recruitment
of CD4+ cells, including eosinophils. However, intraperitoneal or local administration of antibodies to IL16
did not affect eosinophilia in this and other studies (154). From previous studies it is known that murine
eosinophils do not express CD4 on their membrane as determined by FACS analysis (E.M. Hessel,
personal communication). Furthermore, it has been described that IL16 does not prime or activate
eosinophils in vitro (95). Finally, in vivo chemotaxis of CD4+ cells, including eosinophils, by IL16 could not
be detected (J.J. de Bie, unpublished observations) and therefore inhibition of chemotaxis of eosinophils
or lymphocytes by peptide 3 or the antibodies to IL16 is not very likely.
Previously, it was demonstrated that inhibition of endogenously produced IL16 by intraperitoneal
treatment with anti-IL16 inhibits production of antigen-specific IgE (154). In agreement herewith, local
administration of anti-IL16 also inhibited the upregulation of antigen-specific IgE levels in serum after
ovalbumin-challenge (data not shown). However, no effects of peptide 3 on IgE production were observed
(data not shown). It could thus be speculated that peptide 3 has a lower stability or half-life than
antibodies to IL16. However, further research is necessary to elucidate the exact mechanism by which
antibodies to IL16 do inhibit IgE production whereas peptide 3 does not.
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In conclusion, our data suggest that peptide 3, which is based on the predicted amino-acid sequence of
IL16, can significantly inhibit airway hyperresponsiveness, whereas eosinophilia is not affected. Our
results also show that treatment with peptide 3 has the same effects as antibodies to IL16, possibly via
inhibition of interaction between IL16 and its receptor CD4. Therefore, peptide 3 could be useful as a lead
compound in attempting to limit airway hyperresponsiveness via binding to CD4.
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Summary
Allergic asthma is characterized by chronic eosinophilic airway inflammation and by airway
hyperresponsiveness to bronchoconstrictive stimuli. CD4+ type-2 T cells are thought to regulate these
allergic manifestations via production of cytokines such as IL4, IL5 and IL13. IL16 has been described
as a natural soluble ligand for the CD4 molecule with immunosuppressive effects on CD4+ T
lymphocytes in vitro. However, little is known about the effect of IL16 on CD4+ T lymphocyte mediated
immune responses in vivo. In the present study, we examined the potential therapeutic effect of
treatment with IL16 on antigen-induced allergic inflammation and airway hyperresponsiveness.
Treatment with IL16 resulted in a complete inhibition of antigen-induced airway hyperresponsiveness
as well as a strong decrease (>90%) in the number of eosinophils in bronchoalveolar lavage. Next, we
determined whether these effects were mediated by modulation of CD4+ T lymphocytes. First, it
appeared that thoracic lymph node (TLN) cells from in vivo IL16-treated ovalbumin-challenged animals
produced significantly less IL4 (77% reduction) and IL5 (85% reduction) when compared to vehicle-
treated mice. Second, preincubation of TLN cells isolated from ovalbumin-challenged animals with
IL16 in vitro induced a reduction in Th2 type cytokine production and proliferation. It can be concluded
that IL16 is able to inhibit antigen-induced allergic airway responses, which is probably mediated by
inhibition of Th2-type cytokine production. Thus, it can be speculated that IL16 may be of therapeutic
importance in the treatment of allergic asthma.
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Introduction
IL16 is released by CD4+ T cells following mitogen, antigen or anti-CD3 stimulation (29). However, T-
lymphocytes are not the only cellular source of IL16 since it has been shown that both eosinophils and
epithelial cells can release bioactive IL16 (26, 81, 94). Messenger RNA for IL16 is constitutively
expressed in CD4+ and CD8+ T cells and the biologically active protein is secreted from CD8+ T cells
upon stimulation with either histamine or 5-hydroxytryptamine (5-HT, 79, 80).
In previous studies we demonstrated that IL16 immunoreactivity is present in epithelial cells of
ovalbumin-sensitized mice but not in those from naïve animals (154). Upon antigen-challenge, an
increase in epithelial IL16 expression was observed, as well as IL16 expression in inflammatory cell
infiltrates (154). Moreover, presence of IL16 bioactivity in bronchoalveolar lavage (BAL) fluid was
detected. Interestingly, in patients with allergic asthma, IL16 expression in epithelial cells and
presence of bioactive IL16 in BAL fluid after antigen challenge has also been observed (25, 26).
It has been clearly demonstrated that IL16 uses the CD4 molecule as its receptor and exerts diverse
functional activities via CD4 signaling in lymphocytes, monocytes, and eosinophils (29, 90). In human
lymphocytes CD4 ligation by IL16 leads to activation of p56lck and a rise in intracellular IP3 and
subsequent mobilization of Ca2+ (29, 90). The functional consequences of IL16 in resting CD4+ T cells
are the upregulation of IL2R and HLA-DR expression as well as a shift from G0 to G1a (29). In addition,
IL16 synergistically stimulates proliferation of CD4+ T cells when combined with IL2 (76). Finally, it has
been demonstrated that IL16 is a chemoattractant for CD4+ cells in vitro (29). In contrast to these
stimulatory effects, IL16 has been found to inhibit proliferation of CD4+ lymphocytes following
activation with antigen or anti-CD3 (70). Furthermore, IL16 has been reported to inhibit mixed
lymphocyte reactions of human peripheral blood mononuclear cells (69). Thus, IL16 appears to have
both stimulatory and suppressive effects on T-lymphocytes in vitro.
Since IL16 has immunosuppressive actions in vitro, we were interested in the potential beneficial
effects of IL16 on the development of airway symptoms in a murine model of allergic asthma. Here, we
demonstrate that treatment with IL16 during the antigen challenge period of previously sensitized
mice, inhibits allergic airway inflammation and hyperresponsiveness. Furthermore, we show that these
effects are accompanied by a decreased production of Th2-type cytokines by TLN cells derived from
IL16-treated animals. Moreover, we found that IL16 can inhibit cytokine production by lymphocytes
upon antigen-specific stimulation in vitro.
Materials and Methods
Sensitization and challenge
Specified pathogen free male BALB/c mice (age 6-8 weeks) were obtained from the breeding colony of
the Central Animal Laboratory (Utrecht, The Netherlands). All experiments were approved by the animal
care committee of the Utrecht University. The mice were housed in macrolon cages and provided with
food and water ad libitum. Sensitization was performed by 7 intraperitoneal injections of 10 m g ovalbumin
(grade V) in 0.5 ml pyrogen free saline on alternate days. Four weeks after the last injection, the mice
were exposed either to 8 ovalbumin (2 mg ml-1 in saline) or to 8 saline aerosols for 5 min, on consecutive
days (1 aerosol per day). The aerosols were generated with a jet nebulizer (Pari IS-2, Pari-Werk GmbH,
Starnberg, Germany) connected to a plexiglas exposure chamber (5 l). Before each aerosolized antigen
challenge the mice were injected intraperitoneally with 1 m g rmIL16 or rhIL16 (in 0.25 ml saline) or with
vehicle. From literature data and our observations in vitro as well as in vivo it is known that both structure
and biological effects of IL16 of either murine or human origin are well conserved (76).
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Airway responsiveness in vivo
Airway responsiveness was determined in animals treated with either vehicle or rhIL16 by measuring
airway resistance to intravenously administered methacholine as previously published (177). In short, at
24h after the last aerosol challenge animals were anaesthetized by intraperitoneal injection of urethane (2
g kg-1) and trachea and jugular vene were intubated with small catheters. Spontaneous breathing of the
animals was suppressed by intravenous injection of tubocurarine chloride (3.3 mg kg-1). Subsequently,
animals were attached to a ventilator and changes in resistance were measured by use of a
plethysmograph, coupled to a pressure transducer (M45, Validyne Engineering Corp. Northridge, CA,
USA). By use of a pulmonary mechanics analyzer (Model 6, Buxco Corp., Sharon, CT, USA), lung
resistance (RL) was measured by quantitating D PtD V-1 (D Pt = change in tracheal pressure, D V = change
in flow) at points of equal volume (70% tidal volume). Changes in tracheal pressure were measured using
a pressure transducer connected to the tracheal ventilation cannula, changes in flow were measured by
use of a pressure transducer connected to the plethysmograph.
In experiments in which effects of rmIL16 on airway responsiveness were measured barometric
plethysmography was used (166, Buxco Corp.). Before measuring pressure differences between the
chamber containing the animal and a reference chamber, pressure differences, measured with a
pressure transducer (M45), were calibrated using a steady flow. Differences in pressure between box and
reference chamber are caused by changes in volume during a respiratory cycle. Baseline PENH values
were established by averaging for 3 minutes (10 valid breaths were averaged per PENH value). Mice
were then subjected to a saline aerosol, followed by increasing concentrations of nebulized methacholine
(1.5-50 mg ml-1) for 3 minutes, followed by a measuring period of 3 minutes after each aerosol (protocol
adapted from Hamelmann et al., 1997, 166). Aerosol was generated using a jet-nebulizer (Pari IS-2).
Bronchoalveolar lavage
Bronchoalveolar lavages were performed in the same animals that were used for airway responsiveness
measurements. Mice were lavaged 5 times through the tracheal cannula with 1 ml aliquots of pyrogen
free saline at 37°C. The BAL cells were washed with cold PBS (400xg, 4°C, 5 min) and resuspended in
200 m l. The total number of BAL cells was counted by use of a Bürker-Türk chamber (Omnilabo, Breda,
The Netherlands). For differential BAL cell counts cytospin preparations were made and stained with Diff-
Quick (Merz & Dade A.G., Düdingen, Switzerland). After coding, all cytospin preparations were evaluated
by one observer using oil immersion microscopy. Cells were identified and differentiated into
mononuclear cells, neutrophils and eosinophils by standard morphology. At least 200 cells per cytospin
preparation were counted and the absolute number of each cell type was calculated.
Ovalbumin-specific IgE ELISA
Ninety-six well microplates (Nunc A/S, Roskilde, Denmark) were coated with 2 m g ml-1 chimeric fusion
protein of the human high affinity IgE receptor and IgG (Fce R1-IgG) diluted in PBS. After 24h incubation
at 4°C the plates were washed 5 times with PBS supplemented with 0.05% Tween-20 (PBT). Thereafter,
the plates were blocked with ELISA buffer (2 mM EDTA, 136.9 mM NaCl, 50 mM Tris, 0.5% BSA, 0.05%
Tween-20, pH 7.2) for 1h. Diluted serum samples were added to the plates and left to incubate at room
temperature for 2h. Serial dilutions were made of the standard, which was obtained by intraperitoneal
immunization of mice with ovalbumin and arbitrarily assigned a value of 1,000 units ml-1 ovalbumin-
specific IgE. After washing, 10 m g ml-1 of ovalbumin in ELISA buffer was added to each well and after
incubation washing procedures were repeated. Horse-radish peroxidase-conjugated goat anti-ovalbumin
antibody was diluted in ELISA buffer and added to each well. Incubation was continued for 1h followed by
washing procedures. 10 mM OPD substrate solution was added and the reaction was ended at the
appropriate time (after approximately 10 min ) by adding H2SO4 (4M). OD was read at l  492 nm using a
Titertek Multiskan (Flow Labs, Irvine, UK).
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Cytokine production by thoracic lymph node (TLN) cells in vitro
TLN cells were isolated as described previously (206) from animals treated in vivo with either vehicle or
IL16 and challenged with saline or ovalbumin. A single cell suspension was prepared and resuspended in
RPMI (supplemented with 10% FCS, 5 x 10-5 M 2-mercaptoethanol, 50 mg l-1 gentamycine and 1%
glutamax). After isolation these TLN cells were cultured in the presence or absence of ovalbumin (40
m g ml-1) at 1 x 106 cells per ml (in 100 m l). After 5 days, supernatants were harvested and stored at -20°C
for cytokine analysis. IL4, IL5 and IFNg  levels in supernatants of the TLN cell cultures were determined
with ELISA according to the manufacturer's instructions (Pharmingen, San Diego, CA, USA).
Preincubation of TLN cells with IL16 in vitro
To determine the effect of IL16 on antigen-specific stimulation of lymphocytes in vitro, TLN cells were
isolated from ovalbumin-sensitized and ovalbumin-challenged mice. Cells (1 x 106 per ml in a total
volume of 100 m l) were preincubated for 1h with medium or IL16 (0.01-1 µg ml-1). Thereafter, cells were
cultured in the presence or absence of ovalbumin (40 m g ml-1) and after 5 days supernatant was
harvested for cytokine analysis. IL16 remained present during this culture period. Separate cultures were
used to determine proliferation. [3H]thymidine (0.3 m Ci per well, Amersham, Freiburg, Germany) was
added to each well 48h after stimulation and left to be incorporated. After 18h, cells were harvested and
[3H]thymidine uptake was determined by liquid scintillation counting.
Chemicals
Ovalbumin (chicken egg albumin crude grade V), o-phenylenediamine and 3-amino-1,2,4-triazole were
purchased from Sigma Chemical Company (St. Louis, MO, USA), recombinant human Fce R1-IgG, horse-
radish peroxidase-conjugated goat anti-ovalbumin antibody and ovalbumin-IgE reference standard were
generously provided by Dr. P.M. Jardieu (Genentech Inc., South San Francisco, CA, USA). Urethane and
methacholine (acetyl-ß-methylcholine) were purchased from Janssen Chimica (Beerse, Belgium),
tubocurarine chloride from Nogepha (The Netherlands), Tween-20 from Merck (Darmstadt, Germany).
rhIL16 and rmIL16 used in the cultures were obtained from Preprotech (The Netherlands) and
Pharmingen (San Diego, CA, USA), respectively, rhIL16 and rmIL16 used in vivo were obtained from Dr.
W.W. Cruikshank (Pulmonary Center, Boston, MA, USA) and produced as previously published (76).
Data analysis
Comparisons between different treatment groups were made using an ANOVA followed by post-hoc
comparisons using Bonferroni. Data are expressed as arithmetic average ± SEM and a difference was
considered to be significant when P<0.05. Data on proliferation or cytokine levels were analyzed using a
paired student's t-test. Total BAL cell numbers and the number of various cell types were tested with an
analysis of variance (ANOVA). For cell types with low numbers in control animals (i.e. neutrophils and
eosinophils) a Poisson distribution was assumed. Statistical analyses were carried out using SPSS/PC+,
version 4.0.1 (SPSS Inc., Chicago, IL).
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Results
Effect of treatment with IL16 on airway hyperresponsiveness in vivo
In vehicle-treated ovalbumin-challenged mice the increase in airway responsiveness after exposure to
aerosolized methacholine was significantly potentiated when compared to saline-challenged animals
(Figure 1A). At the highest concentration of methacholine (50 mg ml-1) PENH value measured in saline-
treated animals was 4.5±0.9 whereas in ovalbumin-challenged animals PENH value amounted to 9.4±1.7
(P<0.05). Administration of rmIL16 during the aerosol challenge-period completely prevented (P<0.05)
ovalbumin-induced airway hyperresponsiveness (Figure 1B). At the highest concentration of
methacholine the PENH value in rmIL16-treated ovalbumin-challenged animals was 5.0±0.5, whereas
PENH value in saline-challenged mice was 6.2±1.7.
In experiments in which we determined the effect of rhIL16 we measured airway responsiveness to
intravenously administered methacholine (ranging from 40 to 640 m g kg-1). In vehicle-treated ovalbumin-
challenged mice the increase in airway resistance after intravenous administration of methacholine was
significantly (P<0.01) potentiated when compared to saline-challenged animals (Figure 2A). Treatment
with rhIL16 significantly (P<0.05) inhibited development of ovalbumin-induced airway
hyperresponsiveness to methacholine (Figure 2A and B).
Effect of treatment with IL16 on number of eosinophils in BAL
Ovalbumin challenge of vehicle-treated animals resulted in a significant (P<0.05) increase in the number
of eosinophils in BAL fluid compared to vehicle-treated saline-challenged mice (162±85 x 103 vs 0.4±0.3
x 103 cells, respectively, Figure 3A). Treatment with rmIL16 during the aerosol challenge period resulted
in a significant (P<0.05) decrease of ovalbumin-induced eosinophil infiltration into BAL fluid compared to
vehicle-treated ovalbumin-challenged animals (13.9±7.5 x 103 cells, Figure 3A). No significant differences
in infiltration of mononuclear cells or neutrophils were observed between different groups of animals.
Furthermore, no differences were observed in total numbers of cells that were present in BAL fluid (Table
I). A significant (P<0.05) inhibition of antigen-induced eosinophil infiltration was also observed when
rhIL16 (1 m g kg-1) was administered during the challenge period (Figure 3B).
Effect of treatment with IL16 on
ovalbumin-specific IgE levels in
serum
Ovalbumin challenge of vehicle-
treated animals resulted in an almost
5-fold increase (P<0.05) in serum
levels of ovalbumin-specific IgE
when compared to saline-challenged
mice (745±209 vs 174±55 units ml-1
respectively, n=5). Ovalbumin
challenge of rhIL16-treated animals
also resulted in a significant
(P<0.05) increase of serum IgE
levels when compared to saline-
challenged animals (768±50 vs
271±84 units ml-1, respectively, n=5).
No significant differences were
observed between serum IgE levels
of vehicle or rhIL16-treated animals
challenged with either saline or
Table I: Absolute numbers of different cells in BAL fluid
Treatment/
challenge
Mononuclear
cells x 105
Neutrophils
x 102
Total number
of cells x 105
 Veh/Sal   3.6±0.6   6.3±3.3   3.6±0.6
 Veh/Ova   4.9±1.6 37.7±29.1   6.6±2.2
IL16/Sal   3.5±0.5   2.8±1.8   3.5±0.5
IL16/Ova   4.0±0.5
  7.5– 3.2   4.1±0.5
Animals were treated i.p. with either vehicle (Veh) or rmIL16 (1
m g day-1), before each ovalbumin (Ova) or saline (Sal) aerosol.
Data are expressed as arithmetic average ± SEM of at least 6
animals per group.
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ovalbumin.
Effect of treatment with IL16 in vivo on antigen-specific
cytokine production in vitro
No significant differences were observed in the total
number of cells derived from lymph nodes from either
vehicle or IL16-treated saline or ovalbumin-challenged
animals (data not shown). TLN cells, derived from different
treatment groups, were cultured in the presence or
absence of ovalbumin. After five days of culturing,
supernatants were harvested and the presence of IFNg , IL4
and IL5 was determined by ELISA. No significant
differences in IFNg  levels were detected in supernatant of
TLN cells derived from vehicle-treated, saline or
ovalbumin-challenged animals, cultured in vitro in the
presence or absence of ovalbumin (data not shown).
Similarly, in vivo administration of rmIL16 during the
aerosol challenge period did not significantly change IFNg
production (detection limit 0.3 ng ml-1) in TLN cultures (data
not shown). TLN cells derived from vehicle-treated
ovalbumin-challenged animals produced more IL4
(P<0.05) and IL5 after culturing in the presence of antigen
(0.93– 0.33 ng ml-1 and 0.40– 0.22 ng ml-1, respectively)
when compared to cells derived from saline-challenged
animals (0.07– 0.03 ng ml-1 and 0.03– 0.03 ng ml-1,
respectively, Figure 4A and B). In vivo treatment with
rmIL16 during the aerosol challenge period with ovalbumin
largely inhibited the production of IL4 (by 72%) and IL5 (by
85%, to 0.26– 0.08 ng ml-1 and 0.06– 0.03 ng ml-1,
respectively) after stimulation with ovalbumin in vitro
(Figure 4A and B). No differences were observed in IL4
and IL5 production by TLN cells between saline-challenged
animals, treated with rmIL16 (0.14– 0.05 ng ml-1 and
0.01– 0.01 ng ml-1, respectively) or with vehicle (0.07– 0.03
ng ml-1 and 0.03– 0.03 ng ml-1, respectively, Figure 4A and
B). When cultured in the absence of ovalbumin hardly any
IL4 or IL5 could be detected in supernatant of TLN cultures
(Figure 4A and B).
Effect of preincubation with IL16 on TLN cells in vitro
Antigen-specific restimulation in vitro of TLN cells derived
from ovalbumin-sensitized and challenged animals
resulted in an increase in IL4 production when compared to
cells cultured with medium alone (Figure 5A). Preincubation with rmIL16 dose-dependently decreased
this IL4 production up to 56% at 1 m g ml-1. IL5 production was also enhanced (P<0.05) by ovalbumin
stimulation in vitro when compared to cells cultured with medium alone (Figure 5B). Preincubation of TLN
cells in vitro with rmIL16 dose-dependently decreased (P<0.05) ovalbumin-induced IL5 production up to
77% at 1 m g ml-1 (Figure 5B). TLN cells stimulated with ovalbumin in vitro displayed a significant (P<0.05)
increase in proliferation when compared to cells cultured without ovalbumin (Figure 5C). Preincubation of
Figure 3
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TLN cells with rmIL16 (1 m g ml-1) significantly (P<0.05)
decreased in vitro proliferation with 55% after stimulation
with ovalbumin (Figure 5C). Culturing TLN cells with IL16 in
the absence of ovalbumin did not induce IL4 or IL5
production or proliferation (data not shown). Similar inhibitory
effects on antigen-induced cytokine production or
proliferation of TLN cells were observed after incubation with
rhIL16 instead of rmIL16 (data not shown).
Discussion
In this study we are the first to demonstrate that IL16
administration during the antigen-challenge period has
potent immunosuppressive effects in a murine model of
allergic asthma. Intraperitoneal as well as intranasal (rhIL16,
1 m g day-1, 63% reduction, data not shown) IL16
administration decreased antigen-induced eosinophil
infiltration but did not affect upregulation of antigen-specific
IgE levels in serum. Furthermore, treatment with IL16
inhibited development of airway hyperresponsiveness. The
beneficial effects of IL16 appears to be caused by inhibition
of proliferation and cytokine production of antigen-specific
type-2 lymphocytes.
Several studies have demonstrated via depletion of CD4+ T
cells in animal models that these lymphocytes are crucial for
the development of asthma-like features, including airway
hyperresponsiveness and eosinophilic inflammation (207-
209). In addition, using adoptive transfer experiments it has
been clearly demonstrated that reconstitution with solely
CD4+ T cells is sufficient to restore antigen-induced airway
hyperresponsiveness, eosinophilia and goblet cell
hyperplasia (210-212). It is now widely accepted that type-2
CD4+ T cells are also important for inflammatory cell
infiltration and airway hyperresponsiveness in patients with
allergic asthma. Since IL16 uses CD4 as its receptor and
exerts its action via cross-linking of several CD4 molecules
(29), the CD4+ T lymphocyte is a likely target for the
beneficial effects of IL16.
Type-2 CD4+ T cells are characterized by production of
cytokines such as IL4, IL13 and IL5 upon antigen-specific
stimulation (8, 20). In murine models it has been shown that
IL4 is essential for antigen-induced airway
hyperresponsiveness, eosinophilia and increases in goblet
cell numbers since receptor blocking antibodies can
decrease these phenomena (14). Furthermore, it has been
demonstrated in IL4 deficient mice that antigen-specific IgE,
eosinophils and airway hyperresponsiveness were absent
(213). IL4 has also been shown to play a critical role in recruitment of Th2 cells to the lung (212).
Depletion of IL5 by monoclonal antibodies completely abolished airway hyperresponsiveness and
eosinophilia in an animal model of allergic asthma (12). Similar observations were made when IL5
deficient mice were used (16). Vice versa, intranasal administration of IL5 to mice leads to eosinophil
infiltration followed by the development of airway hyperresponsiveness and an increase in mucosal
Figure 4
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exudation (214). In contrast, others did not find a role for IL5 in development of antigen-induced airway
hyperresponsiveness (13, 148). Recent data suggest that the Th2-type cytokine IL13 could also play an
important role in the pathology of asthma (20).
At present, nothing is known about the effect of IL16 on type-2 cytokine production by T lymphocytes. In
this study, we demonstrate that treatment with IL16 in vivo inhibits antigen-stimulated production of IL4
and IL5 by lymphocytes isolated from lung draining lymph nodes. Moreover, preincubation of TLN cells
with IL16 in vitro also inhibits antigen-specific Th2-type cytokine production as well as proliferation. No
significant differences in IFNg  levels upon antigen restimulation could be detected in TLN cultures either
from in vivo IL16-treated animals or from TLN cultures which were in vitro preincubated with IL16 (data
not shown). This strongly suggests that IL16 does not induce a shift from a Th2-type cytokine profile
towards production of Th1-type cytokines by CD4+ T cells. However, based on these data we can not rule
out an effect by IL16 on IFNg  production. Furthermore, our data strongly support the concept that the
CD4+ T cells is a target cell for the beneficial effects of IL16 on manifestations of allergic asthma in the
Figure 5.
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Thoracic lymph node (TLN) cells from ovalbumin-sensitized and challenged animals were cultured in the
presence of ovalbumin. Results are presented as a percentage of the response of untreated TLN (0) cells
in the presence of ovalbumin (100%). TLN cells cultured in the presence of ovalbumin were preincubated
with increasing doses of rmIL16 (ranging from 0-1 m g ml-1). Depicted are IL4 (A), IL5 production (B) and
proliferation of TLN cells (C). In supernatant harvested from cells cultured in the absence of ovalbumin,
no IL4 or IL5 production by TLN cells could be detected (data not shown). Proliferation in the absence of
ovalbumin amounted to 17– 1 %, when compared to cells cultured in the presence of ovalbumin (100%).
Results are expressed as arithmetic average ± SEM of four separate experiments. * (P<0.05) significantly
different from the response of untreated TLN cells cultured in the presence of ovalbumin.
Chapter 5
63
model. However, we can not exclude that IL16 exerts its in vivo immunosuppressive actions on other
CD4-expressing cells such as monocytes (96).
In our study, antigen-specific IgE production was not inhibited by administration of IL16, whereas IL4
production by TLN cells was decreased. This seems to be in contradiction with the essential role of IL4 in
IgE-synthesis by B-lymphocytes (11). However, it has been shown that after a second encounter with
antigen, upregulation of immunoglobulin E production by B-cells is less dependent on cognate B-T cell
contact and on CD4+ T-cell derived cytokines such as IL4 (215). Therefore IL4 could be involved mainly in
the induction of isotype class switching to IgE production by B-cells during sensitization. Moreover, it has
been demonstrated that IL4-independent class switch to IgE in the mouse can occur (216).
In agreement with our data on the suppressive effects of IL16 on T-cell activation in vitro, IL16 has been
shown to suppress the mixed lymphocyte reaction (69) as well as antigen or anti-CD3-induced
proliferation of human CD4+ T cells in vitro when added prior to stimulation (70). These down-regulatory
actions of IL16 are consistent with the inhibitory actions of other CD4 binding molecules including
multivalent HIV-1 gp120 or CD4-antibodies (41, 202). Both monoclonal antibodies to CD4 and gp120
have been shown to induce unresponsiveness after antigen-specific or polyclonal stimulation of CD4+ T
cells in vitro (45, 217). Furthermore, non-depleting antibodies to CD4 can cause T cell unresponsiveness
in vivo, thereby preventing graft rejection (134, 136). It has also been demonstrated that rheumatoid
arthritis can be inhibited when non-depleting anti-CD4 antibodies are used in a murine model (137). With
the present study, we are the first to show that a natural soluble ligand for CD4 also has
immunosuppressive actions in vivo as well as in vitro. Whether the mechanism of action is similar to that
of antibodies to CD4 remains to be elucidated.
One of the mechanisms that could account for the observed antigen-specific unresponsiveness after
treatment with IL16 could be that TCR signaling is impaired by CD4 ligation. From literature data it is
known that cross-linking of CD4, e.g. by gp120, can inhibit subsequent T cell activation via the TCR/CD3
complex (127). Binding of CD4 molecules by IL16 leads to the activation of p56lck (101). p56lck plays a
role in TCR signaling via recruitment and subsequent phosphorylation of ZAP70, after TCR z -chain
phosphorylation (141). Therefore, it has been speculated that when CD4 is cross-linked independently
from TCR activation, subsequent antigen-specific TCR stimulation is inhibited since no p56lck is present
to provide help for TCR/ZAP70 phosphorylation (141, 218). Besides ZAP70, p56lck activation also leads
to p120 phosphorylation, which is implicated in T cell activation (131). Thus, after CD4 ligation, prior to
TCR/antigen interaction, the signaling might be impaired (219), which could explain the
immunosuppressive effects of IL16 on antigen-induced symptoms in vivo as well as in vitro.
Another explanation for the observed decrease in proliferation and cytokine production upon antigen-
specific stimulation could be the induction of apoptosis. In several studies it has been observed that CD4
engagement by either antibodies to CD4 or gp120 induces Fas-dependent cell death (122, 220).
Similarly, induction of Fas-dependent apoptosis could explain our observations that IL16 has
immunosuppressive effects. However, others have reported that preincubation of CD4+ T cells with IL16
in vitro does not lead to increased CD95 expression or subsequent apoptotic cell death (70) and thus it is
very unlikely that the IL16-mediated effects are caused by this mechanism. Furthermore, recent data
clearly demonstrated that IL16 actually protects cells against activation-induced cell death (92).
Previously, we have demonstrated that biologically active IL16 is present in BAL fluid of sensitized mice
early after antigen-challenge (154). It could be speculated that this endogenously produced IL16 also
has immunosuppressive effects in our animal model. However, administration of anti-IL16 during the
challenge period partially decreased bronchial hyperresponsiveness whereas eosinophilic infiltration
was not affected (154). These data argue against an immunosuppressive role for endogenously
produced IL16 in vivo. However, this discrepancy with our present findings can be explained by the
observation that endogenously secreted bioactive IL16 can only be detected after antigen exposure
whereas in this study IL16 was injected prior to the first ovalbumin inhalation. Furthermore, the amount
and localization of exogenously administered or endogenously produced IL16 are probably different.
As already mentioned, IL16 is a potent inducer of CD4+ cell chemotaxis in vitro, including T cells,
eosinophils and monocytes (74, 90). Therefore, it can be argued that the inhibitory effects of IL16 on
airway hyperresponsiveness and eosinophilia are caused by an infiltration of CD4+ cells into the
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intraperitoneal cavity instead of airway tissues. However, when IL16 was administered intranasally
instead of intraperitoneally during the aerosol challenge period, similar effects were observed on
eosinophil infiltration (data not shown). Moreover, intraperitoneal administration of IL16 did not induce any
detectable accumulation of eosinophils into the peritoneal cavity, nor did intratracheal administration of
IL16 induce any increase in number of mononuclear cells or eosinophils (data not shown). Therefore, it is
not very likely that IL16 is a potent inducer of CD4+ cell chemotaxis in vivo. This observation is further
sustained by the fact that administration of antibodies to IL16 do not have any effect on the number of
eosinophils or mononuclear cells in BAL fluid after antigen-challenge in this murine model (154).
In conclusion, we are the first to demonstrate that IL16, a natural CD4 ligand, has immunosuppressive
effects in vivo on both antigen-induced allergic inflammatory responses as well as airway
hyperresponsiveness. Although the precise mechanism remains to be elucidated, we demonstrate that in
vivo immunosuppressive effects of IL16 are associated with inhibition of Th2-type cytokine production. It
is therefore tempting to speculate about the potential therapeutic effects of IL16 in allergic asthma and
other CD4+ T cell-mediated diseases.
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Summary
IL16 is the only known soluble ligand for CD4 that is endogenously produced. In a previous study we
observed that treatment with IL16 completely inhibited development of antigen-induced airway
hyperresponsiveness to methacholine whereas infiltration of eosinophils was largely decreased in a
murine model of allergic asthma. Furthermore, in vivo treatment with IL16 reduced IL4 and IL5
production by TLN cells upon antigen-specific restimulation in vitro.
In the present study we examined the effects of CD4 cross-linking by antibodies to CD4 or IL16 on T cell
responses in vitro. First, we determined the effects of either IL16 or antibodies to CD4 on proliferation of
polyclonally or antigen-specifically stimulated T cells. Secondly, we examined the effect on cytokine
production by lymphocytes isolated from antigen-sensitized and challenged animals. Thirdly, since the
CD4 molecule has been shown to play a role in T cell differentiation, we determined effects of antibodies
to CD4 or IL16 in priming cultures of naive T cell receptor transgenic (DO11.10) CD4+ T cells towards
effector cells that produce a Th0, Th1 or a Th2-type cytokine profile upon restimulation with antigen.
In this study we clearly demonstrate that CD4 cross-linking by either IL16 or antibodies to CD4 inhibits
anti-CD3-induced proliferation of lymphocytes. Furthermore, antigen-induced proliferation and production
of Th2-type cytokines, such as IL4, IL5 and IL10 are also inhibited by CD4 cross-linking. Finally, we
demonstrate that the presence of IL16 or antibodies to CD4 in priming cultures of DO11.10 CD4+ T cells
display a decreased capacity to produce IL4 and IL5 upon restimulation, whereas production of IL10 and
IFNg  are not altered. These in vitro results provide us with novel insights in the mechanisms by which
IL16 inhibits antigen-induced allergic airway responses in vivo.
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Introduction
IL16 is a cytokine that has been discovered in the early 80’s (29, 90) and has been shown to use the CD4
molecule as its receptor. Most in vitro and in vivo data obtained so far propose that IL16 serves as a pro-
inflammatory cytokine (29, 90, 154). IL16 has been found to be a very potent inducer of chemotaxis in
vitro of CD4+ cells, including T cells and eosinophils (90, 95). Furthermore, IL16 may play a role in CD4+ T
cell mediated diseases such as asthma. It has been demonstrated that IL16 expression is increased in
asthmatics upon antigen challenge and that this increased expression correlates with disease status (26).
However, little is known about the effects of IL16 in vivo. Recently, we have shown that exogenously
administered IL16 can inhibit antigen-induced airway hyperresponsiveness and eosinophilia in a murine
model of allergic asthma (59). Furthermore, we found that this in vivo inhibitory action of IL16 was
associated with decreased production of Th2-type cytokines by lymphocytes upon restimulation with
antigen in vitro (221). In agreement herewith, Klimiuk et al. demonstrated that exogenous IL16 can serve
as an anti-inflammatory cytokine in an animal model for human synovitis (222).
It has been extensively demonstrated that IL16-induced effects require cross-linking of CD4 molecules
(29). It is well documented that other ligands for CD4 such as antibodies or gp120 can induce T cell
unresponsiveness (45, 127, 136, 223). Therefore, it could be speculated that IL16-induced CD4 signaling
also induces an unresponsive state in T cells. In order to test this hypothesis, we isolated splenocytes
and determined the effects of IL16 or antibodies to CD4 on polyclonal stimulation of lymphocytes.
Furthermore, we isolated TLN cells from animals sensitized to and challenged with ovalbumin and
measured the effect of IL16 or antibodies to CD4 on antigen-specific proliferation as well as on antigen-
induced cytokine production in vitro.
The observed anti-inflammatory action of IL16 administration in vivo could also be explained by effects of
IL16 on T cell differentiation. It has been clearly demonstrated that besides an accessory function in TCR-
induced signaling, the CD4 molecule also plays a role in differentiation of naive T cells into effector cells
(71). It was shown by Leitenberg et al. that the presence of a functional CD4 molecule is necessary for
induction of Th2 cells whereas CD4-signaling is not a prerequisite for Th1 T cell differentiation (71). To
explore possible effects of IL16 or anti-CD4 antibodies on differentiation of naive CD4+ T cells, we used
an artificial in vitro T cell skewing system (224). In this experimental set-up, differentiation of naive T cells
towards the development of effector cells that display a Th0, Th2 or Th1-type cytokine profile upon
restimulation is directed by culturing in presence of medium only, IL4 or antibodies to IL4, respectively.
Materials and Methods
Animals
Specified pathogen free male BALB/c mice (age 6-8 weeks) were obtained from the breeding colony of
the Central Animal Laboratory (Utrecht, The Netherlands). All experiments were approved by the animal
care committee of the Utrecht University. The mice were housed in macrolon cages and provided with
food and water ad libitum. Sensitization was performed by 7 intraperitoneal injections of 10 m g ovalbumin
(grade V) in 0.5 ml pyrogen free saline on alternate days. Four weeks after the last injection, the mice
were exposed either to 8 ovalbumin (2 mg ml-1 in saline) or to 8 saline aerosols for 5 min, on consecutive
days (1 aerosol per day). The aerosols were generated with a jet nebulizer (Pari IS-2, Pari-Werk GmbH,
Starnberg, Germany) connected to a plexiglas exposure chamber (5 l). For T cell differentiation
experiments, spleens from DO11.10 T cell receptor transgenic mice were used. DO11.10 mice were
generously donated by L. Adorini (Department of Inflammation/Autoimmune Diseases, Hoffmann-La
Roche Inc., Nutley, NJ, USA) and maintained at the Central Animal Laboratory (Utrecht, The
Netherlands).
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Proliferation of lymphocytes with anti-CD3
Anti-CD3-coated plates were prepared by incubating 96-wells plates with anti-CD3 antibodies (10
m g well-1) for 24h at 4° C. Plates were washed twice with phosphate-buffered saline (PBS) before use.
Single cell suspensions were made from spleens derived from naive BALB/c mice. Lymphocytes were
then isolated using a Lympholyte M gradient according to the manufacturer’s instructions (800xg, 20 min,
21° C, Cedarlane, NJ, USA). Thereafter CD4+ T-lymphocytes were negatively selected using a
commercially available CD4+ T cell isolation kit (R&D systems, Minneapolis, MN, USA). CD4-enriched
cells were cultured in medium (RPMI, supplemented with 10% FCS, 5 x 10-5 M b -mercaptoethanol, 50
mg l-1 gentamycine and 1% glutamax) at a concentration of 1 x 106 cells ml-1. Thereafter cells were
incubated for 1h at 37° C and 5% CO2 with medium, rhIL16, rmIL16 (0.06-0.6 m g ml-1) or antibodies to
CD4 (GK1.5, 0.01-1 m g ml-1). Subsequently, cells (1 x 105 cells well-1) were added to the anti-CD3-coated
wells without washing. After 48h at 37° C and 5% CO2, [3H] thymidine (0.3 m Ci per well) was added to
each well and left to be incorporated for 18h. Thereafter, cells were harvested and [3H] thymidine uptake
was determined by liquid scintillation counting (1450 microbeta plus, Wallac Oy, Turku, Finland). All
experiments were performed at least in triplicate.
Antigen-specific restimulation of thoracic lymph node cells in vitro
Thoracic lymph node (TLN) cells were isolated from ovalbumin-sensitized and ovalbumin-challenged
BALB/c mice as previously described (151). TLN cells (1 x 106 per ml, 100 m l well-1) were incubated for 1h
at 37° C and 5% CO2 with either medium alone (RPMI), rhIL16, rmIL16 (0.01-1 m g ml-1) or anti-CD4
antibodies (GK1.5, 0.01-1 m g ml-1). Thereafter, TLN cells were cultured in the presence or absence of
ovalbumin (40 m g ml-1) and after 5 days supernatant fractions were harvested for cytokine analysis. IL16
or antibodies to CD4 remained present during this culture period. Separate cultures were used to
determine proliferation. [3H]thymidine (0.3 m Ci per well) was added to each well 48h after stimulation and
left to be incorporated. After 18h, cells were harvested and [3H]thymidine uptake was determined by liquid
scintillation counting. All experiments were performed at least in triplicate.
In vitro T-cell differentiation
DO11.10 CD4+ T cells were isolated using immunomagnetic negative selection (71, 225). In short, single
cell suspensions were made from spleens derived from DO11.10 mice. Lymphocytes were isolated using
a lympholyte M gradient (800xg, 20 min, 21° C, Cedarlane, NJ, USA). Lymphocytes were left to incubate
(1 x 107 cells ml-1) with antibodies to MHC-II (MKD6), CD8 (YTS69), Thy 1 (YTS154), B220 (RA3-6B2)
and CD16/32 (2.4G2) in previously established optimal dilutions determined by flow cytometry analysis.
After 1h incubation at 4° C on a rotating platform, cells were washed twice in cold medium (RPMI) and
resuspended with a mixture of magnetic beads coupled to antibodies to mIgG2a, rIgG2b and mIgM
(Perseptive Biosystems, MA, USA) and left to incubate for 30 min at 4° C on a rotating platform. Negative
immunomagnetic selection was then performed using a magnetic plate (10 min at 4° C, Perseptive
Biosystems, MA, USA) and non-bound cells were washed twice with medium. The resultant CD4
population, as assessed by standard fluorescent staining was >90% pure (data not shown), the
percentage of CD3-CD4 double positive cells was 80-90% pure (Figure 1). Fluorescent staining was
performed as follows; cells were washed, resuspended in PBS with 1% azide supplemented with hamster
and rat serum (10%) and left to incubate for 30 min at 4° C. After washing, cells were stained (20 min,
4° C) with phycoerythrin (PE)-conjugated anti-CD3 antibodies (145-2C11) and Cy-Cychrome-conjugated
anti-CD4 antibodies (RM4-5) or control antibodies. After washing, surface expression was determined
(FACS, Becton Dickinson and Co., Mountain View, CA, USA).
In order to detect possible effects of IL16 on the differentiation of naive T cells into either Th1 or Th2-type
lymphocytes, a slightly modified system first described by Hsieh et al. was used (224). Splenocytes from
BALB/c mice were used (1 x 106 ml-1) as antigen presenting cells (APC) and these cells were cultured
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with CD4+ DO11.10 T cells (5 x 105
ml-1) in the presence of ovalbumin323-
339 (OVA323-339) peptide (0.3 m M) in a
total volume of 1,5 ml well-1.
Furthermore, cultures were
supplemented with either IL4 (200
units ml-1), antibodies to IL4 (10
m g ml-1) or medium only (control). After
4 days of culturing, supernatant
fractions were harvested, non viable
cells were removed using Lympholyte
M gradient and cells were
resuspended in medium at 5 x 105
cells ml-1. Subsequently, cultures were
restimulated using APC’s (1 x 106 ml-1)
and OVA323-339 (0.3 m g ml-1) without
adding IL4 or antibodies to IL4. After
two additional days of culturing,
supernatants were again harvested for
cytokine analysis. During the first
antigen stimulation either rmIL16 (1
m g ml-1) or antibodies to CD4 (GK1.5,
0.1 m g ml-1) were added to the different
cultures to determine the effects of
CD4 cross-linking on differentiation of
DO11.10 T cells into different Th subsets. Experiments were performed at least in triplicate.
Chemicals
Ovalbumin (chicken egg albumin crude grade V) was purchased from Sigma Chemical Company (St.
Louis, MO, USA), OVA323-339 was obtained from the Dept. of Immunology, Faculty of Veterinary Sciences,
Utrecht University, Tween-20 from Merck (Darmstadt, Germany). Cy-Cychrome-conjugated anti-CD4
(RM4-5) and PE-conjugated anti-CD3 (145-2C11) as well as rmIL16 were obtained from Pharmingen
(San Diego, CA, U.S.A). rhIL16 was purchased from Preprotech. All antibodies used for cell isolations
were purified, using standard protein A or G column affinity, from hybridomas maintained at Veterinary
Faculty, Dept. of immunology, Utrecht University, The Netherlands. Antibodies used in this study were
MKD6 (anti-I-Ad, mIgG2a), YTS169 (anti-CD8, rIgG2b), YTS154 (anti-Thy 1, rIgG2b), RA3-6B2 (anti-
B220, rIgG2b), 2.4G2 (anti-muFc
g
RII; CD16/32, rIgG2b), GK1.5 (anti-CD4, rIgG2b) and 11B11 (anti-IL4,
rIgG1). IL4 and IL2 were generously donated by dr. W. P. Paul, NIAID, NIH, Bethesda, USA.
Data analysis
Comparisons were made using a Student's t-test (paired, two-tailed). Data are expressed as arithmetic
average ± SEM and a difference was considered to be significant when P<0.05. Statistical analyses were
carried out using Microsoft Excel 7.0.
Figure 1
A B
CD3 and CD4 expression of purified T cells from spleens of
DO11.10 mice. Expression was determined using
phycoerythrin-conjugated anti-CD3 (FL-2, x-axis) and Cy-
cychrome-conjugated anti-CD4 (FL3, y-axis). Presented are
background staining for FL-2 and FL-3 (A) and staining with
antibodies to CD3 and CD4 (B). Numbers indicate the
percentage of double positive cells.
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Results
Effect of CD4 cross-linking on anti-CD3-induced
proliferation
Immobilized anti-CD3 significantly enhanced
proliferation of CD4+ lymphocytes when
compared to cells cultured in medium only
(41,600 –  14,300 vs 191 –  48 counts min-1,
P<0.05). Both rmIL16 and anti-CD4 antibodies
concentration-dependently inhibited immobilized
anti-CD3-induced proliferation with maximal
effects at the highest concentration tested (0.6
and 1 m g ml-1, respectively, Figure 2). Anti-CD3-
induced proliferation was inhibited by 44% to
18,068 –  7,476 counts min-1 and by 95%
(P<0.01) to 2,493 –  1,310 counts min-1,
respectively, when compared with proliferation
induced by anti-CD3 alone. rhIL16 also
significantly decreased anti-CD3-induced
proliferation at the highest concentration (0.6
m g ml-1) tested (>30%, P<0.05, data not shown).
Effect of CD4 cross-linking on antigen-specific T
cell stimulation
Stimulation of TLN cells isolated from OVA-
sensitized and challenged animals with
ovalbumin in vitro, significantly enhanced proliferation of these cells when compared with unstimulated
cells (P<0.05, Figure 3A). Incubation with rmIL16 (1 m g ml-1) inhibited ovalbumin-induced proliferation
with more then 50%, when compared with proliferation induced by ovalbumin alone (P<0.05). Anti-
CD4 antibodies (1 m g ml-1) also inhibited ovalbumin-induced proliferation (45% inhibition), when
compared with control (Figure 3A).
Cytokine levels in supernatants of these cultures were also determined. Both rmIL16 and antibodies to
CD4 inhibited production of IL4, IL5 and IL10 in a concentration-dependent manner after antigen-
specific stimulation of TLN cells (Figure 3B, C and D), with maximal effects at the highest
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Effect of CD4 cross-linking on proliferation of T cells
isolated from naive BALB/c mice induced by
immobilized anti-CD3 (black bars). Depicted are the
effects of different concentrations of rmIL16
(hatched bars, average of 4 separate experiments)
or antibodies to CD4 (open bars, average of 3
separate experiments) on immobilized anti-CD3-
induced proliferation. Results are expressed as
arithmetic average ± SEM. # (P<0.05); ## (P<0.01)
significantly different from proliferation induced by
anti-CD3 antibodies (100%). Proliferation of
unstimulated cells was <1%.
Table I: The effect of rhIL16 on antigen-induced cytokine production and proliferation.
Stimulation Proliferation (cpm) IL4 (ng ml-1) IL5 (ng ml-1) IL10 (ng ml-1)
- 
     1,981– 524       0– 0      0– 0 0.3– 0.0
Ova 
   11,447– 2,509 (*)  2.25– 1.55 1.45– 0.46 (*) 3.4– 1.2 (*)
Ova + rhIL16 
     5,954– 1,624 (#)  0.53– 0.24 0.51– 0.29 (#) 1.1– 0.2
TLN cells were isolated from OVA-sensitized and challenged animals and cultured in absence (-) or
presence of ovalbumin (Ova). Shown are the effects at the highest concentration of rhIL16 (1m g ml-1) on
antigen-induced production of IL4 and IL5 as well as on proliferation. Results are presented as arithmetic
average ± SEM of 4 separate experiments. * (P<0.05) significantly different from proliferation or cytokine
production induced by medium alone. # (P<0.05) significantly different from proliferation or cytokine
production induced by ovalbumin.
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concentration of either antibodies to CD4 or rmIL16 (1 m g ml-1). Incubation with antibodies to CD4 or
rmIL16 (both at 1 m g ml-1) decreased IL4 production by 95% and 71%, respectively, after stimulation
with ovalbumin. Production of IL5 was decreased by 70% (antibodies to CD4) and 70% (rmIL16,
P<0.05) and IL10 by 83% (antibodies to CD4, P<0.05) and 64% (rmIL16), when compared with
cytokine production after culturing in presence of only ovalbumin (Figure 3). No significant differences
were observed in IFNg  levels in supernatants (data not shown). Similar effects were observed on
antigen-induced cytokine production and proliferation when lymphocytes were preincubated with
rhIL16 (Table I).
Figure 3
A B
 
0
3
6
9
12
15 *
#
0(-) 0.01 0.1
( m g ml-1)
[3 H
] in
co
rp
or
at
io
n
 
(cp
m
 
x 
10
3 )
1
                 
0
1
2
3
4
0(-) 0.01 0.1 1
( m g ml-1)
IL
-
4 
(ng
 m
l-1
)
C D
0.0
0.5
1.0
1.5
2.0
0(-) 0.01 0.1 1
( m g ml-1)
IL
-
5 
(ng
 
m
l-1
)
*
#
                  
0
1
2
3
4
5
0(-) 0.01 0.1 1
*
#
( m g ml-1)
IL
-
10
 (n
g 
m
l-1
)
TLN cells were isolated from OVA-sensitized and challenged animals and cultured in absence
(crosshatched bars) or presence of ovalbumin (open bars). Shown are the effects of different
concentrations of either antibodies to CD4 (black bars) or rmIL16 (hatched bars) on antigen-induced
proliferation (A), IL4 (B), IL5 (C) and IL10 production (D). Results are expressed as arithmetic average ±
SEM of 4 separate experiments. * (P<0.05) statistically significant difference in proliferation or cytokine
production by cells stimulated with antigen without CD4 ligands, when compared with cells cultured in
medium alone. # (P<0.05) significantly different from proliferation or cytokine production induced by
ovalbumin.
    Chapter 6
72
Effect of CD4 cross-linking on T-cell differentiation
CD4+ T cells were isolated from DO11.10 mice and
cultured in presence of APCs and OVA323-339. In order to
induce differentiation of these DO11.10 T cells towards
either a Th0, Th2 or a Th1-type cytokine producing
effector cells, priming cultures were maintained for four
days in medium only, IL4 or antibodies to IL4,
respectively. During this period, IL16 or antibodies to CD4
were added. Thereafter, non-viable cells were removed
and remaining cells were restimulated with antigen and
freshly isolated APCs and cultured for an additional 2 day
period, without the skewing agents or CD4 ligands.
Cytokine levels in supernatant fractions were determined
both at the end of the first stimulation period and after the
second stimulation period with OVA323-339.
I Th0-type cytokine production
At the end of the first culturing period, cells maintained in
medium and stimulated with OVA323-339 produced some
IL5, hardly any IL10 and a high amount of IFNg  (Table II).
After the second stimulation with OVA323-339, DO11.10
CD4+ T cells cultured in medium alone produced Th2-
type cytokines IL4, IL5 and IL10 as well as the Th1-type
cytokine IFNg  (Table II), indicating a Th0 type cytokine
profile.
Cytokine levels in supernatant fractions isolated after the
first stimulation period from cells cultured in medium with
rmIL16 did not differ from levels measured in cultures
without rmIL16 (Table II). However, upon restimulation
with antigen, these cells produced significantly less IL4 (P<0.05) and IL5 (P<0.05), whereas IL10 and
IFNg  levels in these supernatant fractions were not significantly altered (Figure 4, Table II).
Cytokine levels in supernatant fractions isolated after the first stimulation period from cells cultured in
medium with antibodies to CD4 did also not differ from levels measured in cultures maintained in medium
only (data not shown). Upon restimulation, a decreased production of both IL4 (P<0.05, from 0.2– 0.1 to
0– 0 ng ml-1), and IL5 (from 3.1– 1.1 to 1.9– 0.5 ng ml-1) was also observed, when compared with cells
cultured in medium alone. Furthermore, no significant differences were found in IL10 and IFNg  production
by these cultures (8.5– 2.0 vs 7.0– 1.6 ng ml-1 and 10.4– 0.5 vs 11.0– 0.7 ng ml-1, respectively).
II Th2-type cytokine production
At the end of the first culturing period in the presence of IL4 and OVA323-339, IL5 and IL10 production were
enhanced, although not statistically significant, whereas IFNg  levels were significantly (P<0.05)
decreased, when compared with cytokine levels in supernatants of cells cultured with antigen alone
(Table II). Upon restimulation of these cells, IL4 (P<0.05), IL5 and IL10 (P<0.01) production was largely
upregulated, whereas IFNg  production was almost completely inhibited (P<0.01), indicating a Th2-type
cytokine profile (8, Table II).
The presence of rmIL16 in the priming cultures enhanced production of IL5 (P<0.05) and of IL10 (P=0.06)
when compared with cells cultured without rmIL16 (Table II). Furthermore, IFNg  levels were not
significantly decreased anymore, as was observed in supernatant fractions derived from cells cultured
Figure 4
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CD4+ T cells, isolated from DO11.10 mice
were stimulated with OVA323-339 presented
by splenocytes derived from BALB/c mice
and cultured in the presence (+) or absence
(-) of IL16. After 5 days non-viable cells
were removed and cells were restimulated
with splenocytes and OVA323-339 and
subsequently cultured for 2 days. Presented
are levels of IL4 (open bars), IL5 (hatched
bars), IL10 (black bars) and IFNg
(horizontally striped bars) after the second
culturing period. Presented is a
representative example of four independent
experiments.
Table II: Cytokine production during different stages of T cell differentiation
Without IL16 present during the first antigen-specific stimulation.
Cytokine IL4 IL5 IL10 IFNg
Stimulation Period/
Skewing conditions
I II I II I II I II
- 0.01– 0.0   0.9– 0.2 1.4– 0.5   8.4– 3.7   0.0– 0.0   7.0– 0.4 10.0– 0.1   9.2– 0.7
IL4 nd
  1.4– 0.0 (*) 2.5– 0.3 14.0– 3.0   1.3– 0.7 10.7– 0.4 (**)   8.6– 0.2 (*)   2.5– 0.9 (**)
anti-IL4 nd
  0.1– 0.1 (*) 1.1– 0.8   1.0– 0.5 (*)   0.1– 0.1   1.9– 0.5 (**)   9.8– 0.1 10.0– 0.1
With IL16 present during the first antigen-specific stimulation.
Cytokine IL4 IL5 IL10 IFNg
Stimulation Period/
Skewing conditions
I II I II I II I II
- 0.01– 0.0   0.6– 0.2 (#) 1.5– 0.5   5.5– 3.2 (#) 0.6– 0.3   8.3– 1.2   9.8– 0.3   8.5– 1.1
IL4 nd
  1.4– 0.1 4.5– 0.6 (#) 12.6– 2.7 3.4– 1.5(P=0.06) 10.9– 0.2   9.1– 0.2   2.0– 0.3
anti-IL4 nd
  0.0– 0.0 1.7– 1.0   1.6– 1.1 0.3– 0.2   3.8– 1.0   9.8– 0.1   9.7– 0.1
Cytokine levels (ng ml-1) in supernatant fractions from DO11.10 CD4+ T cells, stimulated with OVA323-339 presented by BALB/c splenocytes after the first culturing
period (I) with or without IL16 (1.0 m g ml-1) and after the second stimulation period (II). Cells were cultured during the first stimulation period in medium alone, in the
presence of IL4 or in the presence of antibodies to IL4 (anti-IL4). During the second stimulation period with OVA323-339, cultures were maintained in medium only.
Results are expressed as arithmetic average ± SEM of 4 separate experiments. IL4 levels after the first stimulation period were not determined (nd). * (P<0.05); **
(P<0.01) significantly different from the cytokine level measured in supernatant fractions from cells cultured in medium. # (P<0.05) significantly different from the
cytokine level measured in supernatant fractions from cells cultured without IL16 present during the first antigen stimulation.
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without rmIL16 (Table II). No differences were observed in IL4, IL5, IL10 and IFNg  levels in supernatants
harvested after the second stimulation, when compared with cells cultured without rmIL16 (Table II).
Adding antibodies to CD4 during the first stimulation period of these cultures also enhanced production of
both IL10 and IL5 (2.8– 2.0 vs 4.9– 1.6 ng ml-1 and 1.7– 1.3 vs 3.4– 2.5 ng ml-1, respectively), although this
did not reach statistical significance. Again, no differences in cytokine production were observed in
supernatants upon restimulation (data not shown).
III Th1-type cytokine production
No significant differences were observed between cytokine levels in supernatant fractions obtained from
cells cultured in presence of antibodies to IL4 when compared to cells maintained in medium alone at the
end of the first stimulation (Table II). When antibodies to IL4 were present during the initial phase, only
IFNg  was produced upon restimulation (Table II), which is indicative of a Th1-type cytokine profile (8).
No significant differences in cytokine levels were observed between cultures supplemented with rmIL16
after the first stimulation with antigen, when compared with cells cultured in presence of only antibodies to
IL4 (Table II). Furthermore, no differences in cytokine production due to rmIL16 were observed upon
restimulation (Table II).
Presence of antibodies to CD4 also did not alter cytokine levels measured in supernatant fractions
harvested either after the first stimulation or upon restimulation, when compared to cells that were initially
cultured in presence of only antibodies to IL4 (data not shown).
Discussion
In this study we demonstrate that IL16 and antibodies to CD4 concentration-dependently inhibit
proliferation of lymphocytes that are either polyclonally or antigen-specifically stimulated. Moreover, Th2-
type cytokine production by these antigen-stimulated cells is also significantly decreased. In addition,
upon restimulation of priming cultures that were maintained in presence of IL16 or antibodies to CD4,
TCR transgenic T cells display a marked reduction in IL4 and IL5 production, but not IL10 and IFNg , when
compared with effector cells that were generated in absence of IL16.
Previously, we found that treatment with IL16 inhibits airway hyperresponsiveness and decreases
infiltration of eosinophils after treatment with either rhIL16 or rmIL16 in a murine model of allergic asthma
(226). It has been clearly demonstrated that development of airway hyperresponsiveness and
eosinophilia in different animal models of allergic asthma, as well as the Th2-type cytokine production
upon in vitro restimulation are caused by CD4+ T cells (151, 227, 228). IL16 is a cytokine that uses the
CD4 molecule as its receptor and cross-linking CD4 by IL16 has been shown to be a prerequisite for IL16
to exert its biological activities (29, 90). Thus the CD4+ T cell is likely to be affected by treatment with IL16
in vivo. In agreement herewith, we demonstrated previously that treatment with IL16 in vivo largely
decreased IL4 and IL5 production by TLN cells upon antigen-specific restimulation in vitro (221). This
CD4+ T cell inhibitory activity by IL16 treatment is supported by a recent publication in which it was
demonstrated that in vivo administration of rhIL16 is capable of inhibiting CD4+ T cell mediated responses
in a murine model for human rheumatoid synovitis (222). However, the mechanisms via which IL16 exerts
these anti-inflammatory actions are not known yet.
In the present study we examined the effects of IL16 on T cell responses in vitro. Here, we demonstrate
that CD4 cross-linking with IL16 or with antibodies to CD4 decreased anti-CD3-induced proliferation of T
cells. These observations are in agreement with the inhibitory effects of rhIL16 on proliferation of freshly
isolated PBMCs after stimulation with immobilized anti-CD3 (69). More importantly, inhibition of antigen-
induced T cell proliferation by rhIL16 has also been demonstrated (69, 70). Furthermore, we found that
both antibodies to CD4 and IL16 inhibit antigen-induced proliferation as well as production of the Th2-type
cytokines produced by CD4+ lymphocytes. It is well known that Th2 type cytokines such as IL4 and IL5
are necessary for induction of allergic manifestations in murine models of allergic asthma (11, 13, 163,
229, 230). Therefore, decreased antigen-induced proliferation and cytokine production by antigen-specific
T cells could very well be the cause of the inhibition of airway hyperreactivity and eosinophilia after in vivo
treatment with IL16 (chapter 5). In agreement with these findings, binding of CD4 molecules by e.g.
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antibodies to CD4 or gp120, prior to T cell receptor-mediated activation of T cells also causes the T cell to
become unresponsive (45, 127, 136, 223).
The observed anti-inflammatory action of IL16 administration in vivo could also be explained by effects of
IL16 on T cell differentiation. It has been clearly demonstrated that besides an accessory function in TCR-
induced signaling, the CD4 molecule also plays a role in differentiation of T cells into Th2-type effector
cells (71). In the present study, we demonstrate that DO11.10 CD4+ effector T cells, raised in presence of
IL16 without skewing agents during priming cultures, display reduced production of IL4 and IL5 upon
antigen-specific restimulation, whereas IL10 and IFNg  levels are not affected. Similar observations were
made after CD4 cross-linking with antibodies to CD4. Differentiation of naive CD4+ T cells towards
effector cells is likely to occur during in vivo antigen challenge. In previous studies we showed that TLN
cells, isolated from ovalbumin-sensitized saline-challenged mice do not produce any Th2-type cytokines
upon antigen-specific restimulation in vitro, whereas TLN cells isolated from antigen challenged animals
do (151, 206). It can thus be speculated that in this murine model naive T cells are recruited to lymph
nodes upon antigen challenge and subsequently differentiate towards effector cells that produce
cytokines such as IL4 and IL5. Decreased IL4 and IL5 production, combined with normal levels of IL10
and IFNg  could offer an explanation for the results obtained after in vivo treatment with IL16. As already
mentioned, both IL4 and IL5 are necessary for development of allergy associated parameters. Both IL10
and IFNg  have been demonstrated to be potent inhibitors of Th2-type T cell-mediated responses (231,
232). IL10 has been clearly shown to inhibit antigen-dependent T cell activation, probably via effects on
APCs (233, 234).
Furthermore, IL10 administration inhibits antigen-induced responses in different murine models of allergic
asthma (231, 232). IFNg  also is a potent suppressor of development of antigen-induced airway
hyperresponsiveness and eosinophilia in murine models (165, 235). However, after in vivo treatment with
IL16 of antigen-sensitized and challenged mice, we were unable to detect enhanced antigen-induced
IFNg  production by TLN cells (unpublished observations). Therefore, IFNg  is not very likely to be the
cause of the inhibitory effects of treatment with IL16 in our murine model of allergic asthma.
The observation that we did not detect any effect of IL16 in priming cultures on restimulation of T cells
that were skewed towards a Th2 profile seems to be in contrast with a recent report stating that CD4-
signaling is crucial for Th2 development (71). However, in our experimental set-up presence or absence
of IL4 during the initial stimulation determines T cell differentiation (224), whereas in the study by
Leitenberg et al. the affinity of the ligand that is used during the initial stimulation for the TCR determines
the cytokine profile that is produced upon antigen-specific restimulation (71). In agreement with our
observations, it was shown in the latter system that IL4 is capable of bypassing the necessity for CD4-
signaling in development of Th2-type cytokine responses (71). Furthermore, in the ovalbumin model in
BALB/c mice approximately half of the T and B cell responses is directed against other epitopes of
ovalbumin (with other affinities for the TCR) than against the immunodominant epitope
 
OVA323-339.
Therefore our in vitro skewing conditions could be different from circumstances that determine T cell
differentiation in vivo (E. M. Janssen et al., Am. J. Respir. cell Mol. Biol., in press).
The observation that IL16-treated DO11.10 cells under non-skewing circumstances do not display
decreased cytokine production at the end of the first antigen stimulation, seems to be in contrast with our
observation that proliferation and cytokine production by antigen-specific T cells, isolated from antigen-
sensitized and challenged animals, are decreased by CD4 ligation in vitro. However, it is well
documented that memory cells in particular are susceptible to CD4-induced unresponsiveness, whereas
naive T cells are not (236). An explanation for this difference in sensitivity could be the level of CD4
expression since this level increases if T cells are exposed to antigen (i.e. become effector/memory cells).
Freshly isolated DO11.10 CD4+ T cells indeed demonstrate a naive phenotype, as was indicated by high
expression of CD45RB and CD62L/L-selectin (data not shown), whereas TLN cells, isolated from antigen-
sensitized and repeatedly challenged animals are likely to have a memory/effector phenotype and are
therefore more susceptible to CD4-mediated unresponsiveness. Interestingly, recent evidence suggests
that the lymphocytes that are responsible for the passive transfer of allergic inflammation indeed have a
CD4high, CD62LlowCD25+ phenotype (211).
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Cells that were skewed towards a Th2-type cytokine profile and cultured in presence of IL16 have an
increased production of IL5 and IL10 during the first stimulatory period and a similar tendency was
observed with antibodies to CD4. The fact that Th2 differentiation is enhanced by CD4 cross-linking is in
agreement with observations by others (237). However, no differences were observed after the second
stimulation with antigen of cells that were initially cultured in presence of IL4. Thus, this effect appears to
be short-lasting and depending on the presence of CD4 ligands. As already mentioned, the observed
increase in IL10 levels could be an explanation for the IL16-induced effects in vivo. In contrast, enhanced
IL5 production, as was observed in vitro after culturing with IL16 under Th2-skewing circumstances,
would actually increase the antigen-induced responses in vivo. It has been clearly demonstrated that IL5
is important for antigen-induced airway hyperresponsiveness and eosinophilia in different animal models
of allergic asthma (12, 214, 229). However, this enhanced Th2-type cytokine production by CD4 ligands
was only observed under very strict circumstances that promote differentiation towards a Th2-type T cell
(224). Since in vivo treatment with IL16 inhibits development of antigen-induced airway
hyperresponsiveness and eosinophilia, it is not very likely that IL16 induces production of IL5 in vivo upon
antigen-specific stimulation. Moreover, this would be completely opposite to the observation that TLN
cells isolated from IL16-treated animals display decreased production of IL5 upon antigen restimulation in
vitro. It is not known at present which in vitro conditions accurately reflect the microenvironment of T cell
differentiation in vivo. However, based on our in vivo results it seems to be that the conditions in which no
skewing agents are present resemble the in vivo conditions in our model most.
In conclusion, the in vitro data presented in this study provide novel insights in how IL16 can inhibit
antigen-induced responses in vivo. However, further research is necessary to explore which of these
possibilities is the cause of the inhibition by IL16 of antigen-induced airway hyperresponsiveness and
eosinophilia.
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Summary and General Discussion
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Introduction on allergic asthma
Allergic asthma is a disease which affects an increasing number of people. Patients with this illness
suffer from variable airflow obstruction and increased airway responsiveness to a variety of stimuli.
Furthermore, an inflammatory response in the lungs occurs, accompanied by enhanced mucus
production (10). In serum of these patients enhanced levels of IgE antibodies can be detected
(reviewed in 238, 239).
Currently, several different drugs are available for people who suffer from asthma. These medicines
include corticosteroids, b 2-agonists, leukotriene antagonists and phosphodiesterase inhibitors (240-
244). Corticosteroids are the most effective and most used drug at this moment in the treatment of
asthma to reduce the inflammatory component and hyperresponsiveness (245). However,
corticosteroids are not very selective and affect a whole range of inflammatory and non-inflammatory
cells (246-248). More importantly, all drugs that are available for people who suffer from allergic
asthma do not cure these patients but only reduce the clinical symptoms of this disorder. Therefore,
current research is focused on development of strategies that treat asthmatics at a more causal level
of their illness.
It is now widely accepted that T-helper type 2 (Th2) lymphocytes play a causal role in allergic asthma
(10, 249, 250). Th2 cells produce a limited set of cytokines including interleukin-3 (IL3), IL4, IL5, IL9,
IL10 and IL13. Both in human asthmatic patients and murine models of allergic asthma Th2 subsets
have been detected (8, 9) and it is extensively documented that the cytokines produced by these cells
are crucial for development of allergic symptoms. New strategies could therefore be aimed at
specifically targeting this T cell subset or the cytokines produced by these T cells (18, 251, 252).
Murine models of allergic asthma
Over the past decades several different animal models have been developed which display
phenomena characteristic of allergic asthma (13, 20, 149, 164, 166, 186, 253). These models have
been demonstrated to be very useful for the development of new therapeutic strategies for the cure of
allergic asthma and to gain insight in the immunological disorders underlying the cause of this
disease. In the murine model we have used in our studies, several allergy associated parameters can
be measured, including increased airway hyperresponsiveness to non-specific bronchoconstrictive
agents as well as an inflammatory response in the lungs (148-151). Furthermore, elevated levels of
antigen-specific IgE upon challenge and production of Th2-type cytokines by CD4+ T cells isolated
from lung-draining lymph node cells can be detected (149, 151, 165, 254). As is the case in human
allergic disease (reviewed in 255), several of these parameters can be influenced by treatment with
corticosteroids (149).
Detection of Early and Late Bronchoconstrictive Responses and kinetics of airway
hyperresponsiveness and eosinophilia
One of the characteristics of allergic asthma in humans is the occurrence upon contact with allergens
of the so-called acute bronchoconstrictive response (256). In the animal model we use, we can also
measure increased airway constriction upon provocation with antigen, using either forced oscillatory
techniques (257) or whole body plethysmography (chapter 2). This acute airway response is believed
to be caused by mediators released by mast cells. These inflammatory cells degranulate upon cross-
linking of antigen-specific IgE molecules bound to high affinity Fc e  receptors present on the cell
membrane. It is possible to determine mast cell degranulation via measurement of MMCP-1 levels, an
enzyme normally present in mucosal mast cells (171). Increased serum MMCP-1 levels could be
detected after antigen challenge in murine the model we use (chapter 2) indicating that mast cells
degranulate. This is in agreement with previous experiments in which a clear mast cell degranulation
was observed upon a single antigen challenge, using electron microscopy (170). Besides the early
bronchoconstrictive responses, late asthmatic responses (LAR) have been reported in humans, which
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are associated with the infiltration of inflammatory cells into the lungs. The development of LAR in
human asthmatics occurs as a spectrum ranging from no LAR to severe late asthmatic
bronchoconstricitive responses following antigen challenge, which seems to be at least partially
dependent on the dose of antigen (reviewed in 157). Furthermore, it is thought that there is a direct
correlation between infiltration of eosinophils and the occurrence of LAR in asthmatic patients (157,
160). However, others observed that eosinophilia or the presence of mediators released by
eosinophils could not predict the emergence of LAR (161). This LAR usually occurs at several hours
after contact with the antigen. Decreased serum corticosteroid levels during night time (258-260) could
be the explanation for the observation that this response typically occurs during the sleeping period.
We used several different approaches to induce such late bronchoconstrictive responses in the
murine model. Our attempts included inhibition of endogenous corticosteroid production using
metyrapone (149), which has been demonstrated to increase occurrence of late responses in dogs
(168) and to increase antigen-induced responses in rats (169). Furthermore, metyrapone has also
been found to increase both the number of eosinophils and the degree of airway hyperresponsiveness
after ovalbumin-challenge in the used murine model (149). Since correlations between infiltration of
eosinophils and the occurrence of LAR in asthmatic patients and between the dose of antigen and
LAR have been reported to exist (157), we measured bronchoconstrictive responses after increasing
antigen deposition via local administration of ovalbumin and at times when eosinophils are already
present in the lungs. Despite these attempts, we were unable to demonstrate such late
bronchoconstrictive responses in the animal model, even at times when eosinophils are already
abundantly present (chapter 2). This might be due to the fact that eosinophils are not or only mildly
activated in this model of allergic asthma. Indeed, it has been demonstrated that eosinophils in murine
models of allergic asthma were not activated since no major basic protein release (178) or eosinophil
peroxidase in cell free bronchoalveolar lavage (BAL) fluid could be detected (E.M. Hessel,
unpublished observations). However, others did report eosinophil activation and subsequent
morphologic changes of the airways upon antigen-challenge (179). Another reason for not detecting
late bronchoconstrictive responses whereas both airway hyperresponsiveness and eosinophilia are
present could be that these phenomena are not causally related in mice. This could accurately reflect
the situation in human asthmatics, because numerous patients do exhibit airway hyperresponsiveness
or eosinophilia upon antigen-provocation without detectable LAR (157, 161).
Besides detection of early and late asthmatic responses, we measured development of airway
hyperresponsiveness and eosinophilia in time. It appeared that eosinophilia and airway
hyperresponsiveness are only correlated during the period in which animals are daily challenged with
antigen. After ending antigen provocations, airway hyperresponsiveness declines within 5 days
whereas eosinophils are still present in the lungs at that time (chapter 2). From previous experiments it
is well known that eosinophilia is not always correlated to airway hyperresponsiveness in this murine
model (148). In particular, treatment with antibodies to IL5 in this and an other model revealed that
airway hyperresponsiveness can still develop even though no detectable eosinophilia is present (13,
148). This dissociation between presence of eosinophils and airway hyperresponsiveness has also
been reported for human allergic patients (reviewed in 180, 181, 261-263). It has e.g. been described
that patients have eosinophils in the bronchoalveoar lavage fluid without displaying airway
hyperresponsiveness (181). Furthermore, patients have been described that suffer from airway
hyperresponsiveness, whereas no eosinophils could be detected in the lungs (262). However, others
did observe positive correlations between airway hyperresponsiveness and presence of eosinophils
(reviewed in 5, 264).
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IL16 in the murine model; effects of histamine and 5-HT receptor antagonists
Using this murine model of allergic asthma, we explored the function of IL16, a cytokine that has been
reported to be associated with CD4+ T cell mediated diseases. In asthmatics, it was observed that
IL16 levels in BAL fluid increased upon antigen challenge, as well as after histamine provocation (26,
29). Furthermore, in atopic dermatitis, a positive association between the number of CD4+ T cells and
IL16 levels was detected (265). A similar correlation was observed in synovium from patients suffering
from rheumatoid arthritis (107). Finally, a correlation between disease activity index and levels of
circulating IL16 has been detected in systemic lupus erythematosus (SLE, 266). These data suggest
that IL16 is involved in several different CD4+ T cell-mediated diseases.
The first discovered source of IL16 was the T cell (74, 75). CD8+ T cells secrete IL16 following
stimulation with either histamine or serotonin (5-hydroxytryptamine, 5-HT, 79, 80) whereas CD4+ T cells
release IL16 following mitogen, antigen or anti-CD3 stimulation (29). In contrast to CD8+ T cells, CD4+
T cells do not contain preformed IL16 (29). In agreement herewith, it has recently been shown that
resting CD8+ T cells contain active capsase-3 that is capable of cleaving pro-IL16, whereas CD4+ T
cells require activation for the appearance of active capsase-3 (267). Caspase-3 is necessary for the
processing of pro-IL16 into biologically active IL16 (86). Besides T-lymphocytes, it has been shown
that both eosinophils and epithelial cells can release bioactive IL16 (26, 81, 94), whereas in
rheumatoid arthritis (RA) CD68- synovial fibroblasts have been shown to be the source of IL16 (107).
One of the major sources of IL16 in the airways could very well be epithelial cells, which have been
demonstrated to contain IL16 protein upon antigen-challenge in both humans (26, 29, 90) and the
murine model of allergic asthma we use (154). Furthermore, biologically active IL16 can be measured
in BAL fluid within hours after antigen-challenge (154). From literature it is known that preformed IL16
is released from CD8+ T cells after stimulation via histamine type 2 (H2) or 5-HT type 2 (5-HT2)
receptors and by epithelial cells upon stimulation with histamine (29, 79, 80). Since murine mast cells
are known to release both histamine and 5-HT upon stimulation in vivo (152, 153) and since murine mast
cells degranulate upon antigen challenge (chapter 2), it can be speculated that both 5-HT and histamine
are set free, which induces release of IL16. Therefore we tried to inhibit this release using different
histamine or 5-HT receptor-specific antagonists (chapter 3). Both eosinophil infiltration and airway
hyperresponsiveness were partially decreased after blocking either the H2 (using cimetidine) or 5-HT2
receptors (using ketanserin), whereas after blocking H1 and 5-HT1 receptors (using mepyramine and
methiotepine, respectively) these effects were not observed (chapter 3). Treatment with a combination
of cimetidine and ketanserin completely inhibited development of airway hyperresponsiveness,
whereas eosinophilia was not further decreased.
As was previously stated, mast cells can secrete both histamine and 5-HT (152, 153) and mast cells
degranulate upon antigen challenge in our model. Furthermore, it is well known that mast cells are
important in the onset of airway hyperresponsiveness (15, 173) and that mast cells play a pivotal role
onset of the inflammation via e.g. TNFa , IL4 and IL5 release (185, 196). Together with the observed
effects of both cimetidine and ketanserin on airway hyperresponsiveness, it is very tempting to speculate
that mast cells are involved in development of airway hyperresponsiveness and eosinophilia via release
of both histamine and 5-HT upon antigen challenge.
We did not detect any differences in presence of biologically active IL16 levels in bronchoalveolar
lavage fluids after treatment with either the receptor antagonists alone or after treatment with the
combination of antagonists (chapter 3). It is therefore very likely that autacoids, such as histamine or
5-HT are not the only inducers of IL16 release in vivo. Other sources of IL16 could e.g. be the CD4+ T
lymphocyte, which has been demonstrated to release IL16 after challenge with antigen (29, 90).
Moreover, eosinophils constitutively release IL16 (81) and IL16 presence has been shown in
inflammatory cell infiltrates, which contain eosinophils, in lung tissue upon antigen-challenge (154). It
could thus be speculated that even though specific histamine and 5-HT receptor subtypes that were
reported to mediate IL16 release in vitro, were blocked, other cells, such as T cells and eosinophils
are major sources of IL16 in the mouse model upon antigen provocation. Finally, mast cells
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themselves have been shown to release IL16 upon stimulation with C5a or PMA and could thus be a
source of IL16 upon activation (82).
IL16 in the murine model; effect of blocking peptides or antibodies
Another approach to determine the role of endogenous IL16 in development of allergy associated
parameters in the murine model, was to use either antibodies to IL16 or different peptides of which the
amino acid sequences were based on different parts of the predicted sequence of human IL16 (76).
Peptides 1 and 2 were based on different C-terminal located regions of the predicted amino acid
sequence of rhIL16. These peptides have been demonstrated not to interfere with rmIL16-induced
chemotaxis of murine lymphocytes in vitro in our study (chapter 4) or with OKT4 binding to CD4 or rhIL16-
induced chemotaxis in another study (76). Peptide 3, which was based on the C-terminal hydrophilic
region of human IL16 was shown to decrease rhIL16 induced chemotaxis of human CD4+ T cells (76).
Furthermore, peptide 3 can partially prevent the binding of monoclonal antibodies to CD4 (76). These
data, together with the observation that IL16 uses CD4 as receptor, suggest that the C-terminal
hydrophilic region of IL16 is involved in binding of CD4. Furthermore, based on these data it could be
suggested that peptide 3 interacts with CD4, thereby inhibiting cross-linking by IL16 and subsequent
signaling. Cross-linking of CD4 molecules has been demonstrated to be a prerequisite for IL16 to be
biologically active (29, 90). We therefore intranasally treated mice either with these peptides or with
antibodies to IL16 during the antigen-challenge period to inhibit effects caused by endogenously
produced IL16. Using the different peptides, we demonstrated that the in vitro IL16-blocking peptide
was also active in vivo (chapter 4). Intranasal administration during the antigen challenge period of
either peptide 3 or antibodies to IL16 partially decreased airway hyperresponsiveness whereas
inflammation was not affected (chapter 4). These results indicate that treatment with peptide 3 causes
the same effects as antibodies to IL16, possibly via inhibition of interaction between IL16 and its receptor
CD4. Therefore, peptide 3 could be useful as a lead compound in attempting to limit airway
hyperresponsiveness via binding to CD4.
These results also indicate that endogenous IL16 at least has an effect on airway hyperresponsiveness in
vivo, since we observed a decrease in development of airway hyperresponsiveness by treatment with
either antibodies to IL16 or peptide 3. However, this was not accompanied by a decreased inflammatory
response. From this observation it could be concluded that endogenously produced IL16 is not a crucial
factor for chemotaxis of eosinophils in the murine model. These data appear to be in contrast with in vitro
studies in which pro-inflammatory properties of IL16 have been detected. IL16 in resting CD4+ T cells
upregulates expression of IL-2R and HLA-DR and induces a shift in cell cycle from G0 to G1a (29). In
addition, IL16 synergistically stimulates proliferation of CD4+ T cells when combined with IL2 (76) and
induces chemotaxis of CD4+ cells, including T cells, monocytes and eosinophils (29, 90). Furthermore,
IL16 can function as a competence growth factor for CD4+ T cells (reviewed in 268). Finally, it has
been observed that upon antigen challenge IL16 is the most important chemoattracting factor present in
BAL fluid in human asthmatics after antigen-challenge (25) and that antibodies to IL16 can protect
against induction of colitis in mice (108). It could be speculated that a great redundancy is present in the
inflammatory process that regulates the infiltration of inflammatory cells and that therefore antibodies to
IL16 do not reduce antigen-induced eosinophilia in this model. Furthermore, based on the observation
that decreased airway hyperresponsiveness does not correlate with decreased presence of eosinophils in
BAL fluid it can be concluded that these two phenomena are not necessarily causally related in this
model.
Effect of treatment with IL16 in vivo and in vitro
Besides blocking endogenously produced IL16, we also administered IL16 in this murine model during
antigen challenge. As demonstrated in chapter 5, intraperitoneal administration of IL16 before each
antigen challenge inhibits development of airway hyperresponsiveness and infiltration of eosinophils.
Intranasal application of IL16 also inhibits infiltration of eosinophils upon antigen challenge (data not
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shown). IL16 uses the CD4 molecule as its receptor and the antigen-specific CD4+ Th2-type T cell has
abundantly been proposed to be the regulatory cell in asthma-related pathology. In agreement herewith,
antigen-specific restimulation of thoracic lymph node cells appears to be affected by in vivo treatment with
IL16 since these cells display a decreased Th2-type cytokine production upon in vitro restimulation with
antigen. Thus IL16, probably via inhibition of CD4+ T cell functioning, has potential beneficial properties in
the treatment of features reminiscent of allergic asthma. Interestingly, no effects were observed on
production of antigen-specific IgE by in vivo treatment with IL16, indicating that memory B cell responses
were not affected.
When we further examined this T cell unresponsiveness-inducing property of CD4 cross-linking, we
observed that lymph node cells which were preincubated in vitro with either IL16 or antibodies to CD4,
were unable to respond to antigen (chapters 5 and 6) or to polyclonal stimulation of lymphocytes (chapter
6). This IL16-induced T cell unresponsiveness is in agreement with observations by others who
demonstrated that IL16 inhibits T cell activation (69, 70). Analogous to this observation, other CD4
ligands, such as antibodies to CD4 or gp120, can induce anergy (see chapter 1). It has been clearly
demonstrated in several animal models that use of non-depleting antibodies to CD4 in vivo can be of
potential therapeutic importance for different CD4+ T cell-mediated disorders (133, 136, 137, 269). It
has been shown e.g. that CD4 cross-linking by antibodies to CD4 results in long-term survival of
cardiac grafts in mice (136) and inhibits development of collagen-induced arthritis (CIA) as well as
adoptive transfer of CIA into SCID mice (137).
Since the CD4 molecule plays a role in T cell differentiation (71), besides acting as an accessory
molecule in TCR-mediated T cell activation (37, 41), we also determined effects of CD4 cross-linking on
T cell differentiation. It was shown by Leitenberg et al. that the CD4 molecule is required for induction of
Th2 type T cell differentiation, whereas it is not for development of Th1 type T cells (71). To explore
possible effects of IL16 or anti-CD4 antibodies on differentiation of naive CD4+ T cells into effector cells
with a Th0, Th1 or a Th2-type cytokine producing phenotype we determined effects of these CD4
agonists in an artificial in vitro T cell skewing system. In this experimental set-up, medium only, IL4 or
antibodies to IL4 are used to direct differentiation of naive TCR transgenic (DO11.10) T cells towards the
production upon restimulation of Th0, Th2 or Th1-type cytokines, respectively (224).
When naive DO11.10 T cells were cultured with IL16 or antibodies to CD4, and stimulated with antigen
without skewing agents, no apparent effects were noted on cytokine production. However, when these
cells were restimulated with antigen, the capacity to produce IL4 and IL5 was markedly reduced, whereas
IL10 and IFNg  levels were not affected in these cultures (chapter 6). This observation could offer an
explanation for the results obtained after in vivo treatment with IL16. Both IL4 and IL5 are crucial for
development of allergy associated parameters, whereas both IL10 and IFNg  have been demonstrated to
be potent inhibitors of Th2-type T cell-mediated responses (reviewed in 251). IL10 has been clearly
demonstrated to inhibit antigen-dependent T cell activation, probably via effects on antigen presenting
cells (APC, 233, 234). Furthermore, IL10 administration has been shown to inhibit antigen-induced
responses in different murine models of allergic asthma (231, 232). IFNg  has also been shown to be a
potent inhibitor of development of antigen-induced airway hyperresponsiveness and eosinophilia (165).
Furthermore, IFNg  receptor knock-out mice have an impaired ability to resolve antigen-induced
inflammation of the airways and sustained Th2-type cytokine production by lymphocytes (235). IFNg
production has also been demonstrated to be increased in a synergistical manner when T cells were
incubated with a combination of IL16 and IL2 (88). In agreement herewith, we observed that IL16
combined with IL2 enhances IFNg  production by murine CD4+ lymphocytes (unpublished observations).
This synergistical enhancing effect by the combination of IL2 and IL16 on IFNg  could be caused by an
IL16-induced upregulation of IL2 receptor expression (29, 90).
Hypothesis on effects of exogenously administered IL16
These observations lead us to the following hypothesis on the effects induced by in vivo treatment with
IL16. When IL16 is administered before proper T cell receptor stimulation via MHC-II and antigen
interaction, IL16-induced CD4 cross-linking could induce T cell unresponsiveness in memory cells
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(Figure 1). On the other hand, naive T cells that are stimulated with antigen in presence of IL16 may have
a decreased capacity to produce the Th2-type cytokines IL4 and IL5 upon restimulation, whereas
production of IL10 and IFNg  is not affected (Figure 1). It can be speculated that in the murine model we
use, naive T cells are continuously recruited to lymph nodes during repetitive antigen challenge.
Differentiation of naive CD4+ T cells towards effector cells is likely to occur during in vivo antigen
challenge. In previous studies we showed that thoracic lymph node (TLN) cells, isolated from ovalbumin-
sensitized saline-challenged mice do not produce any Th2-type cytokines upon antigen-specific
restimulation in vitro, whereas TLN cells isolated from antigen challenged animals do (151, 206). It could
thus be suggested that the balance between production of allergy-associated cytokines (such as IL4 and
IL5) and anti-inflammatory cytokines (such as IFNg  and IL10) by effector cells, is disrupted by exposure to
IL16 under priming conditions (Figure 1). Moreover, non-specific “bystander” T cells could be
synergistically activated by IL16 and endogenously produced IL2, leading to production of IFNg . In BAL
fluid derived from asthmatic patients with bronchial asthma increased IL2 concentrations were detected
when compared with normal subjects (270). This IL2 could be produced by eosinophils, epithelial cells or
T lymphocytes (271-273).
Figure 1
Histamine + 5-HT
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IL16
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Eo
“naive”
“memory”
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CD8  T cell+
IL10 + IFN g
IL4 + IL5
IFN
g
‘allergenic’ ‘suppressive’
CD4  T cell+
CD4  T cell+ “bystander T cell”
+IL2
MC
Possible mechanisms of action of IL16 in a murine model of allergic asthma (see text for explanation).
Abbreviations used: AHR; Airway Hyperresponsiveness, IL; Interleukin, Ag; Antigen, APC, Antigen-
Presenting Cell, MC; Mast Cell, TCR, T Cell Receptor; Eo, Eosinophil; CD, Cluster of Differentiation, (-)
inhibitory effect.
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In its turn, IFNg  has been demonstrated to be a potent inhibitor of Th2-type T cell responses (165).
However, no IFNg  could be detected when TLN cells, derived from in vivo IL16-treated animals, were
stimulated with antigen. Production of IFNg  is also associated with increases in IgG2a antibody
production (274, 275) and we were unable to detect any increase in IgG2a levels after treatment with IL16
(unpublished observations). Therefore, IFNg  production, induced by in vivo treatment with IL16, is
probably not the cause of the observed effects. Treatment with IL16 of IL10 knock-out (276) mice or co-
administration of IL16 and antibodies to IL10 or its receptor in the model could resolve the issue whether
IL10 is responsible for the IL16-induced effects.
One of the issues that remains unanswered by our studies is the fact that in vivo small amounts of IL16 (1
m g animal-1 day-1) are capable of inducing anti-inflammatory effects whereas in vitro concentrations up to
1 m g ml-1 are necessary to change CD4+ T cell functions, such as antigen-induced proliferation and
cytokine production. An explanation for this discrepancy could be that IL16 has synergistical effects in
vivo with other mediators which are not present in our in vitro systems. Furthermore, it could very well be
suggested that other CD4+ cells, such as monocytes or different subsets of dendritic cells are affected by
in vivo IL16 treatment, instead of CD4+ T cells. IL16 has been demonstrated to induce CD4-dependent
signaling in macrophages (105) and these cells have been demonstrated to play an important regulatory
role in development of features reminiscent of allergic asthma (reviewed in 277). Alveolar macrophages
have e.g. been demonstrated to produce both IL10 and IL12 (278) and these cytokines have been
extensively documented to inhibit allergic manifestations in murine models (151, 231, 232). However,
contradictory evidence on the function of macrophages exists since alveolar macrophages increase Th2-
type cytokine production by lymphocytes upon stimulation with antigen (279). Besides macrophages, a
subset of dendritic cells has the CD4 molecule on its membrane (280). Dendritic cells are of crucial
importance for the development of chronic eosinophilic airway inflammation in response to antigen (281).
Therefore, future experiments focused at other CD4+ cells than T cells might further unravel the
mechanisms via which treatment with IL16 reduces antigen-induced responses in vivo.
Hypothesis on endogenously produced IL16
The observation that intratracheal or intraperitoneal treatment with IL16 does not lead to an inflammatory
response by itself (chapter 5), indicates that IL16 might not be a potent in vivo chemotactic factor for
CD4+ cells. This theory is further supported by the observation that IL16 transgene mice do not display
any signs of inflammation due to local overexpression in the lungs of IL16 (G. Chubb, personal
communications). Furthermore, antibodies to IL16 do not inhibit development of antigen-induced
inflammation (chapter 4). Finally, other CD4 binding molecules, such as antibodies to CD4 or gp120 also
induce in vitro chemotaxis of CD4+ cells, e.g. of eosinophils, (95), without having pro-inflammatory
properties in vivo. As already mentioned this is not in agreement with in vitro evidence which suggests
that IL16 can attract CD4+ T cells (29).
We (chapters 5 and 6) and others (222) have clearly demonstrated that exogenously administered
IL16 has anti-inflammatory activity. In contrast, endogenously produced IL16 has also been found to
have pro-inflammatory effects (reviewed in 90) and (29, 25). Furthermore, we demonstrated that
inhibition of endogenously produced IL16, using either an antibody to IL16 or peptide 3 which inhibits
interaction between IL16 and its receptor, partially decreased induction of airway
hyperresponsiveness, whereas eosinophilia remained present (chapter 4). This is in agreement with
previous experiments in which systemic treatment with antibodies to IL16 also partially inhibited
development of airway hyperresponsiveness, without decreasing eosinophilia (154). It has also been
shown that IL16 can protect lymphocytes from apoptosis (92) and is a competence growth factor for
CD4+ lymphocytes (268), which implicates that IL16 plays a role in accumulation of CD4+ antigen-
specific T cells at the site of allergen deposition.
Thus IL16 could have pro-inflammatory properties on the one hand, whereas IL16 has also been
demonstrated to have immunosuppressive properties. Both the timing and local concentrations of IL16
in the microenvironment of e.g. CD4+ T cells may be important factors between either playing a role in
development of airway hyperresponsiveness or induction of T cell unresponsiveness. Furthermore, as
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already mentioned, we only focused on effects of CD4 cross-linking by IL16 on T cells in our studies,
whereas other CD4+ cells, such as monocytes or dendritic cells, can not be excluded to play a role in
causing the inhibitory effects observed after treatment with IL16 in vivo.
Another possible explanation for the results obtained with peptide 3 (chapter 4) could be that by
binding CD4 molecules, monovalent peptide 3-CD4 interaction actually induces similar responses as
treatment with IL16. This would contradict the observation that CD4 cross-linking is necessary for IL16
to be biologically active (29). However, recent literature suggests that CD4 cross-linking is not a
prerequisite for IL16-induced biological activity (87). According to literature, it is not unlikely that
monovalent CD4 binding instead of CD4 cross-linking is capable of inhibiting CD4+ T cells functions.
Using gp120 as a CD4 ligand it has been extensively demonstrated that monovalent CD4 binding can
inhibit stimulation of T cells by either antigen of polyclonal stimulation (45, 126, 282-284). It has also
been shown that monovalent interaction with CD4 does not necessarily lead to p56lck activation and
that p56lck-independent inhibition of T cell responses can occur (117, 285-287), suggesting a
regulatory role for the extracellular domains of CD4. In contrast, others did observe activation of
p56lck upon CD4-gp120 interaction (70, 114), as was e.g. measured by enhanced
autophosphorylation and the phosphorylation of the exogenous substrate enolase (115). Furthermore,
it has been reported that a secondary antibody to gp120 to cross-link CD4 molecules was needed to
inhibit proliferation of CD4+ T cells (45, 127). Therefore, it remains disputable whether CD4 cross-
linking is an absolute requirement for induction of CD4-mediated T cell unresponsiveness. If peptide 3
indeed has similar biological effects as IL16, it could be suggested that preincubation of CD4+
lymphocytes with peptide 3 would logically inhibit IL16-induced migration. In contrast with the
hypothesis that CD4 cross-linking is not necessary for IL16 induced effects is the observation that
peptide 3 by itself does not induce any detectable chemotaxis in vitro as does IL16 (76).
Based on the observation that peptide 3 is capable to bind to CD4 (76), it could be postulated that
peptide 3 (or monomeric IL16) inhibits T cell activation via inhibition of dimerization of CD4 or inhibition
of MHC-II/CD4 interaction (see chapter 1; Figure 4A and E). The amino acid sequence of peptide 3 is
based on the part of IL16 that binds CD4 and peptide 3 has been shown to partially inhibit binding of
antibodies to CD4. Furthermore, it is known that IL16 binds CD4 in the D4 region and this particular
region has been shown to be of importance for CD4 dimerization and CD4/MHC-II interaction and thus
to be important for optimal T cell activation (43).
The observation that development of airway hyperresponsiveness was partly impaired after
administration of antibodies to IL16 (chapter 4) could also be explained by enhancing half-life of IL16
instead of capturing endogenously produced IL16. Similar life-time enhancing effects have been
described with other antibodies. It has been clearly shown that antibodies can actually function as
carrier proteins, thereby prolonging the circulatory half-life of molecules such as insulin (reviewed in
288). Furthermore, it has been demonstrated that antibodies to IL4, IL3 and IL7 are capable of
enhancing biological activity of the cytokines they are directed against (289, 290). In agreement
herewith, it has been found that either autoantibodies or monoclonal antibodies against IL6 stabilize
the cytokine and thus constitute a reservoir of masked, but potentially active cytokine (291-293).
Alternatively, the immunecomplex of IL16 with antibodies could induce an immune response by itself
(294), thereby causing the observed inhibitory effects on airway hyperresponsiveness.
This could implicate that endogenously produced IL16 has similar inhibitory effects on antigen-induced
immune responses as were observed after treatment with IL16. If so, e.g. local concentrations of
endogenously produced IL16 might just not be high enough to inhibit development of antigen-induced
characteristics of allergic asthma. This hypothesis would provide an alternative explanation for the
correlation between disease severity and levels of circulating IL16 (266). Furthermore, if endogenously
produced IL16 indeed serves as an anti-inflammatory molecule, the mechanism that causes induction
of airway hyperresponsiveness must be more susceptible to IL16-induced inhibitory effects than
eosinophilia. If endogenously produced IL16 serves as an immunoinhibitory molecule, it could be
suggested that timing of IL16 treatment is not of crucial importance. This would be in agreement with
the study by Klimiuk et al., who clearly demonstrated that treatment with IL16 is capable of inhibiting
an already established inflammatory response (222). Future experiments, using e.g. IL16 knock-out
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mice, F(abs) of anti-IL16 antibodies, or cocktails of different antibodies to IL16 will have to provide the
answers to these questions. Furthermore, to resolve the issue on possible importance of timing of
treatment, effects of IL16 therapy will have to be determined in already established inflammatory
responses.
IL16 as a treatment for CD4+ T cell-mediated diseases
Based on our results it is very tempting to speculate on the use of IL16 as a cure for allergic diseases,
or more broadly, as a therapeutic for any CD4+ T cell mediated disease. Indeed, it has recently been
demonstrated that exogenously administered IL16 (1 m g animal-1 day-1) is capable of inhibiting CD4+ T
cell mediated responses in a murine model for human rheumatoid synovitis (222). In this particular
study it was demonstrated that IL16, derived from CD8+ T cells, inhibits inflammatory responses in
transplanted human inflamed synovium into non-obese diabetic (NOD)- severe combined
immunodeficient (SCID) mice. Furthermore, it was found that administration of rhIL16 inhibited tissue
cytokine production in human synovium-SCID mouse chimeras, suggesting a down-regulatory function
of IL16 in these immune responses (222). In our studies we observed an inhibitory effect by treatment
with IL16 on antigen-induced airway hyperresponsiveness and eosinophilia in a murine model of
allergic asthma. This decrease in allergic manifestations was accompanied by decreased production
of IL4 and IL5 by TLN cells upon restimulation in vitro, suggesting that CD4+ T cells are involved in the
mechanism via which treatment with IL16 causes these effects. Interestingly, no effects were observed
on production of antigen-specific IgE, indicating that memory B cell responses are not affected. The
observation that production of IgE is not affected whereas development of both airway
hyperresponsiveness and eosinophilia are inhibited is similar to effects caused by treatment with
corticosteroids (149). It has been clearly demonstrated that the CD4+ T cell is one of the main targets
of therapy with corticosteroids in both human asthmatics and murine models (255, 295-298).
Therefore, it could be suggested that patients who respond badly to treatment with steroids could
benefit from additional treatment with IL16.
Based on in vitro data it could be suggested that IL16-induced T cell unresponsiveness only occurs
upon subsequent stimulation of the T cell via the TCR. It has e.g. been shown that PHA-induced T cell
responses are not inhibited by treatment with IL16, whereas polyclonal or antigen-specific stimulation
is decreased (this thesis, 69, 70). This would implicate that simultaneous immunotherapy, combined
with IL16 treatment could be beneficial for patients who suffer from allergic asthma.
Both on our in vitro observations and literature data, it can be theorized that only memory cells are
susceptible for IL16-induced CD4 cross-linking. We clearly demonstrate that no direct effects can be
observed on naive T cells when stimulated with antigen. However, upon restimulation, these cells
display decreased cytokine production which appears to be limited to IL4 and IL5. Therefore, caution
is necessary since, even though CD4 cross-linking before stimulation of CD4+ T cells with antigen
could lead to clonal anergy, other CD4 molecules on either naive or memory T lymphocytes would
also be affected. Thereby, unwanted side effects could occur since as long as IL16 binds to CD4,
clonal anergy could be induced against e.g. any opportunistic infection which needs CD4+ T cell help
for clearance and is resident during or after the treatment. Furthermore, research will have to provide
answers on duration of IL16-induced unresponsiveness and long term effects of IL16 as a therapy.
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Introductie
In de geïndustrialiseerde landen lijdt naar schatting 10% van de bevolking aan allergische astma en
dit aantal neemt nog steeds toe. Het merendeel van de patiënten met allergische astma vertoont
overgevoeligheidsreacties voor gras- of boompollen of voor de uitwerpselen van de huisstofmijt (dit
zijn dan de antigenen).  Patiënten die lijden aan allergische astma kampen met een verhoogde
gevoeligheid van de luchtwegen voor niet-specifieke mediatoren zoals histamine en serotonine maar
ook mist (de zogenaamde luchtweg hyperreactiviteit). Tevens wordt in het merendeel van deze
patiënten een ontstekingsreactie in de longen waargenomen die voornamelijk bestaat uit eosinofiele
granulocyten. Gedacht wordt dat er een causaal verband is tussen het voorkomen van deze
eosinofiele granulocyten en de aanwezigheid van de luchtweg hyperreactiviteit. Deze
ontstekingsreactie gaat ook vaak gepaard met een verhoogde productie van slijm (mucus).
In het serum van deze mensen kunnen antistoffen, zogenaamde immuunglobulines, van het type E
worden gemeten. Dit IgE, wat kan binden via specifieke receptoren op mest cellen, kan een interactie
aangaan met het antigeen en dien tengevolge activatie veroorzaken van deze mest cellen. Dit leidt tot
de afgifte van mediatoren (waaronder histamine en serotonine), waardoor de luchtwegen vernauwen.
Dit is de zogenaamd acute astmatische reactie, die zich gewoonlijk voltrekt binnen enkele minuten en
tot enkele uren na contact met het antigeen manifest kan zijn. Naast de acute reactie wordt er bij een
select deel van de patiënten ook een laat astmatische reactie onderscheiden die gewoonlijk na enkele
uren optreedt en meestal binnen 24 uur verdwijnt. Deze respons wordt geassocieerd met de infiltratie
van verschillende ontstekingscellen.
Een van de cellen waaruit het immuunsysteem is opgebouwd is de CD4 positieve (CD4+) T helper 2
(Th2) cel en deze cel wordt geacht een belangrijke rol  te spelen in de pathologie die wordt
waargenomen bij allergische aandoeningen. Deze CD4+ Th2 cellen produceren verschillende eiwitten
waarmee deze cellen “communiceren” met andere cellen van het immuunsysteem. Deze
boodschapper moleculen worden cytokines genoemd. De CD4+ Th2 cel wordt gekenmerkt door de
productie van een aantal van deze cytokines, waaronder interleukine (IL)-4, 5, 9, 10 en 13. Dit profiel
van interleukines wordt gemeten bij patiënten met allergische astma na contact met het allergeen en
het is uitgebreid beschreven dat deze interleukines een belangrijke rol spelen bij het ontstaan van op
allergie lijkende reacties in verschillende diermodellen voor deze aandoening.
Een van deze diermodellen hebben wij gebruikt in de experimenten die beschreven zijn in dit
proefschrift. In dit model worden muizen gesensibiliseerd voor een lichaams vreemd eiwit
(ovalbumine, OVA) en vervolgens blootgesteld aan òf een nevel waarin datzelfde eiwit is opgelost òf
aan een nevel die slechts bestaat uit het oplosmiddel (saline, SAL). Door het gebruik van een nevel
wordt het antigeen in de longen gebracht. Het blijkt dat deze muizen een hyperreactiviteit van de
luchtwegen vertonen, dat ontstekingscellen (voornamelijk eosinofiele granulocyten) infiltreren in het
longweefsel en dat er een evidente toename detecteerbaar is in OVA-specifieke antilichaam
concentraties in het serum van deze dieren, na herhaaldelijke blootstelling van OVA-gesensibiliseerde
muizen aan OVA-nevel.
Detectie van de acute en laat astmatische reactie
Recentelijk is er een nieuwe techniek ontwikkeld waarmee op een niet invasieve manier luchtweg
reactiviteit van muizen bepaald kan worden. Deze techniek heeft als belangrijkste voordeel dat dieren
herhaaldelijk onderworpen kunnen worden aan metingen en dat dan dus de ontwikkeling van
luchtwegovergevoeligheid in de tijd gemeten kan worden. Daarnaast is het mogelijk met deze techniek
om de luchtweg responsen gedurende langere tijdsperioden te volgen om te bepalen of de
zogenaamde acute en laat astmatische respons optreden in dit diermodel. Van de acute respons
wordt verondersteld dat deze wordt veroorzaakt door het vrijkomen uit mest cellen van mediatoren die
glad spierweefsel in de luchtwegen aanzetten tot contractie. De laat astmatische reactie wordt
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geassocieerd met de infiltratie van ontstekingscellen (eosinofiele granulocyten) als gevolg van
antigeen inhalatie.
Zoals ook bij patiënten met allergische astma gebeurt na inhalatie van het allergeen, zijn acute
luchtwegobstructies meetbaar in dit model (hoofdstuk 2). Tevens werd op het moment dat deze
obstructie optreed een verhoging van MMCP-1 gemeten in het serum. Dit is een sterke indicator dat
mest cellen degranuleren als gevolg van antigeen-inhalatie. De laat astmatische reactie, zoals die wel
wordt waargenomen in een deel van de patiënten met allergische astma, hebben wij niet kunnen
detecteren in dit diermodel. Zelfs wanneer de endogene productie van corticosteroïden werd
voorkomen door toediening van metyrapone, gecombineerd met verhoogde depositie van antigeen in
de longen en versterking van de immuunrespons door gebruik te maken van zogenaamde “booster”
(versterker) antigeen-injecties, werden deze responsen niet waargenomen (hoofdstuk 2). Dit zou
verklaard kunnen worden door de hypothese dat in het door ons gebruikte model eosinofiele
granulocyten niet of niet-detecteerbaar geactiveerd worden door antigeen, hoewel dit wel is
aangetoond in andere, soortgelijke, modellen.
Interleukine 16 en het muizenmodel voor allergische astma
Het hoofddoel van dit proefschrift was het bepalen van de rol van IL16 in de pathologie van allergische
astma. IL16 wordt aangetroffen in zowel patiënten met allergische astma als ook in het diermodel na
contact met het antigeen. Van IL16 is aangetoond dat het geproduceerd kan worden door epitheel
cellen, mest cellen, eosinofiele granulocyten, CD8+ en CD4+ T cellen. Een van de eerst ontdekte
eigenschappen van IL16 was dat IL16 een aantrekkende (chemotactische) werking heeft op CD4+
cellen. Deze eigenschap, samen met de observatie dat verhoogde hoeveelheden IL16 aanwezig zijn
na antigeen contact leidde tot de hypothese dat IL16 bijdraagt aan de formatie van met allergie
geassocieerde klachten.
Een van de belangrijkste bronnen van IL16 zou de epitheelcel kunnen zijn omdat hiervan, onder
andere middels histologie, is aangetoond dat deze cellen veel IL16 bevatten. Tevens is bekend dat
epitheel cellen IL16 produceren na stimulatie met histamine terwijl CD8+ T cellen IL16 afgeven na
stimulatie met histamine of serotonine. Aangezien mest cellen in muizen zowel histamine als
serotonine vrijzetten na stimulatie middels IgE-antigeen interactie, werd geprobeerd de IL16 afgifte te
remmen door toediening van selectieve histamine en serotine receptor antagonisten (hoofdstuk 3).
Gebruik van de histamine-type 2 receptor antagonist, zowel als gebruik van de serotonine 2 receptor
antagonist, resulteerde in een gedeeltelijke remming van de luchtweg hyperreactiviteit als ook een
gedeeltelijke verlaging  van de  hoeveelheid eosinofiele granulocyten in de longen. Gebruik van deze
twee receptor antagonisten samen resulteerde in een volledige remming van de
luchtwegovergevoeligheid zonder de aantallen eosinofiele granulocyten verder te verlagen. Metingen
van de hoeveelheid IL16 in de longen bracht aan het licht dat deze onveranderd waren. Het is
daardoor niet erg waarschijnlijk dat histamine en serotonine de enige inductoren zijn voor de productie
en afgifte van IL16.
Een andere methodologische aanpak om de rol van endogeen (door het lichaam zelf aangemaakt)
IL16 te bepalen bestond uit het gebruik van zogenaamde monoclonale antilichamen gericht tegen
IL16. Daarnaast werd ook gebruik gemaakt van peptides (eiwit fragmenten) waarvan de sequentie
(volgorde van de aminozuren, “bouwstenen”) gebaseerd was op IL16 (hoofdstuk 4). Van een van deze
peptides was reeds aangetoond dat deze de werking van IL16 in vitro (in glas) kan remmen, wat
hoogst waarschijnlijk een gevolg is van het feit dat dit peptide bindt aan de receptor voor IL16 (het
CD4 molecuul) zonder deze cellen dan te activeren.
Gebruik van zowel de antilichamen, als het IL16 inhiberende peptide, gedurende de
blootstellingsperiode middels inhalatie van het antigeen, resulteerde in een partiële remming van de
luchtweg hyperreactiviteit, zonder dat een effect werd waargenomen op de mate van ontsteking. Deze
experimenten tonen aan dat endogeen geproduceerd IL16 in ieder geval een rol speelt in de inductie
van luchtweg hyperreactiviteit als gevolg van antigeen inhalatie. Tevens tonen deze experimenten aan
dat IL16 geen rol speelt in de  chemotaxie van eosinofiele granulocyten.
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Een geheel andere methodologie werd ook aangewend om de effecten van IL16 in het muizenmodel
te bestuderen. In verschillende experimenten werd IL16 toegediend gedurende de antigeen-
blootstellings periode (hoofdstuk 5). Toediening van IL16 voor iedere antigeen expositie resulteerde in
een sterke inhibitie van antigeen-geïnduceerde fenomenen. Een volledige reductie werd
waargenomen van zowel de luchtweg hyperreactiviteit als ook nagenoeg complete inhibitie van de
ontstekingsrespons, bestaande uit de infiltratie van eosinofiele granulocyten. De productie van
antigeen-specifieke antilichamen (in het bijzonder IgE) was niet aangetast door behandeling met IL16,
waaruit geconcludeerd kan worden dat de zogenaamde geheugen-B cel respons niet beïnvloed wordt
door IL16.
Een ander interessant fenomeen na behandeling van muizen met IL16 bestond uit de observatie dat
cellen uit lymfeknopen, geïsoleerd uit IL16 behandelde en aan antigeen blootgestelde dieren, minder
capabel  waren om IL4 en IL5 te produceren na stimulatie met antigeen in vitro als deze productie
werd vergeleken met cellen die geïsoleerd waren uit controle dieren. Van zowel IL4 als IL5 is
aangetoond dat dit belangrijke interleukines zijn voor de inductie van allergische symptomen in zowel
patiënten als diermodellen. Tevens werd geobserveerd dat deze cellen minder goed in staat zijn tot
proliferatie (vermenigvuldiging) wanneer zij in aanraking zijn geweest met IL16 in vivo (in het intacte
dier). Naast deze effecten van IL16 in vivo, hebben wij ook gekeken naar mogelijke effecten van IL16
behandeling op antigeen-specifieke T cellen in vitro. Ook na voorbehandeling van CD4+ T cellen in
vitro werd een inhiberend effect waargenomen op zowel antigeen-geïnduceerde cytokine productie als
op proliferatie (hoofdstuk 6).
Aangezien het CD4 molecuul de receptor is voor IL16 en aangezien de belangrijkste bron van IL4 en
IL5 deze CD4+ Th2 cel is, is het erg aanlokkelijk om te speculeren op een mogelijk effect van IL16 op
deze T cel populatie. Geheel in lijn met deze gedachtengang zijn de observaties dat andere CD4-
bindende eiwitten, zoals antilichamen tegen CD4 en gp120 (HIV enveloppe eiwit), ook in staat zijn
CD4+ T cel responsen te remmen. Het is bijvoorbeeld goed gedocumenteerd dat antilichamen tegen
CD4 kunnen beschermen tegen afstotingsreacties na orgaantransplantatie en tegen de inductie van
collageen-geïnduceerde gewrichtsontsteking.
Aangezien het CD4 molecuul niet alleen een rol speelt bij de activatie van T cellen, maar ook bij de
differentiatie van naïeve T cellen in T cellen met een Th2 cytokine profiel, waarvan bekend is dat deze
een cruciale rol vervullen in de pathologie van allergische astma, hebben wij ook gekeken naar de rol
van IL16 in dit soort responsen (hoofdstuk 6). Hiervoor hebben wij een artificieel systeem gebruikt
waarbij de aan of afwezigheid van IL4 (de sturende factoren) tijdens de eerste stimulatie met antigeen
in vitro bepaald of T cellen na restimulatie differentiëren richting een Th1 of Th2 cytokine
producerende cel. Wanneer naïeve T cellen werden blootgesteld aan IL16, zonder de sturende
factoren, was er geen effect waarneembaar op de cytokine productie na de eerste stimulatie met
antigeen. Echter, na restimulatie met antigeen produceerden deze cellen minder IL4 en IL5, wanneer
een vergelijk werd gemaakt met cellen die initieel niet in contact waren geweest met IL16. De
productie van IFNg  en IL10 was echter niet verandert in de IL16 behandelde cellen. Geen effecten
veroorzaakt door aanwezigheid van IL16 werden waargenomen op de cytokine productie na
restimulatie met het antigeen, als de differentiatie van T cellen werd gestuurd richting een Th1 of Th2
cytokine profiel.
Het effect van IL16 op de differentiatie van naïeve T cellen als gevolg van herhaaldelijke blootstelling
aan antigeen zonder dat daarbij sturende factoren aanwezig zijn, zou een mogelijke verklaring kunnen
zijn voor de effecten van IL16 behandeling in vivo. Zoals reeds vermeld, is het wel bekend dat zowel
IL4 en IL5 belangrijk zijn voor de inductie van met allergie geassocieerde fenomenen, terwijl van zowel
IL10 als IFN g   bekend is dat deze interleukines potente inhiberende eigenschappen bezitten.
Het zou heel wel mogelijk kunnen zijn dat IL16 deze effecten veroorzaakt door binding aan het CD4
molecuul. Het CD4 molecuul speelt een belangrijke rol bij de interactie tussen T cel en de cellen die
het antigeen aan de T cel laten zien (antigeen-presenterende cel, APC). Dit proces van antigeen
presentatie aan de T cel is noodzakelijk in het immuunsysteem aangezien op deze manier
gewaarborgd wordt dat de T cel op een gecontroleerde manier geactiveerd wordt (m.a.w. alleen
wanneer het antigeen aanwezig is). Het CD4 molecuul zorgt ervoor dat de interactie tussen APC en T
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cel gestabiliseerd wordt en dat de T cel de juiste signalen krijgt. Wanneer het CD4 molecuul
onafhankelijk van de APC-T cel interactie wordt gebonden dan krijgt de T cel de verkeerde signalen
waardoor de T cel anerg kan worden (dit wil zeggen; niet meer reageert op prikkels waarop de cel
normaal gesproken wel zou reageren). Dit zou veroorzaakt kunnen worden door de signalen die de T
cel krijgt als het gevolg van zg. cross-linking (het verbinden van meerdere CD4 moleculen
tegelijkertijd). In theorie kan IL16 vier CD4 moleculen tegelijkertijd cross-linken terwijl een intact
antilichaam tegen CD4 er twee tegelijkertijd zou kunnen verbinden. In tegenspraak hiermee is de
observatie dat gp120 ook dit soort responsen kan opwekken in CD4 cellen, terwijl gp120 slechts een
monovalente (één op één) interactie kan aangaan met het CD4 molecuul. In het geval waarbij IL16
toegediend werd voor iedere antigeen inhalatie, zou het dus kunnen zijn dat de CD4 moleculen op
CD4+ Th2 cellen reeds gebonden zijn door IL16, waardoor de interactie APC-T cel niet correct kan
plaats vinden óf dat er negatieve signalen worden doorgegeven aan de T cel.
Een van de observaties die hiermee niet verklaard kunnen worden is het feit dat voor de realisatie van
de in vivo effecten door IL16 slechts weinig van dit IL16 nodig is, terwijl in vitro effecten van IL16 pas
bij veel hogere concentraties worden waargenomen. Dit zou veroorzaakt kunnen worden doordat IL16
in vivo synergistische (elkaar versterkende) effecten heeft met andere mediatoren die niet aanwezig
zijn in de in vitro kweken. Een andere mogelijkheid zou kunnen zijn dat IL16 interacties aangaat met
andere cellen dan de T cel, bijvoorbeeld met de macrofaag, die ook CD4 moleculen tot expressie
brengt op de celmembraan. Macrofagen zijn in grote hoeveelheden aanwezig zijn in de longen en
zouden dus mogelijk beïnvloed kunnen worden door therapie met IL16.
De observatie dat antilichamen tegen IL16 een gedeeltelijke remming geven van de luchtweg
hyperreactiviteit is niet in overeenstemming met de observatie dat toediening van IL16 zelf een
volledige remming van de luchtwegovergevoeligheid geeft. Een verklaring hiervoor kan zijn dat de tijd
van toediening van essentieel belang is voor de uitkomst van de behandeling. Op het moment dat de
antilichamen werden toegediend is er nog geen detecteerbare hoeveelheid IL16 aanwezig in de
luchtwegen van deze muizen. Pas na een aantal dagen antigeen blootstelling kan IL16 gemeten
worden in de longen van gesensibiliseerde muizen. Bij toediening van IL16 is er sprake van een
situatie waarbij IL16 aanwezig is in het lichaam op een tijdstip waarop dit normaal gesproken niet het
geval is, waardoor deze discrepantie in resultaten verklaard zou kunnen worden. Een andere
mogelijke verklaring voor dit fenomeen zou kunnen zijn dat in plaats van het wegvangen van IL16 door
de antilichamen tegen IL16, er een verhoging van de halfwaarde tijd plaatsvindt, waardoor het door
het lichaam gevormde IL16 langer aanwezig blijft in plaats van te verdwijnen. Dit is ook waargenomen
bij het gebruik van andere antilichamen tegen verschillende andere interleukines.
Het feit dat het IL16 blokkerende peptide een gedeeltelijke remming laat zien van de
luchtwegovergevoeligheid zou verklaard  kunnen worden door te veronderstellen dat het peptide
dezelfde activiteit heeft na binding met het CD4 molecuul als het intacte IL16. Het is inderdaad
gepubliceerd dat voor T cel inhiberende effectiviteit van CD4-bindende substanties het binden van
slechts een CD4 molecuul tegelijkertijd, in plaats van het koppelen van verschillende CD4 moleculen,
voldoende is.
IL16 als mogelijke therapie voor allergische astma
Omwille van de bovenstaande resultaten is het erg verleidelijk om te speculeren op het gebruik van
IL16 als mogelijke therapie bij de behandeling van allergische astma. Inderdaad is recentelijk
aangetoond dat toediening van IL16 in een diermodel, in dezelfde dagelijkse dosis als die door ons is
gebruikt, het ontstaan van ontsteking (synovitis) kan tegengaan. Bovendien werd in die studies
aangetoond dat dit effect gepaard ging met een verlaging van de aanmaak van boodschapper RNA
voor diverse interleukines. Deze resultaten zijn in overeenstemming met de door ons waargenomen
effecten van therapie met IL16 in het muizenmodel voor allergische astma. Op grond van de literatuur
en het voorgestelde werkingsmechanisme kan geconcludeerd worden dat IL16 therapie niet alleen de
antigeen-specifieke T cellen beïnvloed maar alle CD4+ T cellen. Als deze andere T cellen het antigeen
tegenkomen waar zij specifiek op reageren (bijvoorbeeld een opportunistische infectie) dan zijn deze T
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cellen dus ook niet meer in staat zijn hierop een adequate respons te genereren, wat onvermijdelijk
zal lijden tot voor de patiënt kwalijke gevolgen. Verder is therapie met IL16 alleen zinvol indien de
geinduceerde veranderingen in CD4+ T cellen van lange duur zijn. Verder onderzoek is dus
noodzakelijk om IL16 als therapeuticum verder te ontwikkelen.
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Na 49,706 woorden dan eindelijk het laatste stuk tekst; traditie getrouw gewijd aan iedereen die, direct
of indirect, heeft bijgedragen aan de totstandkoming van dit proefschrift.
Allereerst natuurlijk de promotor, Frans, de aanvoerder van de fijne farmacologie familie! Gedurende
de afgelopen jaren heb ik je leren kennen als een gedreven man, die niet alleen iedereen kent, maar
ook door iedereen gekend wordt. Het aantal keren dat ik gevraagd ben, door voor mij volslagen
onbekenden, om de groeten over te dragen aan jou zijn niet te tellen geweest. Door jouw PR is de
afdeling gegroeid tot de huidige omvang en daar zal het ongetwijfeld niet bij blijven.
Ik verkeerde in de luxepositie dat ik twee co-promotores had, Antoon en Paul. Hoewel dat bij het
schrijven niet altijd een luxe was (tegenovergestelde raadgevingen en adviezen waren niet van de
lucht) heb ik dat altijd als een meerwaarde beschouwd. De vele geplande en ongeplande
(wandelgang) werkbesprekingen waren altijd informatief en bovenal gemoedelijk. Veel heb ik te
danken aan jullie expertise en raad! Daarnaast heb ik vooral Antoon ook in de prive-sfeer goed leren
kennen. Het was en is een genoegen om met jouw in de Primus “even een kleintje te doen”, om
vervolgens te verzanden in “goede gesprekken”  waarbij het goudgele vocht rijkelijk vloeide. Ik hoop
dat we dit ook na deze promotietijd gewoon kunnen voortzetten!
En dan natuurlijk Eline;  mijn “guardian angel”. Niets was je te dol, aerosollen in het weekend werd
door jou zonder morren gedaan. Een “last-minute change in plans” was nooit een probleem. Iets
nieuws proberen was voor jou altijd een uitdaging. Ik heb het werken met jou als bijzonder prettig
ervaren, niet in het minst doordat jij mij altijd weer wist behoeden voor mijn eigen vergeetachtigheid.
Het is dan ook vanzelfsprekend dat je vandaag een van mijn paranimfen bent.
Besides Antoon and Paul, I’ve also had a “third” co-promotor, dr. W.W. Cruikshank (Bill), godfather of
IL16. Dear Bill, it has been my honour and privilege to work with you and your IL16! It was always a
delight to discuss my results on IL16 (usually while having beers and burgers!) with you! Thanks again
for all the knowledge you passed on to me and of course I’ll end this short message with one of the
yells you teached me: “down the hatch!”.
En dan de studenten: Mark en Judith; de resultaten van jullie noeste arbeid is terug te vinden in
respectievelijk hoofdstuk 2 en 6. Mijn dank voor het vele werk wat jullie mij uit handen hebben
genomen is groot! Dit geldt natuurlijk ook voor  de “scriptie-studenten”: Klaas, Manou en Daphne,
bijzonder bedankt voor jullie intensieve literatuurstudies. Van alle scripties zijn delen van de resultaten
terug te vinden in dit proefschrift. Ook jullie bedankt voor het mij uit handen nemen van bijzonder veel
werk!
“Het groepje van Antoon” wat in de loop van de tijd bestaan heeft uit de volgende mensen:  Edith J,
Betty, Jeroen, Gerard, Claudia, Daphne, Heleen, Peter en Edith H, ook aan jullie ben ik veel
dank verschuldigd vanwege de vele weekenddiensten die we voor elkaar over hebben kunnen nemen,
de vele invalsbeurten en het ad hoc geregel om toch nog iets tot een goed eind te kunnen brengen.
Natuurlijk wil ik jullie ook bedanken voor de vele leerzame discussies en suggesties.
Wat mij vanzelf brengt bij de FFF! Bedankt voor de (Kerst)borrels, de vrijdagmiddag borrels, de
zomaar op maandag (of elke andere dag van de week)-avond borrels, en natuurlijk de vele
congresborrels (margarita’s). Zoals daar bijvoorbeeld waren; de jaren zeventig disco in Chicago, de
Starlight Lounge in San Fransisco, Jimmy’s in Harrogate, het Casino in Lake Tahoe, de kamerborrels
in Lunteren en Noordwijkerhout etc., etc. Het is een genoegen geweest om mee te mogen draaien in
de mallemolen van het (farmacologisch & pathofysiologisch) leven!
Furthermore, I would like to thank Prof. Dr. Kim Bottomly and her collegues at Yale University for
sharing their thoughts with me on T cell differentiation and for letting me do some experiments at their
lab.
Dan wil ik nog graag bedanken: JC-‘Welterusten Harrie’, SB-‘Fris en Fruitig’ en alle overige vrienden
en kennissen voor het altijd maar weer moeten luisteren naar verhalen over piepende muizen. Dit
geldt natuurlijk in het bijzonder voor “En, hoe is het met de muizen” familie van der Werf.
Het thuisfront; Pa & Ma; Esther en Henri (en kleine max) jullie steun is van ongekende afmetingen
geweest. In alle opzichten hebben jullie mij niet alleen met raad en daad bijgestaan maar ook met
114
liefde en plezier. Ondanks het feit dat ik vaak in geheimtaal sprak hebben jullie altijd geprobeerd op de
hoogte te blijven van waar ik nou mee bezig was (iets met muizen en astma) wat zeker geen
eenvoudige opgave was. Het is fijn te weten dat er altijd mensen zijn op wie je terug kan en mag
vallen.
En dan blijft er nog maar een over, Meinske, de andere paranimf. Gedurende de afgelopen jaren heb
je er heel wat mee te stellen gehad, met als absolute hoogtepunt een nachtelijk verblijf in de
proefdierstallen omdat ik zo nodig nog even moest aerosollen. En dat altijd zonder morren of
klagen…..en je weet het: belofte maakt schuld……………..
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De auteur van dit proefschrift werd geboren op 1 december 1970 te Veghel. In augustus 1989
behaalde hij het Gymnasium-b  diploma aan “Gymnasium Bernrode” te Heeswijk-Dinther. In hetzelfde
jaar werd door hem een aanvang gemaakt met de studie medische Biologie aan de Faculteit
Geneeskunde van de Universiteit van Utrecht. In augustus 1990 behaalde hij het propedeutisch
examen, gevolgd door het doctoraal examen in augustus 1995. Tijdens deze studie heeft hij een
drietal wetenschappelijke stages volbracht. Onder begeleiding van Prof. Dr. A.J.P. Schrijvers (UU,
Fac. Geneeskunde, vakgroep Algemene gezondheidszorg & Epidemiologie) werd een studie volbracht
naar de gevolgen van een beleidsverandering in het Westeinde Ziekenhuis te ‘s Gravenhage, als
onderdeel van het bijvak getiteld; “Beleid en Management van de Gezondheidszorg”.
Onder begeleiding van Dr. E.M. Hessel en Dr. A.J.M. van Oosterhout (UU, Fac. Farmacie, vakgroep
Farmacologie en Pathofysiologie) werd gedurende negen maanden onderzoek gedaan met als titel
“modulatie van bronchiale hyperreactiviteit en ontsteking in een muizenmodel voor allergische astma”.
Hierna werd een extra-curriculaire stage volbracht onder supervisie van Dr. P. Okunieff (NHI, NCI,
Radiation Oncology Branch, USA) naar de voorspelbaarheid van genezing op grond van zuurstof
verdeling in verschillende humane plaveiselcel carcinomen als het gevolg van het aanbieden van
radiotherapie. Na het behalen van het doctoraal examen begon hij aansluitend met een door Glaxo-
Wellcome gesubsidieerd promotie onderzoek naar de rol van interleukine 16 in een muizenmodel voor
allergische astma. Dit onderzoek werd uitgevoerd aan de Fac. Farmacie, vakgroep Farmacologie en
Pathofysiologie in samenwerking met mw. Ing. E.H. Jonker onder supervisie van Dr. A.J.M. van
Oosterhout en Dr. P.A.J. Henricks. Als promotor fungeerde Prof. Dr. F.P. Nijkamp. Het resultaat van
dit onderzoek ligt thans voor U. Inmiddels is de schrijver dezes verbonden aan het Department of
Clinical Trial Operations van N.V. Organon.
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